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CHAPTER 1
General introduction
Part of this chapter is based on:
Familial gastric cancer: detection of a hereditary 
cause helps to understand its etiology
Ingrid P. Vogelaar*, Rachel S. van der Post*, 
Tanya M. Bisseling, J. Han J.M. van Krieken, 
Marjolijn J.L. Ligtenberg and Nicoline Hoogerbrugge
Hereditary Cancer in Clinical Practice 2012 12;10(1):18
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CHAPTER 1
General introduction
Cancer is a leading cause of death worldwide. In 2012, approximately 8.2 million people died 
of cancer and it is predicted that the number of cancer cases will rise from 14 million in 2012 
to 22 million in the next twenty years.1 Gaining more insight in molecular alterations under-
lying tumor development will allow for earlier recognition of individuals at risk of cancer and 
may provide opportunities for improvement of cancer surveillance programs and therapies, 
thereby reducing the number of cancer deaths in the future.
Cancer is a genetic disease that is caused by the step-wise acquisition of specific alterations 
in the DNA. These DNA alterations can involve large chromosomal copy number alterations 
or rearrangements (inversions, translocations), as well as small deletions, duplications or 
sequence mutations, which cause a normal cell to become a cancer (or ‘malignant’) cell. 
Studies in which different tumor types have been sequenced identified mutations in genes 
that can 'drive' the process of tumorigenesis. In a recent report, it was estimated that the total 
number of genes carrying these so-called driver mutations is approximately 140, and that a 
typical tumor contains two to eight mutations in this type of genes. Based on these studies, 
the driver genes were divided in 12 pathways regulating three core processes of the cell: cell 
fate, cell survival and genome maintenance.2
Two types of ‘driver genes’ exist; oncogenes and tumor-suppressor genes. Oncogenes nor-
mally promote cell growth or inhibit apoptosis. Mutations in these genes cause them to be 
continuously active, also in situations where the wild-type gene would not be active. Examples 
of oncogenes are components of the RAS pathway (e.g. KRAS, NRAS, BRAF and PTPN11) and 
MYC. Tumor-suppressor genes normally control cell growth and induce apoptosis. Mutations 
in these genes, caused by point mutations or insertions and deletions of the gene, as well 
as epigenetic silencing, makes the proteins less active.3 In 1971, Knudson described the 
hypothesis that for a tumor-suppressor gene to become inactivated, both alleles have to be 
mutated.4 This hypothesis, referred to as “Knudson’s two-hit hypothesis”, was based on the 
first tumor-suppressor gene discovered, RB1. Other examples of tumor-suppressor genes are 
TP53, mutated in a large number of tumors, and APC, mutated in a specific subset of tumors. 
A specific subgroup of tumor-suppressor genes are involved in DNA maintenance. These 
genes do not play a role in cell growth or apoptosis, but instead are responsible for correction 
of mistakes made by the replication machinery during DNA replication. This group of genes 
includes the mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2), the nucleotide-ex-
cision repair genes (for example XPA, ERCC1 and RAD23A), base-excision repair genes (for 
example MUTYH) and genes like BRCA1, BLM and ATM, important in the maintenance of 
chromosomal stability. If mutations in these genes occur, replication mistakes in other genes, 
including crucial oncogenes or tumor-suppressor genes, cannot be repaired anymore.3
13
GENERAL INTRODUCTION
In addition to mutations in the DNA, also epigenetic changes play a role in cancer develop-
ment. There are three types of epigenetic changes; DNA methylation, histone modifications/
chromatin remodeling and posttranslational gene regulation by noncoding RNAs, including 
microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). DNA methylation plays an import-
ant role in transcriptional regulation as well as the maintainance of genomic integrity. If a 
gene is hypermethylated, the transcription is impaired; hypomethylation of a gene has the op-
posite effect.5 Therefore, it is no surprise that in cancer, tumor-suppressor genes (like MLH1 
and BRCA1) are hypermethylated, whereas oncogenes (like MYC) are hypomethylated.6 Fur-
thermore, histone modifications and chromatin remodeling may also be involved in cancer 
by affecting gene regulation.7 Chromatin, which consists of histones and DNA, has two basal 
‘states’. Heterochromatin is densely packed and transcriptionally inactive and euchromatin is 
less compact and therefore transcriptionally active. Histone modifications in specific genomic 
regions can change the state of the chromatin and this can result in changed gene expres-
sion. One of these histone modifiers is EZH2, which can methylate histones at a specific site. 
This protein is associated with the aggressive behaviour of different types of cancer.8 Mi-
RNAs are small RNAs of approximately 22 nucleotides. They are involved in posttranslational 
gene silencing by binding the mRNA to prevent translation into proteins.9 Alterations in these 
miRNAs, resulting in altered ability to silence genes, are implied in different type of cancers, 
including gastric cancer.10
Cancer and the immune system
Interestingly, two of the tumor hallmarks described by Hanahan and Weinberg involve the 
immune system; avoiding immune destruction and tumor-promoting inflammation.11 This in-
dicates that the immune system plays an important role in cancer. 
The immune system protects a host against infections and is composed of innate (non-spe-
cific) and antigen-specific adaptive immune responses. The innate immune system consists 
of monocytes, macrophages, dendritic cells (DCs), and natural killer (NK) cells and mediates 
the ‘acute’ immune responses.12 When pathogens enter the human body, they are recognized 
through their pathogen-associated molecular pattern (PAMP) by pattern recognition receptors 
(PRRs), for example Toll-like receptors (TLRs). These receptors are present on the surface of 
the innate immune cells.12 The recognition leads to the secretion of multiple pro-inflammatory 
cytokines, including tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β), interleukin-6 
(IL-6) and interleukin-12 (IL-12).12 These proteins cause activation of the complement cas-
cade and NK cells, as well as phagocytosis of pathogens by phagocytes.12 The activated NK 
cells secrete IFN-γ, which activates macrophages to secrete various inflammatory cytokines 
which, amongst others, initiate the adaptive immune response by helping to activate T-cells.12 
The adaptive immune system consists of B- and T-cells and is involved in the long-lived re-
sponses and immune memory formation. The proliferation of B- and T- cells is promoted by 
inflammatory cytokines produced by both T-lymphocytes and the innate part of the immune 
system, such as interleukin-2 and interleukin-12.12 Naïve T-cells recognize degraded patho-
gens presented by antigen-presenting cells, while naïve B-cells recognize soluble antigens 
without a role for antigen-presenting cells.12 Two important subpopulations of CD4+ helper 
T-cells are the Th1 and Th17 cells that secrete IFN-γ and the proinflammatory cytokine IL-17, 
respectively. In addition to macrophage activation, IFN-γ plays an important role in immune 
responses against infections12 and in tumor control due to its anti-tumor effects.12 IL-17 pro-
motes inflammation by inducing various proinflammatory cytokines that recruit inflammatory 
cells.13 
The process described above is referred to as immunosurveillance.14 Cancer cells are also 
under immunosurveillance and can be recognised by the immune system because their im-
munogenic potential changes with the transition from normal cell to cancer cell. This rela-
tionship between the immune system and cancer cells is dynamic.14-16 Even though cancer 
immunosurveillance can control or eliminate some premalignant lesions, with time, tumor 
cells under selective pressure from immunosurveillance can undergo a process referred to as 
‘cancer immunoediting’ and eventually escape the immune system.14-16 Cancer immunoedit-
ing consists of three phases. The first phase is elimination, or the immunosurveillance as de-
scribed above. Cells of the innate and adaptive immune system try to eradicate the tumor and 
prevent tumor formation. The second step, called equilibrium, is the period after incomplete 
tumor destruction. In this ‘steady state’, under tight control of immunosurveillance, tumor 
cells can be permanently maintained. Tumor cells can eventually be eliminated by the im-
mune system or they can escape from the immune system in phase three of immunoediting, 
called ‘escape’, which is possible because of various escape strategies tumor cells acquire 
during tumor development.14-16 
The relation between cancer and the immune system is further supported by the fact that sev-
eral infections with viruses as well as bacteria are associated with an increased risk for can-
cer development in the infected host. For example, human papilloma virus (HPV) infection is 
a cause for development of cervical cancer17, Epstein-Barr virus (EBV) infection increases the 
risk of developing nasopharyngeal cancer, Burkitt lymphoma, Hodgkin lymphoma and stom-
ach cancer.18 Infection with Human Immunodeficiency Virus is associated with an increased 
risk of developing Kaposi sarcoma, cervical cancer, non-Hodgkin lymphoma19,20 and stomach 
cancer.21 The most well-known example of a bacterial infection causing cancer is Helicobacter 
pylori. This infection is commonly acquired during childhood and persists unless eradicat-
ed.22 In the stomach, H. pylori can induce a sequence of gastritis, intestinal metaplasia and, 
eventually, dysplasia. Ultimately, this may lead to the development of gastric cancer.23 Since 
infection with H. pylori increases the risk of developing GC about six-fold24, the World Health 
Organisation (WHO) has classified H. pylori as a class I carcinogen in 1994.25,26
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Hereditary cancer syndromes
Germline mutations in certain tumor-suppressor genes and oncogenes cause cancer pre-
disposition. The increased risk of cancer in these individuals is caused by the fact that one 
of the mutations that contributes to cancer formation is already present in every cell of their 
body. Characteristics of hereditary cancer predisposition are the early age of onset compared 
to individuals with sporadic forms, the occurrence of multiple tumors, and the presence of a 
positive family history. Syndromes in which gastric cancer and/or colorectal cancer are part 
of the disease spectrum are depicted in Table 1. Two cancer predisposition syndromes are de-
scribed in detail below: hereditary diffuse gastric cancer, caused by germline mutations in the 
CDH1 gene, and Lynch syndrome, caused by mutations in one of the mismatch repair genes.
Hereditary diffuse gastric cancer (HDGC)
Annually, almost one million people develop gastric cancer (GC) and approximately 723,000 
people die of this disease worldwide. This makes GC the fifth most common malignancy and 
the third leading cause of cancer-related mortality worldwide.1 In the Netherlands, approxi-
mately 1,500 people develop gastric cancer each year.28
Gastric carcinoma is a heterogeneous disease and different classification schemes are used 
to divide GC in histopathological subtypes. The most commonly used are those of the World 
Health Organization (WHO)29 and Laurén.30 The Laurén classification divides GC roughly into 
three main types: the diffuse type, the intestinal type and a rest group composed of mixed 
and indeterminate type.30 Intestinal-type GC shows glandular or tubular components with 
various degrees of differentiation. Diffuse-type GC consists of poorly cohesive single cells 
without gland formation. Often signet ring cells are present; therefore it is also referred to as 
signet ring cell carcinoma.29 
Gastric cancer is the result of a combination of environmental factors and genetic alterations. 
Environmental factors are mainly involved in the etiology of intestinal-type GC. As described 
above, the main environmental factor involved is Helicobacter pylori (H. pylori) infection.25,26
Familial aggregation of gastric cancer is known to occur in approximately 8-30% of the pa-
tients31-35 and epidemiological studies have shown that in the general population, the risk 
of gastric cancer in first-degree relatives with any type of gastric cancer is increased 2–3 
fold.36 An increased risk of developing both diffuse and intestinal type GC has been shown in 
several well-known hereditary cancer syndromes, including Lynch syndrome and Li-Fraumeni 
syndrome (Table 1). The lifetime risk of GC in these syndromes varies substantially between 
the populations that are studied, but is generally low. 
In 1998, Guilford et al. identified germline mutations in the CDH1 gene as a cause of hered-
itary diffuse gastric cancer (HDGC).37 CDH1 encodes the protein E-cadherin, which plays an 
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important role in cell–cell adhesion and the maintenance of epithelial integrity.38 The muta-
tion detection rate is approximately 50% in families with two gastric cancers in first-degree 
relatives with at least one diffuse gastric cancer (DGC) diagnosed before age 50, or three or 
more DGC in close relatives diagnosed at any age.39 The percentage decreases if also single 
cases of DGC below the age of 35 are included.40 The most common types of mutations are 
small insertions and deletions (35% of the mutations). Missense variants occur in 28% of 
16
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Table 1. Hereditary cancer syndromes with gastric and/or colorectal cancer  
in their disease spectrum 
Syndrome OMIM number Genes 
involved 
Types of cancer  
Familial 
adenomatous 
polyposis (FAP) 
175100 APC Colorectal, duodenal, papillary thyroid, pancreatic, 
hepatoblastoma, CNS tumors 
MYH-adenomatous 
polyposis (MAP) 
608456 MUTYH (MYH) Colorectal, duodenal, gastric, ovarian, bladder, 
breast, endometrium, sebaceous gland tumors, 
thyroid 
Juvenile polyposis 
syndrome (JPS) 
174900 SMAD4 / 
BMPR1A 
Colorectal, gastric, duodenal, pancreatic 
PTEN Hamartoma 
tumor syndrome 
158350 PTEN Gastric, breast, thyroid, endometrium  
Peutz-Jeghers 
syndrome 
175200 STK11 Colorectal, gastric, pancreatic, breast, and ovarian 
cancers 
Lynch syndrome 609310 
120435 
614350 
614337 
613244 
MLH1 
MSH2 
MSH6 
PMS2 
EPCAM 
Colorectal, endometrial, stomach, ovarian, 
pancreas, ureter or renal pelvis, biliary tract, brain 
tumors (glioblastoma), carcinoma of the small bowel 
and sebaceous gland adenomas and 
keratoacanthomas (in Muir–Torre syndrome) 
Li-Fraumeni 151623 TP53 Soft tissue sarcoma, osteosarcoma, breast, brain, 
adrenocortical, leukemias, colorectal, esophageal, 
pancreatic, stomach, renal cell, endometrial, 
ovarian, prostate, gonadal germ cell, Hodgkin and 
non-Hodgkin lymphomas, lung, skin, thyroid 
Hereditary breast 
and ovarian cancer 
604370 
612555 
BRCA1 
BRCA2 
Breast cancer, ovarian cancer, gastric cancer 
(BRCA2 mutation carriers), prostate, pancreatic 
Hereditary diffuse 
gastric cancer 
137215 
- 
CDH1 
CTNNA11 
Gastric cancer, breast cancer 
 
Polymerase 
proofreading-
associated polyposis 
615083 
612591 
POLE 
POLD1 
Colorectal 
 
1 CTNNA1 has recently been described to be involved in gastric cancer predisposition27, therefore no OMIM 
number is available at this time.
families, nonsense mutations and splice site mutations are both observed in 16% of the fam-
ilies. Large exonic deletions are relatively rare, with a frequency of about 5%.39,41 For both men 
and women, CDH1 mutation carriers have a cumulative risk of gastric carcinoma by 80 years 
of age of 80%, with a mean age at diagnosis of 40 years. Additionally, women carrying a CDH1 
mutation have a 60% lifetime risk for developing lobular breast cancer.42 Also, there seems 
to be an association between CDH1 mutations and orofacial clefts (OFC). The presence of 
patients with OFC in two CDH1 families was first described by Frebourg et al.43 In one of these 
families the CDH1 mutation cosegregated with the diffuse gastric cancer and cleft cases.43 
The association was later supported by data from Kluijt et al., who reported clinical data of 10 
Dutch CDH1 families. Here, OFC was found in seven individuals from three families.44
Genetic counseling and criteria for CDH1 mutation testing
Genetic counseling is an essential component of the management of HDGC. It includes the 
analysis of the family history of at least three generations and histopathological confirmation 
of gastric (pre-) malignancies. The revised international criteria established by the Interna-
tional Gastric Cancer Linkage Consortium (IGCLC) to select patients with an increased risk 
of familial gastric cancer for CDH1 mutation testing are shown in Table 2.42 Genetic testing 
is preferably initiated in an affected relative. In most countries the youngest age at which 
relatives at risk should be offered testing is set at age 18. Rare cases of gastric cancer before 
age 18 have been reported, but the overall risk of DGC before the age of 20 is very low.45,46
Prophylactic total gastrectomy in CDH1 mutation carriers
Prophylactic gastrectomy is currently the only option to eliminate risk of GC development in 
CDH1 mutation carriers.47 The estimated overall mortality for total gastrectomy is 2–4% with 
a nearly 100% risk of long-term morbidity. Associated problems following gastrectomy include 
abdominal pain after eating, dumping syndrome, lactose intolerance, fat malabsorption and 
steatorrhoea and postprandial fullness.42,48-50 The optimal timing of prophylactic gastrectomy 
in individuals with CDH1 mutations is not yet known. Preventive gastrectomy specimens of 
CDH1 mutation carriers reveal multiple small signet ring cell lesions with low proliferation 
rates; few of these lesions progress to an aggressive carcinoma beyond the muscular mu-
cosa.51 Blair et al. advise CDH1 mutation carriers with normal gastric biopsies to consider 
gastrectomy once the individuals are older than 20 years of age.46 Other authors recommend 
considering preventive gastrectomy when the CDH1 mutation carrier is 5 years younger than 
the youngest family member with DGC, which generally means that preventive gastrectomy 
is postponed to an age later than 18 years.52 Pathological analysis of the entire gastrectomy 
sample includes a thorough microscopic assessment with haematoxylin and eosin (H&E) and 
a mucin stain, such as periodic acid-Schiff (PAS). PAS-staining has proven to be helpful as a 
primary stain, increasing the detection rate of small invasive signet ring cell foci and reducing 
screening time.53 
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Pathology of HDGC
Pathological mapping of complete gastrectomy specimens has shown that early-stage HDGC 
is characterized by the presence of a few to up to hundreds foci of stage T1a signet ring cell 
carcinoma (SRCC) restricted to the superficial lamina propria, without nodal metastases (Fig-
ure 1a and 1b).46,52,54,55 The proposed histologic model for HDGC development by Carneiro et 
al. starts with signet ring cell carcinoma in situ (Tis), followed by increased pagetoid prolifera-
tion of signet ring cells and eventually to invasive carcinoma.56 Advanced HDGC presents as a 
poorly differentiated diffuse carcinoma with sometimes a few signet ring cells (linitis plastica) 
but also undifferentiated or mixed subtypes with mucinous and sometimes tubular dediffer-
entiation are seen. (Van der Post et al., unpublished data) These advanced gastric carcino-
mas of CDH1 mutation carriers do not show any characteristics that might discriminate them 
from sporadic gastric cancers.
Surveillance endoscopy
Diffuse GC is difficult to detect at an early and treatable stage since the lesions tend to spread 
into the lamina propria without visible exophytic masses.57 Several studies have shown that 
even though CDH1 mutation carriers had negative biopsies prior to prophylactic gastrectomy, 
foci were detected in their gastrectomy specimens.47,51,54,55 The ‘Cambridge surveillance pro-
tocol’ is advised for CDH1 mutation carriers who do not (yet) want to undergo a prophylactic 
gastrectomy, to individuals at 50% risk of being carrier who are not (yet) willing to be tested for 
the mutation as well as for members from HDGC families without a known CDH1 mutation.42 
Colorectal cancer and Lynch syndrome
Colorectal cancer (CRC) has a worldwide incidence of 1,361,000 new cases per year, with a 
mortality of approximately 50 percent.1 Risk factors for colorectal cancer include smoking, 
excessive alcohol consumption, obesity and red meat consumption.58 The majority of CRC 
cases are sporadic, familial CRC occurs in approximately 20% of cases.59 Lynch syndrome 
is the most common hereditary form of CRC and accounts for approximately 3-5% of all CRC 
cases.60,61 Lynch syndrome is caused by a heterozygous germline mutation in one of the MMR 
genes: MLH162-64, MSH265-67, MSH668 and PMS2.69 A second somatic event affects the wild-
18
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Table 2. Clinical criteria for testing for CDH1 germline mutations  
Revised criteria published in 201042 
- One diffuse gastric cancer case below age 40 or 
- Two gastric cancer cases in a family, one confirmed diffuse gastric cancer  
  below the age of 50 or 
- Three confirmed diffuse gastric cancer cases in 1st or 2nd degree relatives  
  independent of age or 
- Personal or family history of diffuse gastric cancer and lobular breast cancer,  
  with one diagnosis below age 50 
 
type allele of the respective gene and will result in inactivation of the MMR system, leading to 
microsatellite instability (MSI), a hallmark of Lynch syndrome-associated tumors. 
Lynch syndrome mutation carriers have a lifetime risk of up to 80% to develop CRC. In addi-
tion they are at high risk to develop endometrial cancer (EC) and several other cancer types.70 
Cancer surveillance in Lynch syndrome patients starts at age 25 and includes a colonoscopy 
once every 1–2 years as well as surveillance for extracolonic cancers.70 The diagnosis Lynch 
syndrome is essentially made in four steps. The first step is collecting the family history of 
the patient by a genetic counselor to determine whether the Amsterdam-II and/or Bethesda 
criteria are met (Table 3). The Amsterdam criteria were initially determined in 199171 and were 
broadened a few years later (Amsterdam-II criteria), not only considering CRC but also extraco-
lonic tumors seen in Lynch syndrome.72 After the Amsterdam-II criteria, the broader Bethesda 
Guidelines were developed to select patients eligible for the second step in the diagnostic 
process, MSI testing.73 Pathologists can also initiate further research in patients suspect-
ed for Lynch syndrome in the so-called MSI-testing-indicated-by-a-Pathologist (MIPA)-proce-
dure.74 Here, pathologists initiate MSI testing based on the MIPA criteria (Table 3).73-75 
In patients suspected of Lynch syndrome, the tumor is tested for MSI using microsatellite 
markers. In case the tumor is instable in two or more of these markers, it is referred to as 
‘microsatellite instable’ or ‘MSI-High’ (MSI-H).76 If the tumor is MSI-H, immunohistochemistry 
(IHC) is performed using antibodies against the different MMR proteins. This allows for a 
more specific analysis of the gene in which the germline mutation may be present. Since the 
MSH2 protein is in a functional complex with the MSH6 protein, a tumor with a germline and 
a somatic mutation in MSH2 will display loss of nuclear expression of both the MSH2 and 
the MSH6 protein using IHC, while in case of a germline MSH6 mutation and concomitant so-
matic second hit, the tumor will only show loss of MSH6. The same is the case for MLH1 and 
PMS2; a germline mutation and somatic second hit in MLH1 causes a loss of both proteins, 
while the presence of these mutations in PMS2 only leads to loss of the PMS2 protein.77 
As a final step in the Lynch syndrome diagnosis process, germline mutation analysis can be 
performed for patients with an MSI-high tumor, providing the conclusive diagnosis of Lynch 
syndrome. In case a patient was tested via the MIPA procedure, the pathologist reports the 
MSI test result to the surgeon or gastroenterologist and advises on referring the patient for 
genetic counseling in case of a positive MSI test, after which mutation analysis can be per-
formed.74,78,79 
Not all patients with an MSI-high tumor and loss of one of the MMR proteins carry a germline 
mutation in one of the MMR genes. A large proportion of the tumors that show loss of the 
MLH1 protein and have MSI are caused by hypermethylation of the MLH1 promoter. These 
cases present at a later age and are considered sporadic. Furthermore, in a subset of pa-
tients suspected of Lynch syndrome who have MSH2-deficient tumors, a germline deletion 
of the 3’ end of the EPCAM gene has been identified. This gene is located directly upstream 
19
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of MSH2 and the deletion results in allele-specific methylation and subsequent silencing of 
the transcription of MSH2.80 The underlying genetic cause for LS in a group of patients with 
MLH1-deficient tumors at early age but without germline MLH1 mutations has also been 
identified. They carry an MLH1 epimutation, which causes somatic methylation of one allele, 
thereby losing transcription from this allele and subsequently the second allele is lost as well, 
for example by loss of heterozygosity.81 This has been described both sporadically, where the 
mutation is not passed on to the next generation82-85, but also families have been described 
with transmission of the epimutation.84,86,87 
Missing hereditability 
Even though great progress has been made in identifying genetic causes for GC and CRC, 
not all familial cases can be explained yet. In approximately two thirds of families fulfilling the 
strict HDGC criteria, no germline CDH1 mutation is found. In families with intestinal-type GC 
exhibiting an autosomal dominant inheritance pattern, genetic susceptibility genes may also 
play a role. No gene has been associated with this type of GC yet. Also, in a number of CRC 
patients meeting the Amsterdam-II and Bethesda criteria, no germline mutations in the MMR 
genes can be identified. These predisposition genes were found in families with an autoso-
20
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Table 3. Amsterdam II criteria, Bethesda Guidelines and MIPA criteria 
Amsterdam Criteria II72 
-  At least three relatives with a Lynch-syndrome-associated cancer1: 
- One is a first-degree relative of the other two 
- At least two successive generations are affected 
- At least one tumor diagnosed <50 years of age 
- Familial adenomatous polyposis (FAP) should be excluded in the  
- CRC cases (if present) 
- Tumors should be confirmed by a pathologist 
Bethesda Guidelines73 
- CRC diagnosed in a patient who is <50 years of age 
- Presence of synchronous or metachronous colorectal, or other Lynch syndrome-associated  
  tumors2 regardless of age 
- MSI-H CRC diagnosed <60 years of age 
- CRC or Lynch syndrome-associated tumor2 diagnosed <50 years of age in at least one FDR 
- CRC or Lynch syndrome-associated tumor2 diagnosed at any age in two FDR or SDR 
MIPA criteria74  
- CRC or EC diagnosed before age 50 or  
- Second CRC before the age of 70 or 
- CRC and a Lynch syndrome-associated cancer before age 70 or 
- Colorectal adenoma with high grade dysplasia before 40 years of age 
 
1Colorectal cancer, endometrial, small bowel, ureter/renal pelvis; 2Colorectal, endometrial, stomach, ovarian, 
pancreas, ureter or renal pelvis, biliary tract, brain tumors (glioblastoma), carcinoma of the small bowel and 
sebaceous gland adenomas and keratoacanthomas (in Muir–Torre syndrome), and; FDR: first-degree relative; 
SDR: second-degree relative.
mal dominant inheritance pattern and multiple generations affected. Using linkage analysis 
and subsequent Sanger sequencing of genes in the linkage regions, the causative genes in 
these families could be identified. The challenge with the identification of new susceptibility 
genes is that the number of cases that carry these mutations is most likely lower than for the 
genes that have been identified until now. Large, well-defined patient cohorts are required to 
confirm the role of these genes and/or specific gene mutations in predisposition to cancer. 
Genome-wide association studies have been performed for both diseases88-91, testing cases 
and controls for numerous SNPs in the genome, but they identify candidate regions rather 
than actual genetic defects. Array comparative genome hybridization (aCGH) has also been 
applied to identify copy number variations (CNVs) underlying cancer predisposition, being 
replaced later on by SNP arrays.92
The most recent technical development in disease gene identification is the introduction of 
next-generation sequencing methods, such as whole-exome sequencing (WES) and whole-ge-
nome sequencing (WGS). These methods have been successfully applied to identify candidate 
genes for, amongst others, gastric cancer and colorectal cancers.27,93,94 Besides identification 
of novel candidate genes, these new techniques also allow for so-called ‘deep sequencing’, 
which facilitates the detection of mutations present at smaller percentages, like mosaic mu-
tations. 
The identification of the genetic cause underlying GC or CRC predisposition will provide more 
insight in the mechanisms by which tumors develop and may provide opportunities for the 
development of novel therapies. For patient care, identifying novel susceptibility genes has 
two major implications. First, it is important for patients to understand what has caused their 
disease and what the risk could be of developing new primary tumors for the mutation carrier 
as well as their relatives. Furthermore, the clinical management of mutation carriers may 
change based on the mutation that they have. For example, patients with EPCAM deletions 
have a high risk of colorectal cancer, but only patients with a deletion that stretches close to 
the MSH2 promoter also have an increased risk of endometrial cancer. This is an important 
association that may have future implications for surveillance strategies.95
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Aims and outline of this thesis
The aim of this thesis is to improve the recognition of individuals at risk for hereditary gas-
tric- and colorectal cancer in order to apply appropriate surveillance strategies for cancer 
prevention, thereby reducing the mortality for these cancers. Studies have been performed 
on the known predisposing genes for Hereditary Diffuse Gastric Cancer and Lynch Syndrome. 
Furthermore, exome sequencing has been used to identify novel susceptibility genes for gas-
tric cancer.
In chapter 2.1 we report on the sensitivity of the clinicopathological criteria to predict germ-
line CDH1 mutations in Hereditary Diffuse Gastric Cancer.
In chapter 2.2 we describe the identification of germline mutations in the cancer predispos-
ing gene CDH1 in patients with orofacial clefts.
In chapter 2.3 the new clinical guideline for Hereditary Diffuse Gastric Cancer, with an em-
phasis on CDH1 mutation carriers, is presented.
In chapter 3.1 we describe a patient with early-onset gastric cancer and recurrent Candida al-
bicans infections in whom we identified a germline homozygous missense variant in MYD88.
In chapter 3.2 we report on the occurrence of gastric cancer in three relatives of a patient 
with a biallelic IL12RB1 mutation.
In chapter 4 we describe how exome sequencing can be used to identify candidate genes for 
genetic predisposition to early-onset and familial gastric cancer.
In chapter 5.1 we report that somatic mutations in MLH1 and MSH2 are a frequent cause of 
mismatch repair deficiency in Lynch syndrome - like tumors.
In chapter 5.2 we focus on the MLH1 c.-27C>A and c.85G>T variants, which are linked to an 
inherited MLH1 epimutation and show that they are linked to a European ancestral haplotype.
In the final chapter the work presented in this thesis is discussed and suggestions for further 
research are given.
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CHAPTER 2
Abstract 
Background & Aims: Germline CDH1 mutations predispose to familial gastric cancer. This 
study evaluates the internationally accepted hereditary diffuse gastric cancer (HDGC) criteria 
for selection of individuals for CDH1 mutation analysis. 
Methods: Results of CDH1 mutation analysis of 499 families tested in the Netherlands be-
tween 1999 and 2014 were linked with family history and clinicopathological data.
Results: There were 18 pathogenic CDH1 mutations in 499 families (4%), 16 of which were 
present in the 118 families that met the HDGC criteria (14%). Classified per criterion: (i) two or 
more gastric cancer (GC) cases, one diffuse gastric cancer (DGC) below 50 years 15% (8/53); 
(ii) three or more DGC cases at any age 50% (5/10); (iii) one DGC patient below 40 years 
5% (2/41); (iv) personal or family history of DGC and lobular breast cancer (LBC), with one 
below 50 years 9% (1/14). In the remaining 381 families (242 not meeting HDGC criteria and 
139 with incomplete data and/or availability of only first-degree relatives) two families tested 
positive. They were tested because of DGC at age 45, and DGC at age 59 with a first degree 
relative with GC NOS at age 32, respectively. No CDH1 mutations were found in 93 families 
with intestinal-type GC cases, nor in 20 families with exclusively LBC patients.
Conclusions: In our cohort the HDGC criteria have a positive predictive value for the detection 
of a germline CDH1 mutation of 14% and a sensitivity of 89%. All individuals tested positive 
had a personal or family history of DGC. 
Key words: CDH1, e-cadherin, predisposition, stomach cancer
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Introduction
Gastric cancer (GC) is the fifth most common malignancy in the world and with 723,000 
deaths, the third leading cause of cancer-related mortality.1 There are substantial differ-
ences in GC incidence between and within continents, countries and regions, and between 
ethnic groups.2 Both environmental exposures as well as genetic constitution contribute to 
this extensive variation. Like in other western countries, the incidence in the Netherlands of 
non-cardia GC has declined markedly during the last century.3 Each year approximately 1,500 
patients are diagnosed with GC, which accounts for 1.5% of all new cancer cases.4 Around 
8-30% of patients with GC have a family history of GC.5-9 
Hereditary diffuse gastric cancer (HDGC) can be caused by heterozygous germline mutations 
in CDH1.10 This gene encodes the cell adhesion protein E-cadherin. Loss of E-cadherin affects 
epithelial architecture, cell adhesion and cell polarity, which can lead to sustained cell divi-
sion and invasion.11,12 Individuals with a heterozygous germline CDH1 mutation have a high 
lifetime risk to develop diffuse gastric cancer (DGC) and women have an additional risk for 
lobular breast cancer (LBC).13
The detection rate of CDH1 mutations in selected, relatively small series fulfilling the original 
HDGC criteria14 was 30-50%.15,16 These criteria were: (i) two or more documented cases of 
DGC, with at least one patient diagnosed before the age of 50, or (ii) three or more cases of 
DGC, independent of age of diagnosis.14 In the updated clinical guidelines of 2010, the HDGC 
criteria were broadened with the addition of two criteria: (iii) one DGC before the age of 40 
without a family history of GC and (iv) personal or family history of DGC and LBC one diagnosis 
before the age of 50; since CDH1 mutations were also detected in these patients.13 
The aim of this study was to examine the predictive value of the 2010 HDGC criteria for clini-
cal management. The CDH1 mutation detection rate was determined in a large set of families 
that had CDH1 mutation analysis in a diagnostic setting in the Netherlands. All tested individ-
uals were retrospectively classified according to the updated HDGC criteria. 
Methods
Patients 
In this study we included all individuals who were tested for germline CDH1 mutations be-
tween January 1999 and January 2014 in the genome diagnostic laboratory of the depart-
ment of Human Genetics, Radboud university medical center, Nijmegen, the Netherlands. All 
patients had received genetic counseling at one of the following national centers: the Neth-
erlands Cancer Institute (Amsterdam), VU University Medical Center (Amsterdam), University 
Medical Center Groningen (Groningen), University Medical Center Utrecht (Utrecht), Academic 
Medical Center (Amsterdam), Maastricht University Medical Center (Maastricht), Leiden Uni-
versity Medical Center (Leiden), Erasmus University Medical Center (Rotterdam) or Radboud 
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university medical center (Nijmegen). Testing for CDH1 mutations was performed after the 
indication for testing had been determined by a clinical geneticist, usually after a multidis-
ciplinary team meeting. It was, however, not required for cases to meet the recommended 
testing criteria. All participating persons consented to genetic testing. 
Mutation analysis
Genomic DNA was extracted from peripheral blood leukocytes (n=531) or from formalin-fixed 
paraffin-embedded tissue without neoplastic cells (n=47). The entire coding sequence of 
CDH1 (NM_004360), including splice junctions, was amplified using polymerase chain re-
action followed by Sanger sequencing using standard procedures. Primer sequences and 
PCR conditions are available on request. Furthermore, DNA extracted from peripheral blood 
leukocytes was tested with multiplex ligation probe-dependent amplification (MLPA) for the 
detection of exon deletions or duplications.
In silico predictions
Missense variants were analyzed using the Alamut 2.0 software package (Interactive Biosoft-
ware, Rouen, France), incorporating SIFT17, PolyPhen-218 and Align GVGD19 and dbSNP (build 
135). Intronic variants were analyzed using the Alamut 2.0 software package (Interactive 
Biosoftware), incorporating SpliceSiteFinder-like20, MaxEntScan21, NNSPLICE22 and Human 
Splicing Finder.23 The Exome Variant Server of the University of Washington24 that contains 
CDH1 sequencing data of approximately 6,500 individuals of European and African descent 
and our in-house exome sequencing database (accessed July 2014) that contains data of 
over 2,000 individuals, mainly of European descent, were used to assess whether variants 
were present in individuals without GC. Based on these analyses, variants were classified into 
five classes according to the system introduced by Plon et al.25
Data collection and analysis
For each family the index case was defined as the youngest patient with GC or LBC tested 
or the first relative tested if no affected cases were available for testing. The occurrence of 
cancer in the index and his/her first- and second-degree relatives had been documented by 
the genetic counselor. All available medical and pathology reports were reviewed. Whenever 
possible, gastric specimens were reviewed. Diagnoses were categorized according to the Lau-
rén26 and WHO27 classifications into intestinal-type (papillary, tubular, mucinous-intestinal), 
diffuse-type (signet ring cell, poorly cohesive, mucinous-diffuse), mixed-type or indeterminate 
GC (rare subtypes). All data were collected together with the mutation analysis results in 
an anonymized database. Subsequently, families were categorized into three categories: (a) 
index patients with a diagnosis of DGC or LBC or obligate carriers (concluded based on their 
position in the pedigree in relation to relatives with DGC) that fulfilled the HDGC criteria; (b) 
families that did not fulfill the HDGC criteria; and (c) families that could not be categorized 
either because the genetic test had been performed on DNA of an unaffected first-degree 
relative of a GC patient (no DNA available from an affected member) and/ or because of 
missing pathology data. Sensitivity, specificity, positive and negative predictive values were 
CHAPTER 2
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calculated combining test results (positive or negative) and categories ((a) fulfilling or (b&c) 
not-fulfilling criteria).
Results
Mutation detection and interpretation
CDH1 mutation analysis was performed in 578 individuals from 499 families. Fifteen dif-
ferent pathogenic CDH1 mutations were detected in 18 out of 499 families. All 13 frame-
shift, nonsense and canonical splice site mutations, detected in 15 families, were considered 
pathogenic (Table 1). In the other three families a likely pathogenic missense mutation was 
detected. The missense mutation c.2195G>A; p.(Arg732Gln) was identified in two families. 
This mutation activates a cryptic acceptor splice site in exon 14, leading to a deletion of 32 
base pairs in exon 14.15 This mutation has also been shown to segregate with the occurrence 
of GC and is therefore considered likely pathogenic.15,28 The missense mutation c.1748T>G; 
p.(Leu583Arg) was classified as a likely pathogenic mutation based on data from functional 
assays and the presence of mucosal signet ring cell carcinomas in prophylactic gastrectomies 
of two asymptomatic carriers of this variant.29 
In our cohort 11 other silent, missense and near splice site CDH1 variants detected in 19 
families were considered less likely to be pathogenic based on their frequency in control 
populations, their putative effect on splicing, in silico predictions of their effect on protein 
function or data from functional analyses (see Table 1 and Supplementary Table 1). 
Pathological review of gastric carcinomas
Gastric specimens of 229 patients from 172 families were reviewed. In 181 of 229 patients 
the Laurén and WHO classification could be obtained from the original pathology report. His-
tological review of gastric specimens confirmed the initial diagnosis in 175 patients (97%): 
33 intestinal-type GC, 136 diffuse-type GC and eight mixed type GC. In six patients the clas-
sification was altered: in two from DGC to mixed-type GC, in one from DGC into intestinal-type 
GC, and in three from intestinal-type GC to respectively DGC, mixed GC and indeterminate 
(medullary GC). For 48 patients the histological classification could not be derived from orig-
inal pathology reports (no classification other than “adenocarcinoma”) and was completely 
dependent on the review of the gastric specimen (18 intestinal, 27 diffuse, 1 mixed and 2 
indeterminate type GC). 
Specimens of the remaining 279 families with a diagnosis of GC were not available for re-
view: 49 intestinal, 133 diffuse, 9 mixed, 1 indeterminate (EBV-associated lymphoepitheli-
oma-like), 82 unknown. As the concordance between initial diagnosis and review was 97%, 
for these patients the original pathology reports were used for categorization of the families.
Categorization of families and correlation with genotype data 
Based on the medical records and pathology data all families were assigned into one of three 
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categories (Table 2): (a) 118 families fulfilled the HDGC criteria; (b) 242 families did not fulfill 
the HDGC criteria; and (c) 139 families could not be categorized either because the genetic 
test had been performed on DNA of an unaffected first-degree relative of a GC patient (no 
DNA available from an affected member, n=25) and/or because of missing pathology data 
(n=114).
Sixteen of 18 (89%) CDH1 mutations were identified in families fulfilling the HDGC criteria 
as set in 2010 based on index patients with a diagnosis of DGC or LBC or obligate carriers 
(concluded based on their position in the pedigree in relation to relatives with DGC). Thirteen 
mutations were found in the 63 families (21%) fulfilling the original HDGC criteria14 and an 
additional three mutations were found in 55 families (5%) that were included based on the 
criteria that were added in 2010.13 One family with a CDH1 mutation did not fulfill the HDGC 
criteria 2010 as the mutation was found in a patient with DGC at age 45 with a negative 
four-generation family history. The parents and two siblings of the patient were not tested, 
therefore a de novo mutation cannot be excluded. One other family with a CDH1 mutation 
could not be formally classified, because of the lack of medical and pathological data to con-
firm the GC diagnosed at age 32 in the parent of the index patient who herself had been diag-
nosed with DGC at age 59 and with ductal breast cancer at age 56. This is a relatively small 
but highly suspect nuclear family (index patient without siblings). The detailed five-generation 
family pedigree also mentioned a third-degree relative who died of gastric cancer at age 40. 
No pathogenic germline CDH1 mutations were found in 93 families with intestinal-type 
non-cardiac GC, or with a combination of relatives with intestinal-type GC, DGC and/or mixed-
type GC. Also no CDH1 mutations were found in 20 families with exclusively LBC without DGC, 
nor in six families with young onset of signet ring cell colorectal cancer.
Discussion
Germline CDH1 mutations were detected in 4% of the 499 families that were referred for test-
ing by a clinical geneticist based on the suspicion of GC predisposition. The CDH1 mutation 
detection rate in families that met the HDGC criteria was 14% (16 of 118 families). Our results 
are in agreement with a previous report on CDH1 mutation testing in a diagnostic setting, in 
which a detection rate of 18% (11/61 families) was reported.30
The current HDGC criteria and accompanying mutation detection rates of 30-50% are based 
on small, highly selected series of GC patients.15,16,28,31,32 Most of these studies were pub-
lished before 2010 and included families that fulfilled the original strict HDGC criteria: (i) two 
or more GC in first-degree relatives with at least one DGC diagnosed before age 50 or; (ii) 
three or more DGC in first-degree relatives diagnosed at any age. For these two criteria the 
CDH1 mutation detection rate in our cohort is 21% (13/63). This lower mutation detection 
rate might be due to lack of a founder mutation, the diagnostic setting with a low bias towards 
highly suspected families, and a strict categorization of missense mutations leading to less 
HEREDITARY DIFFUSE GASTRIC CANCER AND CDH1
42
CHAPTER 2
 
1
 
 Ta
b
le
 2
. 
C
la
ss
if
ic
a
ti
o
n
 o
f 
fa
m
ili
e
s 
th
a
t 
h
a
d
 C
D
H
1
 m
u
ta
ti
o
n
 a
n
a
ly
si
s 
C
ri
te
ri
a
 
N
o
. 
o
f 
fa
m
il
ie
s 
te
st
e
d
 
M
u
ta
ti
o
n
s
 
M
u
ta
ti
o
n
 d
e
te
c
ti
o
n
 r
a
te
 (
%
) 
M
e
e
ti
n
g
 H
D
G
C
 c
ri
te
ri
a
 2
0
1
0
*
 
≥
2
 G
C
, 
1
 D
G
C
 <
5
0
 y
e
a
rs
 
5
3
 
8
 
1
5
.1
 
3
 D
G
C
 a
n
y 
a
g
e
 
1
0
 
5
 
5
0
.0
 
1
 D
G
C
 <
4
0
 y
e
a
rs
 
4
1
 
2
 
4
.9
 
D
G
C
 a
n
d
 L
B
C
, 
1
<
5
0
 y
e
a
rs
 
1
4
 
1
 
7
.1
 
N
o
t-
m
e
e
ti
n
g
 H
D
G
C
 c
ri
te
ri
a
 2
0
1
0
 
D
G
C
*
*
 
1
 D
G
C
 >
4
0
 y
e
a
rs
  
2
 D
G
C
 >
5
0
 y
e
a
rs
 
D
G
C
 a
n
d
 L
B
C
 >
5
0
 y
e
a
rs
 
3
6
 
3
1
 
2
 
3
 
1
 
1
 
0
 
0
 
2
.8
 
3
.2
 
0
.0
 
0
.0
 
(F
)I
G
C
 o
r 
m
ix
e
d
 G
C
*
*
 
F
IG
C
 (
≥
2
 I
G
C
, 
1
 <
5
0
 y
e
a
rs
 o
r 
≥
3
 I
G
C
) 
1
 I
G
C
 o
r 
m
ix
e
d
 G
C
 <
4
0
 y
e
a
rs
 
O
th
e
r 
 
9
3
 
4
3
 
1
2
 
3
8
 
0
 
0
 
0
 
0
 
0
.0
 
0
.0
 
0
.0
 
0
.0
 
F
a
m
ily
 a
n
d
/o
r 
p
e
rs
o
n
a
l 
h
is
to
ry
 o
f 
L
B
C
*
*
 
≥
2
 L
B
C
 <
5
0
 y
e
a
rs
 
≥
1
 L
B
C
, 
a
n
y 
a
g
e
 
2
0
 
5
 
1
5
 
0
 
0
 
0
 
0
.0
 
0
.0
 
0
.0
 
O
th
e
r 
In
d
e
x 
u
n
k
n
o
w
n
 p
ri
m
a
ry
 c
a
n
ce
r 
<
4
0
 y
e
a
rs
 
In
d
e
x 
si
g
n
e
t 
ri
n
g
 c
e
ll 
co
lo
re
ct
a
l 
ca
n
ce
r 
<
4
0
 y
e
a
rs
 
In
d
e
x 
in
te
st
in
a
l-
ty
p
e
 a
d
e
n
o
ca
rc
in
o
m
a
 e
so
p
h
a
g
u
s 
<
4
0
 y
e
a
rs
 
F
a
m
ily
 a
n
d
/o
r 
p
e
rs
o
n
a
l 
h
is
to
ry
 o
f 
d
u
ct
a
l 
B
C
 a
n
d
 D
G
C
 
R
e
st
 g
ro
u
p
 
9
3
 
6
 
6
 
7
 
2
6
 
4
8
 
0
 
0
 
0
 
0
 
0
 
0
 
0
.0
 
0
.0
 
0
.0
 
0
.0
 
0
.0
 
0
.0
 
In
co
m
p
le
te
 c
lin
ic
o
p
a
th
o
lo
g
ic
a
l 
d
a
ta
 f
o
r 
H
D
G
C
 c
ri
te
ri
a
 2
0
1
0
 
In
d
e
x 
w
it
h
 D
G
C
 o
r 
L
B
C
, 
in
co
m
p
le
te
 p
a
th
o
lo
g
y 
d
a
ta
 o
f 
re
la
ti
ve
s 
In
d
e
x 
w
it
h
o
u
t 
D
G
C
 o
r 
L
B
C
 (
F
D
R
),
 f
a
m
ily
 m
e
e
ts
 H
D
G
C
 c
ri
te
ri
a
 
In
d
e
x 
w
it
h
o
u
t 
D
G
C
 o
r 
L
B
C
 (
F
D
R
),
 in
co
m
p
le
te
 p
a
th
o
lo
g
y 
d
a
ta
 o
f 
re
la
ti
ve
s
 
8
0
 
2
5
 
3
4
 
1
 
0
 
0
 
1
.3
 
0
.0
 
0
.0
 
T
o
ta
l 
4
9
9
 
1
8
 
3
.6
 
 
Ab
br
ev
ia
tio
ns
: G
C=
 g
as
tr
ic
 c
an
ce
r; 
H
D
G
C=
 h
er
ed
ita
ry
 d
iff
us
e 
ga
st
ric
 c
an
ce
r; 
D
G
C=
 d
iff
us
e 
ga
st
ric
 c
an
ce
r;
 (F
)IG
C=
 (f
am
ili
al
) i
nt
es
tin
al
 g
as
tr
ic
 c
an
ce
r;
 B
C=
 
br
ea
st
 c
an
ce
r; 
LB
C=
 lo
bu
la
r b
re
as
t c
an
ce
r; 
FD
R
=
 fi
rs
t-d
eg
re
e 
re
la
tiv
e.
 *
In
de
x 
pa
tie
nt
s 
w
ith
 a
 d
ia
gn
os
is
 o
f D
G
C 
or
 L
B
C 
an
d 
ob
lig
at
e 
ca
rr
ie
rs
 w
er
e 
in
cl
ud
ed
 
in
 th
is
 g
ro
up
. *
*
In
de
x 
pa
tie
nt
s 
w
ith
 a
 d
ia
gn
os
is
 o
f G
C 
or
 B
C 
w
er
e 
in
cl
ud
ed
43
variants being classified as pathogenic or likely pathogenic. In 2010, two additional HDGC 
selection criteria were added: inclusion of individuals with DGC before the age of 40 without 
a family history, and inclusion of individuals and families with diagnoses of both DGC and 
LBC (one case below the age of 50).13 For these two additional criteria, when present without 
presence of the original criteria, our mutation detection rate was 5% (3/55), while the detec-
tion rate in families with sufficient histology data but meeting none of the HDGC selection 
criteria was only 0.4% (1/242). By broadening the criteria in 2010 three out of five mutation 
positive families that would have been missed based on the original criteria are detected, at 
the expense of a decrease in mutation detection rate from 20 to 14%. 
The ability to apply the HDGC criteria largely depends on the histological diagnosis. In our 
setting the original histological classification was concordant with that of the review in 97% 
(175/181). However in 21% of the available pathology specimens the histological type of 
GC was missing in the original report. The introduction of pro-format pathology reporting will 
probably reduce this issue in the near future. No CDH1 mutation was detected in 93 families 
that presented with intestinal-type non-cardiac GC and only one CDH1 mutation was detected 
in the 80 families that could not be classified because of shortage of pathological data only, 
demonstrating the merit of selecting patients with diffuse-type GC for mutation testing. 
In our cohort almost all CDH1-mutation families fulfilled the HDGC criteria as defined in 2010 
(16/18). In contrast, Benusiglio et al. found that 39% of mutation carriers did not fulfill the 
HDGC criteria.30 They and other studies reported germline CDH1 mutations in families with 
exclusively lobular breast cancer (LBC) without DGC.30,33-35 Based on these data, Petridis et al. 
and Benusiglio et al., advise CDH1 mutation screening in women with bilateral LBC and/or 
lobular carcinoma in situ without a family history of GC.30,35 In our cohort no pathogenic CDH1 
mutations were detected in 20 LBC families without DGC (five of them with two LBC’s under 
the age of 50). Schrader et al. screened 318 women with early-onset LBC or familial LBC for 
CDH1 mutations and found only four variants of uncertain significance. Therefore, they con-
cluded that CDH1 mutations are at most infrequent in this group.36 
A positive family history is a strong and consistently reported risk factor for GC; CDH1 is the 
most important DGC susceptibility gene. There are small numbers of GC families reported 
with germline mutations in DNA mismatch repair genes, CTNNA1, TP53, APC, BRCA1, BRCA2, 
STK11 and PTEN, but the molecular basis for familial aggregation of GC remains largely un-
known.37-43 The endoscopic surveillance strategy for families that fulfill the HDGC criteria, but 
in whom no pathogenic mutation can be identified, is complicated. The IGCLC recommends 
annual intensive endoscopic screening with extensive biopsy taking (>30) in an expert cen-
tre.13 This way, Lim et al. reported signet ring cell carcinomas in 2/7 CDH1 mutation negative 
individuals.44 Also in another study by Majewski and Kluijt et al. endoscopic screening led to 
the detection of intramucosal signet ring cells in four individuals from a large family without a 
pathogenic CDH1 mutation.37 Because of these findings, exome sequencing was performed 
which led to the identification of a germline CTNNA1 mutation in this family.37 However, focal 
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signet ring cell carcinoma are endoscopically difficult to visualize and patients who opt to 
undergo endoscopic screening should be informed that gastroduodenoscopy with random 
biopsies is not 100% accurate in detecting focal lesions. 
Taken together, this study shows both the strengths and limitations of the current HDGC crite-
ria. Despite the positive predictive value of only 14%, the HDGC criteria have a high sensitivity 
of 89% and a high negative predictive value of 99% for finding a CDH1 mutation. Confirmation 
of diffuse-type gastric cancer is an important requisite to select patients eligible for CDH1 
mutation analysis. However, we feel that the lack of data on pathological classification should 
not prohibit families from being tested, especially when nowadays these tests become less 
expensive. If the histological GC subclassification is known, the HDGC criteria of 2010 seem 
to be an adequate tool for clinical geneticists to select patients for CDH1 mutation analysis. 
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Abstract
Orofacial clefts (OFC) are among the most common birth defects worldwide. The etiology of 
non-syndromic OFC is still largely unknown. During embryonic development, the cell adhesion 
molecule E-cadherin, encoded by CDH1, is highly expressed in the median edge epithelium of 
the palate. Furthermore, in multiple families with CDH1 mutations, OFC cases are observed. 
To determine whether CDH1 is a causative gene for non-syndromic OFC and to assess wheth-
er CDH1 mutation screening in non-syndromic OFC patients enables identification of families 
at risk of cancer, direct sequencing of the full coding sequence of CDH1 was performed in 
a cohort of 81 children with non-syndromic OFC. Eleven children had heterozygous CDH1 
sequence variants, 5 cases with 4 distinct missense mutations and 8 cases with 4 intronic 
variants. Using a combination of in silico predictions and in vitro functional assays, three 
missense mutations in four non-syndromic OFC patients were predicted to be damaging to 
E-cadherin protein function. The intronic variants, including one tested in an in vitro assay, 
appeared to be benign, showing no influence on splicing. Functionally relevant heterozygous 
CDH1 missense mutations were found in 4 out of 81 (5%) patients with non-syndromic OFC. 
This finding opens a new pathway to reveal the molecular basis of non-syndromic OFC. Cancer 
risk among carriers of these mutations needs to be defined.
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Introduction
Orofacial clefts (OFC) are among the most common birth defects worldwide.1 They have a 
major clinical impact requiring surgical, dental, orthodontic, speech, hearing and psychologic 
treatments. Two types of OFC exist, cleft lip with or without cleft palate (CLP) and cleft pal-
ate only (CP).1 Recently, advances have been made in the identification of causative genetic 
mutations underlying syndromic forms of OFC. The etiology of non-syndromic OFC, however, 
is still largely unknown.2 A meta-analysis of genome-wide association studies has confirmed 
and identified several loci that are implicated in the etiology of non-syndromic OFC, but the 
specific causal variants on these loci remain to be identified.3 Determining the relative risk of 
non-syndromic OFC based on genetic background will be useful for genetic counseling and 
development of future preventive measures.
The fusion of the palate is the result of complex cell–cell interactions that are controlled 
by structural and regulatory proteins.4 The CDH1 gene encodes the cell adhesion molecule 
E-cadherin, which is essential for the establishment of intercellular junction complexes and 
required for the adhesive properties of epithelial cells.5 E-cadherin is highly expressed in the 
frontonasal prominence in the fourth and fifth week and in the lateral and medial nasal prom-
inences in the sixth week of human embryogenesis, showing that it is expressed during the 
critical stages of lip and palate development.6 
Inactivating germline mutations in CDH1 are rare and tightly associated with hereditary dif-
fuse gastric cancer (HDGC, OMIM: 137215), an autosomal dominant cancer predisposition 
syndrome.7 HDGC is characterized by the presence of invasive diffuse signet ring cells and 
accounts for 1–3% of all gastric cancers.8 Carriers of a CDH1 mutation are counseled to have 
a high lifetime risk of developing diffuse gastric cancer (DGC) of up to 80%.9,10 In addition to 
the risk of DGC, female CDH1 mutation carriers are counseled to have a 60% lifetime risk of 
developing lobular breast cancer (LBC).10 Due to the lack of effective surveillance programs, 
the absence of preneoplastic lesions, and the highly invasive behavior of this type of cancer, 
prophylactic gastrectomy is currently advised to adult carriers of mutations in CDH1 to elimi-
nate the risk of lethality in this gastric cancer (GC) syndrome.11-14 
Contradictory results have been published on the risk of cancer in individuals with OFC.15-19 
An overrepresentation of OFC patients was observed in CDH1 mutation carriers.6 OFC were 
reported in two HDGC families with germline CDH1 mutations, and in one family, CDH1 mu-
tations cosegregated with DGC and OFC.6 The association between OFC and CDH1 was later 
supported by Kluijt et al.20, who reported the occurrence of OFC in seven individuals from 
three HDGC families carrying a CDH1 mutation. Functionally relevant mutations in CDH1 have 
not yet been described in non-syndromic OFC patients, although non-coding polymorphisms 
at the CDH1 locus were found in such patients.21,22 
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In conclusion, the clinical and genetic evidence suggests that CDH1 is a susceptibility gene 
for non-syndromic OFC. Thus, we decided to study, for the first time, the relevance of germline 
CDH1 mutations in a cohort of 81 children with non-syndromic OFC with unknown family 
history of HDGC.
Results
CDH1 mutation analysis and in silico analyses
In the current study, 81 patients with non-syndromic OFC were screened for CDH1 mutations. 
Eleven patients presented heterozygous CDH1 sequence variants. Four distinct missense 
and four intronic variants were identified, which are shown in Tables 1 and 2, respectively.
All sequence variants were initially studied using in silico predictions. Afterwards, the ones 
with a putative impact on E-cadherin function (three missense and one intronic variant) were 
further analyzed using various in vitro functional assays. 
The variant c.88C>A (p.Pro30Thr) was detected in two CLP patients. In silico predictions of 
the impact of the p.Pro30Thr variant varied between the different programs used. Although 
SIFT and AlignGVGD predicted this variant to be tolerated, PolyPhen predicted this variant to 
be possibly damaging to protein function. Structural modeling of the variant using FoldX pre-
dicted this variant to impact the total energy of the protein, inducing destabilization (ΔΔG = 
1.35 kcal/mol). Based on SIFT, PolyPhen and AlignGVGD predictions, the variant c.1108G>T 
(p.Asp370Tyr), found in one patient with CLP, is predicted to interfere with E-cadherin func-
tion. Structural modeling using FoldX suggests that this amino acid alteration leads to the 
establishment of an additional H-bond in the calcium coordination site between EC2-EC3, 
resulting in a decrease in the total energy (ΔΔG = -1.36 kcal/mol) of the protein. 
Although the variant c.2413G>A (p.Asp805Asn), identified in a patient with CP, seems to be 
structurally tolerated (ΔΔG = 0.02 kcal/mol), the SIFT, PolyPhen and AlignGVGD algorithms 
predict a pathogenic effect of this variant. 
The intronic variant c.531+3A>G might interfere with the recognition of the splice donor site 
of exon 4, although not all splice site-prediction programs are consistent. 
For the variant c.337A>G, none of the programs predicted a functional impact. This was also 
the case for all the other intronic variants that were identified. Thus, functional assays were 
limited to the missense variants p.Pro30Thr, p.Asp805Asn and p.Asp370Tyr and the intronic 
variant c.531+3A>G.
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In vitro functional assays for identified missense variants
To test the functional significance of the missense variants, Chinese Hamster Ovary (CHO) 
cells were transiently transfected with constructs encoding the wild-type (WT) protein and 
the different variants, as well as the empty vector (Mock). Transfected cells were analyzed 
for cell–cell adhesion competence, invasive capacity and E-cadherin expression levels and 
subcellular localization. 
The slow aggregation assay showed that all three missense variants had an impact on cell–
cell adhesion ability, but the type of aggregation showed distinct phenotypes (Figure 1A). 
When compared with the aggregates formed by the WT E-cadherin-expressing cells, the vari-
ants p.Pro30Thr and p.Asp805Asn displayed smaller cellular aggregates, whereas the variant 
p.Asp370Tyr completely abrogated cell–cell adhesion and exhibited an isolated phenotype, 
similar to the phenotype of Mock-transfected cells. 
The invasion assay revealed that, contrary to the cells expressing WT E-cadherin, the variant 
p.Asp370Tyr has lost the ability to suppress cell invasion through a Matrigel matrix (P=0.0078) 
(Figure 1B), indicating that this variant is more invasive than the WT-expressing cells.
Analyzing total E-cadherin expression by Western Blot, it seems that the variants p.Pro30Thr, 
p.Asp370Tyr and p.Asp805Asn do not interfere with the total amount of E-cadherin expressed 
in the cell (Figure 1D). However, using immunostaining, abnormal E-cadherin localization was 
observed (Figure 1C). Whereas WT E-cadherin was correctly located at the plasma mem-
brane, the variants p.Pro30Thr, p.Asp370Tyr and p.Asp805Asn presented reduced membra-
nous E-cadherin expression. 
Taken together, the in vitro results indicate that the variants p.Pro30Thr, p.Asp370Tyr and 
p.Asp805Asn affect E-cadherin protein function and its subcellular localization and thus can 
be considered as relevant mutations. The mutation p.Asp370Tyr shows the most dramatic 
impact on E-cadherin function.
In vitro functional assays for the c.531+3A>G intronic variant
To determine the possible effect on splicing, we transfected HeLa cells with a construct con-
taining the CDH1 variant c.531+3A>G flanked by exons 3 and 5 of RHO. A cycloheximide con-
trol was used to suppress nonsense-mediated decay of a possible aberrant transcript. Twen-
ty-four hours after transfection, RNA was isolated from transfected cells and a polymerase 
chain reaction (PCR) was performed with primers in the RHO exons. No indication of an al-
tered splicing of CDH1 intron 4 for the construct with the c.531+3A>G variant was obtained.
Discussion
To the best of our knowledge, this is the first report of a systematic analysis of CDH1 muta-
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tions in a consecutive series of non-syndromic OFC patients with an unknown family history 
of GC and/or LBC. We detected heterozygous CDH1 missense variants in 4 out of 81 (5%) pa-
tients. In vitro assays confirmed the functional impact of these variants, which can, therefore, 
be considered as relevant mutations. The data obtained in our study support the hypothesis 
that germline CDH1 mutations increase the risk of non-syndromic OFC. 
The functional effect of missense variants is usually assessed using in silico prediction pro-
grams. Although in silico predictions are very useful and easy to perform, their potential is 
limited to amino acid conservation and the available structural information. In contrast to in 
silico predictions, in vitro assays allow to study the functional behavior of the cells with alter-
ations in the protein in comparison to the WT form. Furthermore, immunocytochemistry analy-
sis enables us to visualize the pattern of protein expression and localization and evaluate how 
the protein is affected in terms of trafficking and membrane expression. 
The limitations of in silico predictions are underscored by the fact that two of the identified 
missense variants, p.Pro30Thr and p.Asp805Asn, for which in silico prediction programs were 
inconclusive, indeed seem to affect E-cadherin function and subcellular localization in our in 
vitro studies. For the p.Pro30Thr variant, the observed effect might be due to the localization 
of the variant in the prodomain. This may affect the processing to the mature form, possi-
bly leading to degradation by endoplasmic reticulum-associated degradation, as described 
for other E-cadherin missense mutations.23,24 Interestingly, p.Pro30Thr has been described 
before in a cohort of patients with LBC, but based only on in silico analyses, the variant was 
considered non-causative.25 However, based on our functional analyses, we conclude that 
this variant affects E-cadherin function and relates to OFC. In light of this new information, 
its role in development of LBC might be reconsidered. The localization in the cytoplasmic tail 
of the variant p.Asp805Asn could impair the binding of other molecular partners, resulting in 
trafficking defects, abnormal cellular signaling or inefficient anchorage to the cytoskeleton, 
as described for other HDGC-associated missense mutations localized in proximity.26,27 The 
change of an Aspartic acid to a Tyrosine at amino acid 370 possibly leads to altered calcium 
affinity. This could result in the establishment of an aberrant conformation, justifying the loss 
of adhesive function observed for this variant in our aggregation assay. 
In our cohort, two patients with CLP carry a p.Pro30Thr mutation. One of these patients 
self-reported a first-degree relative with CLP, the other patient reported a third-degree rela-
tive with OFC. Segregation analysis is needed to confirm whether affected relatives carry the 
CDH1 mutation. OFC were not reported in relatives of the patient carrying the p.Asp370Tyr 
variant. The family history of the patient carrying the p.Asp805Asn variant is unknown. These 
data suggest that the penetrance of developing OFC in subjects with a CDH1 mutation is 
incomplete. This is similar to what has been reported earlier in five CDH1 mutation-positive 
HDGC families with one or multiple cases of OFC.6,20 
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The incomplete penetrance of OFC in CDH1 families suggests that apart from a genetic pre-
disposition, environmental or other genetic factors may be involved in the occurrence of OFC 
in CDH1 mutation carriers. Several studies have shown that drinking alcohol28,29, smoking30,31 
and a lack of folate32,33 during pregnancy may increase the risk of OFC. The 11 chromosomal 
loci, that did not include CDH1, identified in genome-wide association studies of non-syn-
dromic OFC serve as good candidates for harboring genetic modifiers of the CDH1-associated 
risk of OFC.3,34
In HDGC families with CDH1 mutations, missense mutations occur in ~22% of the cases, and 
truncating mutations in about 78%.35 Lifetime risk of developing GC in individuals carrying a 
truncating germline CDH1 mutation has been estimated to be 80% by the age of 80, and the 
risk for women with a CDH1 mutation of developing LBC has been estimated to be 60% by the 
age of 80.9,10 Systematic analysis of the risk of developing GC or LBC for missense mutations 
that affect E- cadherin function has not been described. Therefore, it is not known whether 
the mutation carriers that we identified in this non-syndromic OFC cohort are at increased risk 
of developing GC and LBC. The family history of CDH1-associated cancer types of the muta-
tion carriers identified in our non-syndromic OFC cohort is not yet available.
In conclusion, three functionally relevant missense mutations in CDH1 were identified in four 
patients with non-syndromic OFC. Before we can start implementing CDH1 mutation anal-
ysis in the standard diagnostic work-up of patients with nonsyndromic OFC, a larger study 
is needed to confirm the findings of the current study. Moreover, calculation of cancer risks 
among carriers of functionally relevant missense CDH1 mutation carriers is needed to assess 
whether prophylactic gastrectomy, which is currently the only option to prevent death from 
GC, should be considered in non-syndromic OFC patients with a missense mutation in CDH1. 
Materials and methods
Patients
DNA was isolated from peripheral blood samples from 81 nonsyndromic OFC patients from 
the Aetiologic research into Genetic and Occupational/Environmental Risk Factors for Anom-
alies in Children (AGORA) study, that is a large Biobank at the Radboud University Nijmegen 
Medical Centre collecting questionnaires, phenotype data and DNA from patients diagnosed 
with congenital disorders or childhood cancers. Children in AGORA who had surgery for a cleft 
lip or a CLP were included. The majority of children in our cohort were of European descent 
and born between 1997 and 2011. Fifty-eight patients had CLP and 23 had an isolated CP. 
All parents received questionnaires, with questions about demographic factors, family history 
of birth defects, cancer history of the parents, periconceptional information and pregnancy 
history. In addition, questions were asked about health status, prescribed medication, life-
style and occupation pertaining to the 3 months before conception and during pregnancy.
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The study was performed according to the rules of the Medical Ethics Committee of the Rad-
boud University Nijmegen Medical Centre, registration number 2006/048. As CDH1 is a 
known tumor-suppressor gene, the DNA samples were anonymized. 
Mutation analysis
The full coding sequence of CDH1 (NM_004360.3), including splice junctions, was amplified 
using polymerase chain reaction (primer sequences and PCR conditions are available on 
request) and screened for mutations using Big-Dye terminator sequencing (BigDye Termina-
tors (v 1.1) Applied Biosystems, USA). Analysis was performed on an ABI 3730 DNA Analyzer 
(Applied Biosystems). Subsequently, data were analyzed for variants in CDH1 using Sequence 
Pilot software (JSI Medical Systems, Germany). 
In silico predictions
Missense variants were analyzed using the Alamut 2.0 software package (Interactive Bio-
software, Rouen, France) incorporating SIFT36, PolyPhen-237 and Align GVGD.38 Furthermore, 
FoldX (http://foldx.crg.es/) was used to predict the structural impact of E- cadherin missense 
mutations, as described by Simões-Correia et al.23 The previously established models of the 
different domains of E-cadherin (prodomain, extracellular and cytoplasmic domain) were 
used to calculate the total energies of the variants. The variants were generated with the 
Buildmodel command, and each variant was repeated in five runs. The energies are an auto-
matic output in FoldX, and the native-state stability change between WT and mutant (ΔΔG = 
ΔGWT–ΔGMut) is also generated in a separate file, with the corresponding standard deviations 
and all the energetic penalties associated with each mutation. Mutations with ΔΔG>0.8 kcal/
mol are considered destabilizing. 
Intronic variants were analyzed using the Alamut 2.0 software package (Interactive Biosoft-
ware), incorporating SpliceSiteFinder-like39, MaxEntScan40, NNSPLICE41 and Human Splicing 
Finder.42 
To assess whether variants were present in individuals without OFC, we used the Exome Vari-
ant Server of the University of Washington43 that contains CDH1 sequencing data of 6,500 
individuals of European and African descent and our own in-house exome sequencing da-
tabase (accessed July 2012), which contains data of over 1,000 individuals, mainly of Eu-
ropean descent. Finally, we used dbSNP (incorporated in the Alamut package, Build 135, 
accessed July 2012) to assess whether identified variants were recurrent. 
Plasmids construction
Human E-cadherin cDNA was cloned in the pIRES2-EGFP vector according to the manufactur-
er’s instructions (Clontech, Takara Bio, Mountain View, CA, USA), and the variants c.88C>A 
(p.Pro30Thr), c.1108G>T (p.Asp370Tyr) and c.2413G>A (p.Asp805Asn) were constructed by 
site-directed mutagenesis, following the protocol described by Wang and Wilkinson.44 The 
empty vector was used as control. 
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Cell culture and transfection 
CHO cells (ATCC number: CCL-61, Barcelona, Spain) were grown at 37⁰C under 5% CO2 humid-
ified air, in α-minimum essential medium (MEM) (+) medium (Gibco, Invitrogen, Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum (HyClone, Perbio, Cramlington, UK) and 
1% penicillin/streptomycin (Gibco, Invitrogen, Grand Island, NY, USA). Cells were transiently 
transfected with the following vectors: empty vector (Mock), WT, p.Pro30Thr, p.Asp370Tyr and 
p.Asp805Asn hE-cad, using Lipofectamine 2000 (Invitrogen, Van Allen Way, Carlsbad, CA, 
USA), according to the manufacturer’s protocol. The transfection efficiency of each exper-
iment was evaluated by flow cytometry measuring green fluorescent protein fluorescence.
Slow aggregation assay
The functional significance of the E-cadherin missense mutations was assessed by a slow 
aggregation assay as described in Suriano et al.45 A 96-well-plate was coated with 50 μl of 
agar solution (100 mg of Bacto-Agar in 15 ml of sterile PBS). Cells were detached with trypsin, 
resuspended in culture medium, and 2 × 104 cells were seeded in each well. The plate was in-
cubated at 37⁰C in a humidified atmosphere with 5% CO2 for 24 h. Aggregation was evaluated 
under an inverted microscope (4× objective) and photographed with a Nikon digital camera 
(Nikon, Tokyo, Japan). Experiments were performed in triplicate.
Matrigel invasion assay
For invasion assays, 24-well matrigel invasion chambers (BD Biocoat, Erembodegem, Bel-
gium) were hydrated by filling the inner and outer compartments with α-MEM medium and 
incubating them for 1 h at 37⁰C. Cells were detached with trypsin, resuspended in culture 
medium, and 5 × 104 cells were seeded in each chamber. The plate was incubated at 37⁰C in 
a humidified atmosphere with 5% CO2 for 24 h. The non-invasive cells and matrigel from the 
upper side of the filters were removed with a prewet ‘cotton swab.’ The filters were washed in 
PBS, fixed in ice-cold methanol for 15 min and mounted in slides with Vectashield with 4′,6-di-
amidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA). The total number 
of invasive nuclei was counted using a Leica DM2000 microscope (Leica, Cambridge, UK).
Immunofluorescence staining
Cells were seeded on top of glass coverslips, and fixation was performed in ice-cold methanol 
for 20 min, followed by washing and blocking in 5% BSA in PBS for 30 min at room tempera-
ture. The mouse monoclonal E-cadherin antibody (BD Biosciences, Erembodegem, Belgium) 
was used at 1:300 dilution in PBS with 5% BSA and incubated at room temperature for 1 h. 
An Alexa Fluor 488 goat anti-mouse antibody (1:500, Invitrogen, Eugene, Oregon, USA) was 
applied as secondary antibody and incubated in the dark for 1 h. Coverslips were mounted 
on slides using Vectashield with DAPI (Vector Laboratories, Burlingame, CA, USA). Images 
were acquired on a Carl Zeiss Apotome Axiovert 200M Fluorescence Microscope using 40× 
objective (Carl Zeiss, Jena, Germany). Images were taken with an Axiocam HRm camera and 
processed with the Zeiss Axion Vision 4.8 software.
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Western blotting
Cells were lyzed in cold Catenin lysis buffer (1% Triton X-100, Sigma, St Louis, MO, USA), 1% 
Nonidet P-40 (Sigma) in PBS, enriched with a protease inhibitor cocktail (Roche, Indianapolis, 
IN, USA) and a phosphatase inhibitor cocktail (Sigma). The proteins were quantified using a 
modified Bradford assay (Bio-Rad, Hercules, CA, USA). For analysis of total protein samples, 
15 μg of proteins were eluted in sample buffer and loaded on a 7.5% SDS PAGE. The proteins 
were then electroblotted onto a Hybond ECL membrane (Amersham Biosciences, Bucking-
hamshire, UK). Membranes were blocked with 5% non-fat milk and 0.5% Tween-20 in PBS 
and immunoblotted with antibodies against E-cadherin (1:2000, Clone HECD1 Invitrogen, 
Camarillo, CA, USA) and α-tubulin (1:10 000, Sigma, St Louis, MO, USA). Sheep anti-mouse 
HRP-conjugated secondary antibody (Amersham Biosciences) was used, followed by ECL de-
tection (Amersham Biosciences). 
Statistical analysis
Two-tailed Student’s t-test was used to compare the number of invasive cells between the cell 
culture of the variants and that of the WT. In all analyses P < 0.05 was required for statistical 
significance.
Functional analysis of intronic variants
A plasmid containing the genomic region encompassing exons 3 to 5 of RHO inserted at the 
EcoRI/SalI sites in the pCI-NEO vector46 was adapted to the Gateway cloning system and used 
for in vivo splicing assays. The plasmid was digested with EcoNI and PflMI (New England Bio-
labs, USA), resulting in the removal of exon 4 and part of the flanking intronic sequences and 
blunted using Large fragment Klenow DNA polymerase I (New England Biolabs), according to 
the manufacturer’s instructions. Subsequently, a blunt-end Gateway cloning cassette contain-
ing attR1 and attR2 sites and the pCI-neo vector were ligated using the Rapid DNA Ligation Kit 
(Roche, Germany) to generate pCI-NEO-RHO exon3,5\DEST. 
PCR fragments containing exons 4 and 5 of CDH1 and surrounding intronic sequences were 
amplified from genomic DNA of the patient carrying the c.531+3A>G variant and a WT control 
using primers with attB sites. Using Gateway cloning technology (Invitrogen, USA), the attB-
PCR product was cloned into pDONR201, sequence verified and subcloned in pCI-NEO-RHO 
exon3,5\DEST.
HeLa cells were transfected with 1 μg of plasmid DNA, using X-tremeGENE HP DNA Trans-
fection Agent (Roche Applied Science, USA), according to the manufacturer’s protocol. After 
transfection, the cells were incubated at 37⁰C under 5% CO2 humidified air for 24 h, the last 
4 h in the presence or absence of cyclohexamide (100 mg/ml), and RNA isolation was per-
formed using the RNAeasy RNA Mini Kit (Qiagen Benelux BV), according to the manufacturer’s 
protocol. RNA was reverse transcribed into cDNA according to standard procedures using 
random hexamer primers.
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The RHO and CDH1 exons were amplified from the cDNA with forward primer 5′-cggaggt-
caacaacgagtct-3′ and reverse primer 5′-aggtgtaggggatgggagac-3′, which are located in RHO 
exon 3 and exon 5, respectively (PCR conditions available on request). The PCR product was 
sequenced as described above.
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Abstract
Germline CDH1 mutations confer a high lifetime risk of developing diffuse gastric (DGC) and 
lobular breast cancer (LBC). A multidisciplinary workshop was organized to discuss genetic 
testing, surgery, surveillance strategies, pathology reporting and the patient’s perspective 
on multiple aspects, including diet post-gastrectomy. The updated guidelines include revised 
CDH1 testing criteria (taking into account first- and second-degree relatives): (1) families with 
two or more gastric cancer patients at any age, one confirmed DGC; (2) individuals with DGC 
before the age of 40 and (3) families with diagnoses of both DGC and LBC (one diagnosis be-
fore the age of 50). Additionally, CDH1 testing could be considered in: patients with bilateral 
or familial LBC before the age of 50; patients with DGC and cleft lip/palate; and those with 
precursor lesions for signet ring cell carcinoma. Given the high mortality associated with inva-
sive disease, prophylactic total gastrectomy at a centre of expertise is advised for individuals 
with pathogenic CDH1 mutations. Breast cancer surveillance with annual breast MRI starting 
at age 30 for women with a CDH1 mutation is recommended. Standardized endoscopic sur-
veillance in experienced centres is recommended for those opting not to have gastrectomy 
at the current time, those with CDH1 variants of uncertain significance and those that fulfil 
HDGC criteria without germline CDH1 mutations. Expert histopathological confirmation of 
(early) signet ring cell carcinoma is recommended. The impact of gastrectomy and mastecto-
my should not be underestimated; these can have severe consequences on a psychological, 
physiological and metabolic levels. Nutritional problems should be carefully monitored. 
Keywords: CDH1, hereditary diffuse gastric cancer, stomach cancer, lobular breast cancer, 
mutation analysis, prophylactic total gastrectomy
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Introduction
Worldwide, gastric cancer (GC) is the fifth leading cause of cancer and the third most common 
cause of death from cancer, with an estimated number of 723,000 deaths annually.1 The 
vast majority of GCs are sporadic, but it has now been established that 1-3% of GCs arise as 
a result of inherited cancer predisposition syndromes. These syndromes include Li-Fraumeni 
syndrome2-4, Lynch syndrome5-7, Peutz-Jeghers syndrome8-10, hereditary breast and ovarian 
cancer11,12, MUTYH-associated adenomatous polyposis (MAP)13, familial adenomatous pol-
yposis (FAP)14-16, juvenile polyposis syndrome17,18, and PTEN hamartoma tumour syndrome 
(Cowden syndrome).19 The lifetime risk of GC in these syndromes varies substantially between 
populations studied, but is generally low. 
Over 15 years ago, linkage analysis implicated germline mutations in the CDH1 gene, en-
coding the tumour-suppressor protein E-cadherin, as the genetic cause of hereditary diffuse 
gastric cancer (HDGC).20 Heterozygous germline CDH1 mutations increase lifetime risk of de-
veloping diffuse gastric cancer (DGC) and lobular breast cancer (LBC). Criteria have been set 
to select families eligible for screening of germline CDH1 mutations and they were updated 
in 2010.21,22 Not all families fulfilling these criteria have mutations in CDH1, indicating that 
other genes may also be involved in DGC predisposition. Germline mutations in CTNNA1 were 
described in three families that presented with DGC, one of them fulfilled the 2010 HDGC 
criteria.23,24 
Increasing awareness of HDGC and the rapid advances in genetic diagnostic tools, endoscop-
ic modalities and the increasing use of laparoscopic surgery led a group of clinical geneticists, 
gastroenterologists, surgeons, oncologists, pathologists, molecular biologists, dieticians and 
patient’s representatives from nine different countries to convene a workshop in order to 
update the management guidelines for this condition set in 2010 and to propose directions 
for future research. The workshop discussions were focused on five major topics: (1) genetic 
counselling and mutation analysis; (2) endoscopic surveillance and screening of cancer; (3) 
risk-reduction surgery of the stomach and breasts; (4) pathological specimen processing and 
diagnosis; and (5) patient’s and dietician’s perspective.
Genetic counselling and mutation analysis
Genetic evaluation of HDGC patients
Genetic counselling is an essential component of the evaluation and management of HDGC. 
The counselling process should include a formal genetics evaluation by a cancer genetics pro-
fessional with expertise in the field. The evaluation should include a detailed three-generation 
family pedigree, histopathological confirmation of DGC diagnoses and/or precursor lesions 
(in situ or pagetoid spreading of signet ring cells) and a discussion on lifetime risks of devel-
oping DGC and LBC. Informed consent for genetic testing is required. In the management 
of individuals with a CDH1 mutation, a full multidisciplinary team (MDT) should be involved 
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comprising those with relevant expertise in gastric surgery, gastroenterology, breast oncology, 
pathology, psychosocial support and nutrition. Genetic testing can be offered from the age of 
consent (and therefore will vary between countries, but will generally be around 16-18 years). 
Testing of younger unaffected family members can be considered on a case-by-case basis. 
Rare cases of clinically significant DGC have been reported in affected families before the age 
of 1825, but the overall risk of this disease before the age of 20 is low.26,27 
Cancer risks in CDH1 mutation carriers
In a recent study, penetrance data for CDH1 mutation carriers has been updated based on af-
fected individuals, who presented clinically with DGC or LBC, from 75 families with pathogenic 
CDH1 mutations. Families with CDH1 missense mutations and families of which no carrier 
test information was available were excluded from this analysis. The cumulative risk of DGC 
for CDH1 mutation carriers by age 80 years is reported to be 70% for men (95% confidence 
interval [95% CI], 59-80%) and 56% for women (95% CI, 44-69%). Furthermore, the cumula-
tive risk of LBC for women with a CDH1 mutation is estimated to be 42% (95% CI, 23-68%) by 
80 years. There is currently no evidence that the risk of other cancer types in individuals with 
a CDH1 mutation is significantly increased.24 
Implications of counselling
Clinical geneticists (or other members of the multidisciplinary team) should inform the coun-
selee about gastric surgery and options of surveillance. Proven pathogenic CDH1 germline 
mutation carriers should be advised to undergo prophylactic gastrectomy (for more details 
see ‘Surgery’ section). Some patients may want to delay prophylactic gastrectomy for person-
al and/or work-related reasons. In these individuals endoscopic surveillance, described in de-
tail under 'Endoscopic surveillance', should be considered in the interim. The management of 
patients and families with clinical features suggestive of HDGC, but without a germline CDH1 
mutation, is not straightforward. We advise intensive endoscopic surveillance in an expert 
centre for first-degree relatives of patients meeting criteria mentioned in Figure 1. This is also 
the case for patients and families who carry a CDH1 variant with unproven deleterious effect. 
Recommendations on breast cancer surveillance and therapy in CDH1 mutation carriers can 
be found below.  
Criteria for germline CDH1 mutation testing
The last guideline in 2010 broadened the clinical criteria to select patients eligible for CDH1 
mutation analysis. The detection rate of CDH1 mutations before 2010, using the guidelines 
established in 199921, was reported to be 25-50%.27,28 Using the new criteria, the CDH1 de-
tection rate in countries with a low incidence of GC has decreased to 10-18% (van der Post 
et al. 2014 under revision).24,29 This decrease may also be explained partly by the enrich-
ment of large and highly suspected families in studies published before 2010 (i.e. ascertain-
ment bias). The detection rate is considerably higher in the New Zealand Maori population 
and is likely higher in the Newfoundland population, where a founder mutation has been 
described.27 It should be noted that these criteria are designed for countries with a low inci-
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dence of sporadic GC. Few small series and case reports of individuals with CDH1 mutations 
have been described in countries with a high incidence of sporadic GC; no large cohorts 
were examined systematically. In small series of South-Korea, Japan and Portugal, mutation 
detection rates of pathogenic germline CDH1 mutations in HDGC and early-onset GC range 
between 8-15%.2,30-33 
During the workshop, it was decided to merge the first (“Two or more GC cases in a family, one 
DGC <50”) and second (“Three or more DGC cases regardless of age”) testing criteria from 
the previous guideline22 into a new criterion: “Two or more GC cases regardless of age, at least 
one confirmed DGC”, in first- and second-degree relatives. The two other testing criteria have 
not been changed. The revised criteria are depicted in the upper panel of the box in Figure 1. 
The revised criterion now covers families for whom detailed pathology is incomplete. However, 
Figure 1. Algorithm for management starting from clinical HDGC testing criteria, genetic testing, role of en-
doscopy and gastrectomy. GC: gastric cancer; DGC: diffuse gastric cancer; LBC: lobular breast cancer; MLPA: 
multiplex-ligation probe amplification
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as in the earlier criteria, confirmed intestinal-type GC cases are not part of HDGC and in these 
families no CDH1 mutation analysis should be performed. To properly assess whether a fam-
ily meets the HDGC criteria, pathology reports and preferably review of gastric specimens by 
a pathologist dedicated to GC, are essential. 
There are other families in which genetic testing may also be considered (Figure 1, lower 
panel). The presence of bilateral LBC at young age (under the age of 50 years) or the pres-
ence of multiple close relatives with LBC (at least two under the age of 50 years) may direct 
towards testing for CDH1 mutations.29,34 Testing should also be considered in individuals with 
a personal or family history of cleft lip/cleft palate (CL/P) and DGC.35,36 Furthermore, in cases 
where expert pathologists detect in situ signet ring cells and/or pagetoid spread of signet ring 
cells in the stomach, genetic testing should be considered since this is rarely (if ever) seen 
in sporadic cases. Genetic testing should, whenever possible, be initiated in an affected pro-
band. If the affected proband is deceased, frozen- or formalin-fixed, paraffin-embedded tissue 
(preferably normal, non-malignant tissue) still may be available for CDH1 germline mutation 
testing. In case tissue of an affected individual is not available or of insufficient quality to per-
form the test, testing of unaffected relatives is acceptable. This should be performed prefera-
bly in at least three first-degree relatives simultaneously, increasing likelihood of detecting a 
CDH1 mutation. However, it has to be made clear to the counselee that unaffected individuals 
have only a 50% chance of having inherited a mutated CDH1 allele. The testing criteria still 
have to be met by the counselee’s family. If no mutation is found in these cases, endoscopic 
screening should be discussed with an expert gastroenterologist on a case-by-case basis. 
Similarly, in small families with DGC or families where family history is unavailable, CDH1 
mutation screening should also be considered on a case-by-case basis.
Genetic testing: lab perspective
Genetic testing on blood or tissue for germline mutations should be performed in certified 
molecular diagnostic laboratories e.g. Clinical Laboratory Improvement Amendments (CLIA) 
approved, ISO 15189 accredited or equivalent. CDH1 analysis should include mutation analy-
sis of the entire open reading frame including intron-exon boundaries, as well as copy number 
analysis of individual exons. At present, analyses are mostly performed by a combination 
of Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA). These 
techniques can be replaced by next generation sequencing if the approach used fulfils the 
requirement of similar sensitivity.
Genetic testing: lab perspective
Genetic testing on blood or tissue for germline mutations should be performed in certified 
molecular diagnostic laboratories, e.g. Clinical Laboratory Improvement Amendments (CLIA) 
approved, ISO 15189 accredited or equivalent. CDH1 analysis should include mutation anal-
ysis of the entire open reading frame, including intron-exon boundaries, as well as copy num-
ber analysis of individual exons to detect intragenic exon deletions or duplications. At pres-
ent, analyses are mostly performed by a combination of Sanger sequencing and Multiplex 
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Ligation-dependent Probe Amplification (MLPA). These techniques can be replaced by next 
generation sequencing if the approach used fulfils the requirement of similar sensitivity.
To date, over 155 different germline CDH1 mutations have been described, the majority 
pathogenic mutations and a number of variants of uncertain significance (van der Post et 
al. under revision).24 The majority of the pathogenic mutations are truncating and thus do 
not lead to a functional protein. Large exonic deletions are relatively rare, with a frequency of 
about 5%.37,38 CDH1 is a tumour suppressor gene and therefore a somatic second hit is re-
quired for initiation of tumour formation. The trigger and molecular mechanism by which the 
second allele of CDH1 is inactivated appears to be diverse and includes methylation, somatic 
mutation and loss of heterozygosity (LOH).39-42
The identification of germline CDH1 missense variants requires additional studies to assess 
their putative pathogenicity. A multidisciplinary approach combining familial and population 
data, in silico analysis and in vitro analysis is currently used to classify the variants as neutral 
or pathogenic.43-47 Genetic parameters such as mutation frequency in healthy control popula-
tions, co-segregation of the mutation within the pedigree and recurrence of the mutation in in-
dependent families should be considered as a first approach.43,45 However, the low number of 
individuals affected by the disease, the small size of the pedigrees and the absence of muta-
tion hotspots (which prevents the establishment of any correlation between the mutation site 
and its functional consequence) are limitations of this approach. In silico experiments predict 
the degree of conservation of a specific nucleotide within species, the effect of missense 
variants on splicing and also the putative impact of the variants on protein structure.45,47 Still, 
in silico results should be carefully interpreted, because the degree of conservation among 
species of each amino acid position is considered separately and do not take into account 
possible compensatory effects of neighbouring amino acids.45,47 Functional in vitro assays 
should be performed in order to evaluate the impact of CDH1 missense alterations in protein 
structure, trafficking, signalling and, consequently, in E-cadherin function.44,46 Compared to 
the cells expressing wild-type E-cadherin, pathogenic missense mutants impair the correct 
binding of key adhesion-complex regulators and likely compromise normal E-cadherin local-
ization and stability at the plasma membrane.46,48 As a consequence, disruption of cell-cell 
adhesion and increased invasive behaviour may be observed in the presence of pathogenic 
variants.44,46 To date, 49 germline CDH1 missense variants were reported for functional eval-
uation to IPATIMUP (Portugal, reference laboratory for functional characterization of CDH1 
missense variants for the IGCLC), the majority being classified as deleterious and thus possi-
bly pathogenic (R. Seruca, personal communication 2014).
Panel sequencing
Penetrance estimates for CDH1 mutation carriers have been derived from the study of highly 
ascertained HDGC families and it is likely that the penetrance for mutations detected in non-
HDGC families will be lower. With the introduction of next generation sequencing based gene 
panels, both in research and diagnostic settings, CDH1 alterations may be found in patients 
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without a personal or family history of GC.49,50 In our opinion, one should be very cautious in 
the interpretation of coding variants identified in non-HGDC families, especially if the alter-
ations do not lead to a premature stop codon.
CDH1 mutation database
Currently, there is no international database containing all germline CDH1 mutations and 
variants identified to date. A database has been designed and is currently under construction. 
This database can be consulted to assess whether a given CDH1 mutation has been found 
by others, and whether it has been considered deleterious and likely disease-causative or not 
based on population data, segregation analysis, in silico analysis and in vitro functional anal-
ysis, and/or recurrence in several individuals/families. We advise researchers and clinicians 
to submit unpublished mutations and variants to the database (contact person Carla Oliveira, 
carlaol@ipatimup.pt), together with the requested information on families/patients and muta-
tions. The publication/submitter of every mutation will always be referred to in the database. 
Psychosocial effects of counselling
Even though it is well recognized that many individuals will benefit from genetic counselling 
and testing for hereditary cancer in general, there have also been reports that it may induce 
a number of psychosocial problems. In a review on individuals requesting genetic counselling 
and testing for hereditary cancer syndromes, six dominant problem areas were identified: (1) 
coping with cancer risk; (2) practical problems (such as obtaining life insurance/loans and 
employment when found to be a mutation carrier); (3) family-related problems (e.g. commu-
nication problems with family members, feeling responsible for family members); (4) chil-
dren-related problems (e.g. concerns for children having increased risk, fear of leaving young 
children); (5) living with cancer (e.g. fear of developing cancer, pain about the loss of family 
members); and (6) emotions (e.g. anxiety, anger, feelings of loss, but also relief and reassur-
ance).51 These topics, when applicable, should be addressed during the counselling sessions. 
Pregnancy and assisted reproduction 
Although scientific data are lacking concerning timing of prophylactic gastrectomy and family 
planning, it is entirely possible for women to give birth to a healthy child after gastrectomy.52 
Nutritional advice and follow-up with a dietician within this context is essential.
Individuals from hereditary cancer families are frequently concerned about the transmission 
of their predisposition of cancer to their children.53,54 Health care professionals, including ge-
neticists and psychosocial workers will be increasingly involved in discussions and decisional 
counselling regarding reproductive options in families with a known cancer predisposing mu-
tation such as CDH1. In the past decades, genetic testing for hereditary cancers before birth 
has become available through prenatal diagnosis (PND) and pre-implantation genetic diagno-
sis (PGD).55 We recommend that carriers of a CDH1 mutation with a desire to have children 
should be informed about all reproductive options, including PND and PGD.
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Future research: other genes involved in HDGC predisposition 
Currently, three families that meet the new criteria have been described to carry germline 
CTNNA1 mutations.23,24 Even though these families show a clinical picture similar to that of 
CDH1-mutation positive families23, insufficient data is available to make a statement on dis-
ease penetrance. Given the functional connection between the two genes they may represent 
a genocopy. Mutation carriers could be given the option of prophylactic total gastrectomy 
(PTG) and other cancer prevention measures recommended for HDGC families, but with the 
precaution that such advice is being given based on very limited data. 
Other families have recently been described with BRCA2 and PALB2 mutations24, however 
we recommend that these families are managed no differently than other families with such 
mutations according to national guidelines. It is likely that other HDGC associated genes will 
be discovered through whole exome-, genome- or other unbiased next generation sequencing 
empowered methodologies. Indeed, using a combination of this approach and linkage anal-
ysis, mutations in MAP3K6 have recently been described.56 More needs to be understood 
about families with MAP3K6 mutations before they could be used to stratify risk in families. 
Until such data is available, a cautious approach in which all first-degree relatives of mutation 
carriers are followed is recommended. Without multiple mutation positive families for newly 
identified genes, it will be extremely difficult to ascribe pathogenicity to such mutations and 
to develop management guidelines.
Screening and surveillance
Gastric endoscopic screening and surveillance 
To clarify the terminology, we consider that individuals having endoscopy who do not know 
their mutation status or those who do not have a proven pathogenic CDH1 mutation un-
dergo screening whereas mutation-positive individuals undergo surveillance. The consensus 
reached at the workshop was that individuals who tested positive for a pathogenic germline 
CDH1 mutation should be advised to consider prophylactic gastrectomy, regardless of endo-
scopic findings. However, the timing of surgery may vary according to the preferences and 
age, as well as the physical and psychological fitness of the individual. In patients proceeding 
for gastrectomy, a baseline endoscopy should be performed prior to surgery to look for mac-
roscopic tumour as this may alter the treatment plan. This endoscopy is also performed to 
ensure that there is no other co-incidental pathology, such as Barrett’s oesophagus, which 
may alter the extent of the resection. When the stomach is macroscopically normal, the infor-
mation on microscopic disease foci is useful to compare with findings in the surgical resection 
specimen and hence to increase knowledge on the likelihood of endoscopic detection of 
microscopic lesions. 
For individuals with a CDH1 mutation in whom gastrectomy is not currently being pursued 
(e.g. through patient choice or existence of physical or psychological comorbidity), regular en-
doscopy should be offered. In patients declining surgery, surveillance can have the advantage 
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of helping individuals to come to a decision about the need for gastrectomy when microscopic 
foci of signet ring cells are detected. However, patients should be aware that delaying surgery 
can be a hazardous decision.57
The management of individuals with a CDH1 variant of uncertain significance and those in 
whom no mutation can be identified in the family is not straightforward. We would recom-
mend that intensive endoscopic surveillance in an expert centre should be offered to these 
families who fulfil the HDGC criteria. Endoscopic screening has a valuable role in guiding 
clinical decision making and in one case series, lesions were detected in 2/7 CDH1-mutation 
negative individuals (1/5 families).57 Specifically, any malignant lesions detected endoscopi-
cally would prompt a referral for gastrectomy. However, all patients undergoing endoscopy for 
HDGC should be informed that, given the very focal and often endoscopically invisible nature 
of these lesions, it is quite possible that lesions will not be detected by random biopsies.
HDGC endoscopy protocol 
Endoscopy should be performed in centres with an experienced multidisciplinary team. How-
ever, it is appreciated that sometimes this is not practical for individuals who have to travel 
long distances. In this case, a local endoscopist in consultation with an expert centre on the 
endoscopy protocol and review of histology may be a helpful alternative.
As noted above, the optimal frequency of endoscopy is not known. Based on current experi-
ence it is recommended that individuals should be offered annual endoscopy. The bleeding 
risk may be slightly higher than for other indications since more biopsies are taken. Therefore 
it is recommended that the local high-risk endoscopy protocol is followed such that, if pos-
sible, anticoagulants (e.g. warfarin and clopidogrel) are stopped prior to the procedure. The 
endoscopy should be performed using a white light high definition endoscope in a dedicated 
session of at least 30 minutes to allow for careful inspection of the mucosa on repeated in-
flation and deflation and for collection of biopsies. The mucosa should be thoroughly washed 
before examination with a combination of mucolytics (N-acetylcysteine) and antifoaming 
agent (such as simethicone) mixed with sterile water. This washing is ideally done via a pump 
operated by a foot pedal. The macroscopic appearances of the gastric mucosa and any focal 
visible lesions should be recorded using still images or video for future reference and specifi-
cally sampled for histology prior to the collection of random biopsies.
Prior to examination for small foci, the stomach should be adequately inflated and deflated to 
check distensibility. Poor distensibility should raise alarm for a submucosal infiltrative process 
like linitis plastica. When this is the case, biopsies should be taken and further imaging such 
as a high resolution multi-detector CT scan combined with endoscopic ultrasonography (EUS) 
is suggested to visualize the gastric wall layers. No objective measures of distensibility are 
currently available and this is an area that may warrant future research.
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Although an association between Helicobacter pylori infection and HDGC has not been prov-
en, it is important to test for H. pylori to document the prevalence of infection. Since H. pylori 
is a WHO class 1 carcinogen, it is agreed that when individuals are infected it should be erad-
icated, especially in those opting for surveillance. A rapid urease test is the preferred test at 
baseline and additionally it is recommended to take random biopsies from the antrum and 
the corpus due to patchy colonization, especially in the presence of acid-suppression. 
Due to the tiny foci of signet ring cells, which can only be recognized by microscopy, multiple 
biopsies are required to maximize the likelihood of diagnosing them.39 The anatomical gastric 
localization in which foci are identified varies between studies; reasons for this remain to be 
clarified, but may include environmental factors or differences in the molecular pathogene-
sis.39,57-65 Therefore, it is recommended that any endoscopically visible lesions are biopsied in-
cluding pale areas. Additionally, random sampling should be performed comprising five biop-
sies taken from each of the following anatomical zones: pre-pyloric area, antrum, transitional 
zone, body, fundus and cardia. A minimum of 30 biopsies is recommended as described 
in the Cambridge protocol (Supplementary Protocol 1).22 Even though this will still lead to 
sampling bias due to the large gastric surface area, taking more biopsies is not feasible in 
practice.65 The biopsies may be taken using a standard forceps, ideally with a spike as this will 
seize the lamina propria in which signet ring cell foci are present. In the case of a well-defined 
visible lesion, an endoscopic mucosal resection can be helpful to achieve a more reliable his-
topathological specimen to document the degree of invasion. However, this should be done 
for diagnostic rather than therapeutic purposes in view of the multifocal nature of the lesions.
Special mention should be given to pale areas, since these are more likely to harbour micro-
scopic foci of abnormal cells, although they lack specificity leading to false positives (Figure 
2).66 Recent data also suggests that these areas are visible on careful examination by white 
light, but Narrow Band Imaging may make them easier to visualize (A. Cats, personal com-
munication 2014). As noted in the previous guidelines, chromoendoscopy with Congo-red 
and methylene blue is no longer recommended due to concerns over toxicity.66 Virtual chro-
moendoscopy using autofluorescence and trimodal imaging does not seem to confer much 
additional benefit over white light.57 In order to maximize the yield from endoscopy, specialist 
histopathology reporting is essential and the guidelines outlined in the pathology section 
below should be followed.
Endoscopic surveillance of colorectal cancer
Although there are case reports of colorectal and appendiceal signet ring cell carcinomas 
in CDH1 mutation carriers26,67-70, there is currently no evidence to suggest that the risk of 
colorectal cancer in CDH1 mutation carriers is significantly elevated and there is insufficient 
data to give recommendations on colorectal cancer screening. In CDH1 mutation families in 
which colon cancer is reported in mutation carriers, information should be collected concern-
ing the age at diagnosis, whether the affected member(s) and first- or second-degree relatives 
are mutation carriers and whether the histopathology showed a mucinous component and/
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or signet ring cells. For such families, enhanced colonoscopy screening should be considered 
at age 40 or 10 years younger than the youngest diagnosis of colon cancer, whichever is 
younger, and repeated at intervals of 3-5 years. In the absence of a family history, the national 
guidelines for colon cancer screening should be followed. It is imperative that data on colono-
scopic screening in these individuals is collected so that these guidelines can be based more 
on evidence than on specialist opinion in the future.
Breast cancer surveillance
Knowledge about breast cancer risk in HDGC has slowly advanced since first reported in 
200026, yet evidence is not sufficient such that recommendations can be made of compa-
rable strength as in BRCA1/2. Genotype-phenotype correlations may eventually show some 
HDGC families do not have an increased LBC risk, but at present it should be assumed all 
women with a CDH1 mutation are at risk. When informing women with CDH1 mutation about 
the role of breast surveillance versus prophylactic mastectomy to manage their risk, the con-
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Figure 2. Pale areas in gastric mucosa of a patient with a germline CDH1 mutation harbouring signet ring cell 
focus during white light endoscopy (A) and narrow band imaging (B). H&E stain of biopsy specimen with signet 
ring cells (C). Scar area after biopsy during previous endoscopy (D).
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sultation covers similar territory as in BRCA1/2. There are however some important differenc-
es which must be carefully explained.
Invasive LBC, the type which typically occurs in HDGC, makes up 5-15% of sporadic breast 
cancer. Invasive ductal cancer occurs in 85-95% of sporadic breast cancer and in BRCA1/2 
cases.71 In contrast to ductal breast cancer, E-cadherin-deficient LBC invades in sheets or 
cords of cells, typically in single file, and does not form a well defined mass. Studies com-
paring different radiological modalities in sporadic LBC show sensitivity on mammography 
ranges from 34-92%.71 Bilateral breast MRI needs to be part of the protocol in CDH1 muta-
tion carriers. Given the fact that mammography has a low sensitivity for LBC, synchronous 
mammography at the time of MRI may add little. We therefore recommend annual breast MRI 
(which can be combined with mammography) starting at age 30 in women with a CDH1 muta-
tion. An oncologist or breast surgeon should guide breast surveillance. Annual clinical breast 
examination and breast cancer awareness from the patient and her physicians are essential. 
Future research on gastric and breast surveillance
In light of emerging endoscopic technologies, such as Narrow Band Imaging, Blue Laser Im-
aging, I scan, autofluorescence imaging, IHb-enhancement and confocal endomicroscopy72, 
research is required to further study the optimal methods for endoscopic monitoring of indi-
viduals at risk for DGC. Given the rarity of this condition, these need to be multicentre studies 
with strictly defined protocols. In addition, it is likely that the multiple biopsy protocol leads to 
scarring which can masquerade as pale areas (Figure 2D). It would therefore be very valuable 
to compare the yield of a targeted biopsy approach only with the current Cambridge proto-
col, which also includes multiple random biopsies. Such studies could also inform on the 
inter-observer variation in the identification of pale areas and help define features indicative 
of a signet ring cell focus. An endoscopic atlas created by endoscopists performing regular 
endoscopies on CDH1 mutation carriers would be very useful to help standardize protocols 
and improve lesion recognition.
There are no studies specifically addressing screening for LBC. Trials on breast screening in 
the general population and MRI screening in high risk groups or BRCA1/2 are informative, 
but do not directly extrapolate to the screening scenario in HDGC. The outcomes of the above 
stated recommendations of breast surveillance in HDGC women should be further prospec-
tively investigated. 
Gastrectomy and mastectomy
Prophylactic gastrectomy: Indications for and timing of surgery
Prophylactic gastrectomy should be strongly advised in carriers of a proven pathogenic ger-
mline CDH1 mutation. Some argue that the term “prophylactic gastrectomy” is inaccurate 
and favour the term “risk reduction gastrectomy”, because most mutation carriers already 
have microscopic signet ring cell carcinomas at the time of their surgery. Total gastrectomy 
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for these patients, however, completely eliminates their risk of GC and is truly prophylactic in 
terms of preventing their death from invasive GC. 
The optimal timing of prophylactic gastrectomy is unknown and is usually highly individu-
alized. Since this surgery has major impact on the quality of life, the decision to undergo 
prophylactic gastrectomy should be well informed, balanced, prepared and timed. Decisional 
counselling, outweighing the pros and the cons of the intervention is essential. The current 
consensus is that the procedure should be discussed and offered to pathogenic germline 
CDH1 mutation carriers in early adulthood, generally between age 20 and 30.58 Based upon 
the physical fitness of the mutation carrier and of surgery-related complications, prophylactic 
gastrectomy at an age above 75 should be carefully considered. Family phenotype, especially 
age of onset of clinical cancer in probands, should be taken into account. There is likely to be 
a dormant period in which the signet ring cell adenocarcinoma does not spread or progress 
since they have a low proliferative index and the age of prophylactic gastrectomy is generally 
lower than that of overt cancer.39 This may explain why so many individuals are found to have 
T-1 N-0 stage tumours after prophylactic gastrectomy.73 Patients who develop symptomatic, 
widely invasive DGC have a poor prognosis with as few as 10% having potentially curable dis-
ease.74 Even if potentially curable, five year survival rate still does not exceed 30%.75 As our 
understanding of the natural history of mucosal signet ring cell carcinoma improves, it may 
be possible to safely postpone prophylactic gastrectomy in some patients but until such time 
it is safer to recommend surgery early in adult life. This has implications for the long-term 
follow-up of prophylactic gastrectomy patients and re-enforces the need for multi-disciplinary 
teams to care for these patients for the rest of their lives, similar to patients who have under-
gone bariatric malabsorptive surgery for obesity.76
Operation details
The requisite operation is a total gastrectomy with Roux-en-Y reconstruction, ensuring that the 
jejuno-jejunal anastomosis is at least 50 cm distal to the oesophago-gastric anastomosis, to 
reduce the risk of biliary reflux. The proximal resection line must be across the distal oesopha-
gus containing squamous epithelium to ensure that no gastric cardiac mucosa is left behind. 
This can be confirmed by frozen section, or examination of the opened resection specimen in 
operating room, and can be guided by the use of on-table endoscopy to mark the squamo-co-
lumnar junction during the surgery.
The optimal extent of lymph node dissection (LND) in prophylactic gastrectomy is controver-
sial.77 Lymph node metastases are not reported in asymptomatic CDH1 mutation carriers with 
negative preoperative surveillance biopsies or small foci of pT1a intramucosal carcinoma. 
Among patients with early stage intestinal adenocarcinoma of the stomach, the frequency of 
lymph node metastasis in patients with early intramucosal (pT1a) tumours is 2-5%78-81, and 
up to 6% in the undifferentiated or diffuse types.78,80 In pT1b tumours, with invasion of the 
submucosal layer, lymph node metastases are found in 17-28%, increasing with the depth 
of submucosal invasion.80,81 The majority of patients undergoing prophylactic gastrectomy 
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for HDGC will have at least T1a cancers. Because a preoperative gastroduodenosopy cannot 
exclude the presence of T1b lesions with their higher risk of metastases during the operation, 
a D1 LND (with the inclusion of lymph node stations 1-7) is reasonable. 
The formation of a jejunal pouch may improve eating for the first year after surgery but, as yet, 
prospective trials comparing pouch to straight Roux-en-Y reconstruction have not convincingly 
demonstrated significant long-term benefits to justify the routine application of this more 
complex reconstructive procedure.82 Surgeons should therefore use the reconstruction they 
are most familiar with. This also applies to whether the preferred surgical approach is open or 
laparoscopic.77,83 There are potential advantages of laparoscopic gastrectomy with reduced 
wound pain and faster overall return to full activities, but conclusive evidence for the superi-
ority of this approach is still lacking. Any surgeon proposing to do a laparoscopic prophylactic 
total gastrectomy must be able to reassure the patient that this is without additional risk 
compared to open surgery.
Prophylactic mastectomy
Prophylactic mastectomy is not routinely recommended but may be a reasonable option for 
some women. Literature about prophylactic mastectomy in HDGC is scarce, it is reasonable 
to consider prophylactic mastectomy on a case-by-case basis taking into account the family 
pedigree. National guidelines for high-risk women should be followed with respect to chemo-
prevention using selective oestrogen receptor modulators or aromatase inhibitors.
Histopathology
Histopathology of biopsies from individuals suspected for HDGC
Biopsies of individuals with a family history of DGC that are endoscopically screened by the 
Cambridge protocol should be examined thoroughly. The biopsies should be stained for Hae-
matoxylin and eosin (H&E) at three levels and periodic acid-Schiff-diastase (PAS-D) as stan-
dard. All lesions should be recorded. Biopsies from potential carriers of a CDH1 mutation 
need careful evaluation by a pathologist with experience in the pathology of HDGC. In mu-
tation carriers the detection of specific lesions may support a decision towards prophylactic 
gastrectomy. In individuals without known gene defects, the detection of such lesions may be 
used as an additional argument that the patient is at high risk of developing cancer and that 
a prophylactic gastrectomy should be discussed. The specific lesions in HDGC are tiny foci of 
typical signet ring cells sometimes admixed with a low number of smaller atypical cells in the 
lamina propria without infiltration beneath the muscularis mucosa (see Figure 3A-D). The two 
pre-invasive lesions of signet ring cell carcinoma are: (1) in situ signet ring cell carcinoma, 
corresponding to the presence of signet ring cells with hyperchromatic and depolarised nuclei 
within the basal membrane of a gland replacing the normal cells of the gland; (2) pagetoid 
spread of a row of signet ring cells below the preserved epithelium of glands and foveolae, 
and also within the basal membrane (see Figure 4A-B).84 
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Figure 4. Precursor signet ring cell lesions: pagetoid spreading of signet ring cells (A)  
and in situ signet ring cell carcinoma (B) (H&E, original magnifications 400x).
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Figure 3. Mucosal signet ring cell carcinoma H&E (A), PAS (B), Cytokeratin (C) and E-cadherin staining (D) 
(pT1a, original magnification 200x)
Criteria for the identification of signet ring cell lesions should be strictly followed in order to 
diminish the risk of overdiagnosing nonspecific changes and to distinguish them from le-
sions that mimic signet ring cell carcinoma (SRCC) or precursor lesions. In the gastrointestinal 
tract various benign “signet cell like changes” may mimic SRCC (Supplementary Figure 1).85-88 
Therefore, confirmation of focal signet ring cell lesions in the stomach by a histopathologist 
with experience in this area is strongly recommended.
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Histopathology of prophylactic gastrectomy: classification of microscopic foci and  
determination of significance
Macroscopic examination and sampling of prophylactic gastrectomies should follow specific 
protocols that can be found in Supplementary Protocol 2. The histological examination should 
be made using a checklist, focusing on the items listed in Table 1. 
Pathology data from over 100 total prophylactic gastrectomies in the setting of HDGC is pub-
lished until now. Nearly all gastrectomies exhibit tiny mucosal foci of SRCC or in situ signet 
ring cells, although sometimes these were only discovered after careful review by a patholo-
gist with experience in this field.25,36,39,59-64,77,91,92 There are numerous T1a carcinoma foci but 
only a low number of in situ carcinoma lesions, suggesting that invasion of the lamina propria 
by signet ring cells may occur without a morphologically detectable in situ carcinoma.63,93 It is 
essential that the location of biopsies within gastrectomy specimens are specifically reported 
to learn more about the distribution of early HDGC in the stomach.
Surgical margin status must confirm that there is no residual gastric mucosa and tumour at 
the margins. However, oesophageal cardiac-type glands (presumably normal constituents) 
are diffusely scattered in the lamina propria through all levels of the oesophagus. The risk to 
develop SRCC in these glands is unknown but has not been reported.94 Also, metaplastic and 
heterotopic gastric mucosa can be seen elsewhere in the gastrointestinal tract. In a prophy-
lactic gastrectomy series of 19 patients, 3 cases (16%) showed heterotopic gastric mucosa 
in the duodenum, and mucosal SRCC was observed in one of them (RT van der Kaaij et al. 
2014, unpublished data). 
Background changes in the gastric mucosa of prophylactic gastrectomy specimens encom-
pass mild chronic gastritis, sometimes displaying the features of lymphocytic gastritis. Fo-
veolar hyperplasia and tufting of surface epithelium, focally with globoid change, is also a 
frequent finding and, in some areas, vacuolization of surface epithelium is very striking, how-
ever this does not seem to be a specific finding.28,36,63,93 Intestinal metaplasia and H. pylori 
infection are absent in most prophylactic gastrectomies described to date. 
Histopathology: advanced HDGC 
Like sporadic DGC, advanced HDGC predominantly presents as linitis plastica with diffuse 
infiltration of the gastric wall. Histology can show mainly or exclusively signet ring cells, how-
ever, more often these tumours are composed of a pleomorphic neoplastic infiltrate with a 
small subset of or without classic signet ring cells (poorly cohesive carcinoma). In a minority 
of cases, tumour cells are arranged in small aggregates, sometimes rosettes or glandular-like 
structures. A component of extracellular mucin may also be present, in which the neoplastic 
cells float. Although there are no specific morphological characteristics indicating the he-
reditary nature of the tumour, in situ lesions and pagetoid spread of signet ring cells in the 
surrounding normal mucosa are important clues to the diagnosis.
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Table 1. Checklist for reporting of prophylactic gastrectomy specimens  
(1) Features of ≥pT1b 
carcinoma(s) 
Growth pattern (diffuse infiltration versus localized tumour) 
Anatomic location (cardia, fundus, body, transitional zone, antrum) 
Measurements 
Histological type according to WHO101 and Laurén’s102 classifications 
Lymphatic, venous and neural invasion (present or absent) 
TNM stage 
(2) Features of intramucosal 
precursor lesions and 
pT1a SRCC 
Number of lesions  
Anatomic location (cardia, fundus, body, transitional zone, antrum) 
Measurements 
Aggressive features: pleomorphism, loss of mucin, spindle cells, small 
cells, mitoses 
Stromal reaction related to lesions: desmoplasia; lymphocytic, 
eosinophilic or granulomatous inflammatory reaction 
Surgical margin status (proximal oesophageal, distal duodenal 
mucosa, including donuts), to confirm there is no residual gastric 
mucosa and no tumour at margins.  
Lymph node status 
(3) Non-neoplastic mucosa: 
changes more commonly 
seen in this condition 
Tufting/ hyperplastic mucosal changes 
Surface epithelial vacuolisation 
Globoid change 
(4) Non-neoplastic mucosa: 
other findings 
Inflammation (acute, chronic, erosion, ulceration) 
Helicobacter pylori 
Intraepithelial lymphocytes  
Lymphoid infiltrates 
Glandular atrophy 
Intestinal metaplasia  
Dysplasia 
Review of gastric specimens of 103 HDGC families without germline CDH1 mutations showed 
a similar morphology compared to the advanced germline CDH1 mutation-related carcino-
mas (van der Post et al. 2014, unpublished data). Typical in situ lesions or pagetoid spread of 
signet ring cells however were not detected in these patients.
Lobular breast cancer
The association of lobular breast cancer and germline CDH1 mutations was first reported by 
Keller et al.90 Large series of the histopathological findings in (prophylactic) mastectomies 
of CDH1 mutation carriers are not reported. Kluijt et al. decribed bilateral widespread foci 
of lobular carcinoma in situ (LCIS) in prophylactic mastectomies of two female patients with 
germline CDH1 mutations.34 There are no unique histopathological findings reported in (pro-
phylactic) mastectomy specimens that can be used to distinguish these (pre-)malignancies 
from sporadic LBC’s. However, only few patients opt for prophylactic mastectomy and these 
mastectomy specimens are generally not fully blocked and examined. 
Histopathology: lobular breast cancer
The association of LBC and germline CDH1 mutations was first reported by Keller et al.95 
Large series of the histopathological findings in (prophylactic) mastectomies of CDH1 mu-
tation carriers are not reported. Kluijt et al. described bilateral widespread foci of lobular 
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carcinoma in situ (LCIS) in prophylactic mastectomies of two female patients with germline 
CDH1 mutations.36 There are no unique histopathological findings reported in (prophylactic) 
mastectomy specimens that can be used to distinguish these (pre-)malignancies from spo-
radic LBCs. However, only few patients opt for prophylactic mastectomy and these mastecto-
my specimens are generally not fully embedded and examined. 
Use of immunohistochemical stains
Widely invasive DGC may be easily detected on H&E sections. The use of histochemical stains 
for neutral mucins, such as PAS-D is useful for the detection or confirmation of tiny intra-
mucosal carcinomas in which the neoplastic cells are dispersed among preserved foveolae 
and glands. This should be performed routinely in the examination of gastric biopsies taken 
during endoscopy and in gastrectomies from HDGC patients.96 A cytokeratin stain can help 
to confirm the epithelial nature of the signet ring cells, if there is any doubt. E-cadherin im-
munoexpression can be reduced or absent in early gastric carcinomas, contrasting with the 
normal membranous E-cadherin expression in adjacent non-neoplastic mucosa.39,40,97 In pag-
etoid spread and in situ carcinomas, E-cadherin immunoexpression can also be reduced or 
absent.63 However E-cadherin expression is not always reduced or absent, this depends on 
the mutation type and specific mechanisms of inactivation of the wild-type allele.40 In DGC of 
patients without germline CDH1 mutations, the expression pattern of E-cadherin is also often 
reduced or absent. Therefore, E-cadherin staining should not be used as a pre-screening 
method to select patients eligible for germline CDH1 mutation analysis. 
In patients that present with both LBC and DGC, either synchronously or metachronously, a 
metastasis should be considered. Two primary tumours may be indicative for a hereditary 
background, but this is not always the underlying reason. Metastases from these tumours are 
often morphologically indistinguishable.98 Breast-associated immunomarkers are ER, BRST-2 
and/or mammaglobin, while CK20 and HNF4A are suggestive for GC.99,100 
Centres of excellence for pathological diagnosis
The pathology of HDGC is unique but not easy to recognize. Experience in this pathology is 
needed to provide high quality diagnosis, both in biopsies and in resection specimens. In 
order to increase the experience of pathologists and the accuracy of the diagnosis, especially 
of precursor lesions of HDGC, it would be useful to build a virtual bank of the different types 
of lesions observed in the setting of HDGC. Furthermore, the working group agreed that the 
use of (scanned) slides to be submitted for evaluation by experienced pathologists in the field 
should be seriously considered. 
It is pivotal to examine the full gastrectomy and full mastectomy specimens of CDH1 mutation 
carriers to determine the stage of cancer and additionally to better understand the pheno-
type and biology of this disease. Experience in the examination of prophylactic gastrectomies 
for HDGC is quite limited in most pathology departments due to the rarity of these surgical 
specimens. Additionally, the routine workload of most centres is incompatible with performing 
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the detailed examination of hundreds of sections typically obtained after totally embedding 
these stomachs. In the event of a lack of pathologist experience in dealing with these cases, 
or restricted time available due to the pathologist’s workload and laboratory resources, the 
entire formalin-fixed gastrectomy or mastectomy specimen can be send to an experienced 
pathology laboratory. An alternative option is to totally embed the stomach or breast, perform 
H&E and PAS-D stain on all blocks and send the slides and blocks to an experienced centre 
for specialist pathology reporting. If these alternative strategies are not feasible, and it is not 
possible to totally embed the gastric or breast specimen, this should be communicated to 
clinicians and the patient. Furthermore, in the event of not finding foci of SRCC, the gastrec-
tomy should not be reported as negative for carcinoma, but as ‘no carcinoma found in xx% of 
mucosa examined’.
Future research on molecular pathogenesis
A critical question that remains unanswered is how long early lesions of HDGC can remain in-
dolent until there is emergence of clinical disease that may be rapidly progressive and lethal. 
Continuing collection of data from patients who opt for endoscopic surveillance is essential 
to help answer this question. Also, a thorough analysis of the mechanisms responsible for 
the second hit inactivation of CDH1 in the very early lesions of HDGC is necessary to define 
strategies for chemoprevention. 
The molecular background of HDGC patients without CDH1 mutations remains to be clarified, 
including any specific morphological features of GC in the setting of other hereditary cancer 
syndromes. Majewski et al. reported a family with a germline CTNNA1 mutation presenting 
with multiple DGC cases and intramucosal signet ring cells. Immunohistochemistry of α-E-cat-
enin showed absent staining in the signet ring cells, while tumours from 10 other HDGC ped-
igrees without CDH1 and CTNNA1 mutation stained positively.23 Two additional families have 
recently been described, one of which shared an immunohistochemical phenotype with loss 
of α-catenin and cytoplasmic rather than membraneous E-cadherin.24 This finding suggests 
either that the pathogenicity of CTNNA1 mutations may be mediated through loss of E-cad-
herin function or that the cancer initiating potential of CDH1 mutations is imparted through 
α-catenin associated pathways. More research is needed to understand the role and muta-
tion detection rate of CTNNA1 mutations.
Postsurgical care and nutrition
Post-operative care
The psychological, physiological and metabolic impact of a total gastrectomy should not be 
underestimated. The physical impact of a gastrectomy is difficult to predict for any individual, 
but there is an expectation that most patients will return to a full and active life after their 
operation. Reassuringly, global quality-of-life scores recover to pre-surgery levels at around 12 
months post-operatively, however problems with eating, abdominal pain and reduced body 
image persist beyond this time.101 
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Enhanced post-gastrectomy recovery programs are now well established. These programs 
may include pre-operative carbohydrate loading, preferably the avoidance of a naso-gastric 
tube or abdominal drain, early mobilization with good analgesia (epidural or local anaesthetic 
wound catheters), resume oral intake within 3-5 days, and discharge from hospital within 
7-10 days. In addition, patients often require considerable support during the first 12 months 
after surgery. Implementation of this support will depend upon the local health care services 
and the distances required for patients to attend the centre. Specialist nurses and dieticians 
should maintain regular contact by telephone and the use of modern video-conferencing 
should be encouraged. Collection of clinical data in a national registry allows patients, if they 
choose, to contribute to HDGC syndrome research. 
There are different issues related to mastectomy (prophylactic or otherwise), a second major 
surgery with a significant recovery period. Mastectomy has a different impact concerning 
self-image, self-esteem, physical appearance and loss of feminine identity. Therefore a team 
of dieticians, physiotherapist and psychologist should be available for optimal physical and 
socio-emotional recovery during post-operative care of both gastrectomy and mastectomy.
Nutrition
The main adjustments with regards to diet and nutrition post-gastrectomy have to do with: 
(1) maintaining weight; (2) ensuring adequate fluid, nutritional and caloric intake, and (3) 
behavioural modifications surrounding eating. Experienced dieticians focus on nutritional 
problems and strategies for maintaining weight after surgery, while patients focus on lifestyle 
changes. Patients are often discouraged by weight loss. The median weight loss one year 
post-surgery is 10 kg.101 This means that patients who are underweight pre-operatively or 
who have a history of eating disorders need very careful counselling and support. Anatomical 
changes can make the act of eating difficult, and patients may become disappointed by these 
hurdles. This can further complicate weight management with the psychological burden of 
eating. In the early stages of recovery, intentional eating, drinking, management of symptoms 
and resting can quickly become draining. It is important for patients to have realistic expec-
tations for their progress and improvement over time. Common post-surgical symptoms, risks 
and treatment options are listed in Table 2.
Following a prophylactic gastrectomy, patients initially have to eat frequent small meals. Eat-
ing too much and/or too quickly will cause abdominal pain. Dumping syndrome is a group of 
symptoms commonly experienced as a result of altered gut anatomy following gastrectomy, 
caused by rapid entry of food into the small intestine at an earlier stage of digestion. This 
leads to a shift of fluid from the bloodstream to the small intestine to aid in digestion, and 
may lead to cardiovascular and abdominal symptoms. Late dumping is caused by a rapid rise 
and subsequent decrease in blood sugar levels by delayed insulin secretion. After gastrecto-
my, food moves rapidly and directly into the small intestine, where it digests faster. Also, the 
pancreas produces more insulin in a short time. This excessive insulin production allows for a 
rapid decrease in the blood sugar.107 These symptoms may be more common in the immedi-
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ate post-operative period and often subside over time. Dumping syndrome can be minimized 
or eliminated through dietary choices and modified eating habits, adequate adjustments are 
unique from patient to patient. With time, however, these symptoms tend to improve.101 Other 
problems may include lactose intolerance, steatorrhoea, small bowel bacterial overgrowth, 
anastomotic strictures and postprandial fullness.108,109 Patients should be warned that their 
tolerance to alcohol will reduce after gastrectomy and that absorption of some medications 
can be affected. 
As a result of malabsorption, post-gastrectomy patients are at risk for nutritional deficiencies. 
Monitoring of nutritional levels in post-surgical follow-up is essential, as deficiencies increase 
risk for other symptoms and health concerns. All patients require lifelong vitamin B12 sup-
plementation (either oral, subcutaneous or intramuscularly) to correct identified deficiencies, 
and close monitoring for conditions such as iron deficiency, anaemia, hypocalcaemia, osteo-
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Table 2. Post-gastrectomy symptoms and treatment options 
Symptoms Treatment 
Early dumping (15-30 min after eating) Modification of diet and eating habits  
Late dumping (1.5-3 hrs after eating) Modification of diet and eating habits  
Lactose intolerance Diet modifications, supplementation with lactase enzymes 
Fat malabsorption Pancreatic enzyme replacement may be necessary, 
especially fats and fat-soluble vitamins such as vitamin 
D102 
Small bowel bacterial overgrowth/  
Blind loop syndrome 
Antibiotics, sometimes surgery 
Dysphagia and anastomotic strictures Modification of eating habits (more deliberate mastication 
and smaller bites) 
Upper endoscopy with balloon dilatation to widen the 
stricture 
Sometimes post-surgical intervention 
Changing response to usage of alcohol Alertness physician and patient 
Absorption of medication can be 
affected 
Alertness physician and patient 
Monitoring deficiencies of iron, vitamin 
B12, folate, and trace elements 
Supplementing of vitamin B12 and/or folate.103-105 
Intravenous iron infusions may become necessary if 
individuals are unable to tolerate iron orally, unable to 
absorb sufficient iron through the gut, or require rapid 
increase in iron levels to avoid other health complications 
or a blood transfusion. 
Hypocalcaemia, osteoporosis, 
osteopenia and osteomalacia 
Calcium and Vitamin D are required to reduce risk of bone 
disease. When levels cannot be maintained through 
consumption of calcium-rich foods, supplements such as 
vitamin D, calcium carbonate, calcium phosphate and 
calcium citrate can be used.  
Calcium citrate does not require acid for absorption, 
making it a strong choice of supplement.106 
Bile reflux (due to the absence of the 
gastroesophageal valve) 
Type of surgical procedure (appropriate length of the Roux 
limb) reduces the occurrence of bile reflux.  
Use of wedge pillow for sleeping 
Limiting oral intake to 2-3 hours before going to bed. 
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porosis and trace element deficiencies. Many dieticians recommend patients to take a daily 
multi-vitamin preparation with iron, however it remains important to monitor iron levels since 
absorption will change after gastrectomy. While these are the most commonly reported symp-
toms, attention should be paid to any significant and prolonged changes, such as hair loss 
or extreme fatigue. These symptoms and changes away from the patient’s baseline may be 
indicative of nutritional deficiencies, which may need to be identified and treated.
Patients should consult a dietician prior to surgery, as an awareness of baseline nutritional 
status and dietary habits will benefit the patient in post-surgical nutrition, diet, and weight 
management. While there are some basic dietary principles that apply to most gastrectomy 
patients, there are no absolute rules. Each patient’s recovery is unique, from food and quanti-
ty tolerances, to comfortable eating habits. Variability is observed between patients, but also 
for individual patients during the course of their recovery. The most notable changes occur 
within the first year, however deficiencies should be carefully followed since they can also 
develop over years. Patients are encouraged to continue to experiment and discover what is 
best suited to their needs and tolerances. 
Future research: nutrition post-gastrectomy
Further studies are needed to elucidate the relationship in post-gastrectomy patients be-
tween diet, nutrition, drug absorption, changes in body composition and the direct impact on 
quality of life, both in the short and long term. 
Patient advocacy and the next steps in patient care and HDGC  
research
In patients’ experience, the process that HDGC families go through to find local medical care 
providers with experience with HDGC is frustrating. Faced with the lack of universal expertise, 
patients and advocacy groups have started working together to locate local care providers 
with expertise, or facilitate connecting local care providers with experts at globally-recognized 
multidisciplinary centres of excellence. Medical expertise in HDGC has to continue to grow 
and this expertise has to be communicated within the medical community, such that support 
structures for HDGC patients will become more easily accessible and established within ex-
isting medical systems.
Given the rare nature of HDGC, there is currently no singular global expertise portal for ge-
netic counselling, psychosocial support, gastroenterology, surgery, pathology and post-sur-
gery follow-up for HDGC families. The geography of existing expertise centres does not nearly 
cover broadly enough the areas where these resources are needed. With the emerging trend 
towards telemedicine, and the development of various patient advocacy groups, notably, “No 
Stomach For Cancer”110, “DeGregorio Family Foundation for Stomach and Esophageal Can-
cer Research”111 in the United States, and “Stichting CDH1”112 in the Netherlands, we see 
the potential for collaboration between patients, medical professionals and patient advocacy 
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groups to the end of empowering patients by directing and connecting them with the appro-
priate resources and expert opinions. 
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Supplementary protocol 1. Endoscopy protocol for HDGC
1.   Annual endoscopy is recommended ideally in a centre with an interest in HDGC.
2.  Endoscopy to be performed using high definition zoom gastroscope and use of mu-
colytics such as acetylcysteine is encouraged to obtain good views.
3.  Inspect and photograph the entire gastric mucosa paying particular attention to any 
focal lesions. 
4.  Clinical biopsies:
 -  Take antral biopsy for CLO at first surveillance endoscopy for H.pylori status
 -  Biopsy focal lesions for clinical histopathology and record the anatomical position 
of any lesion (see below). 
 -  Regardless of targeted biopsies taken now proceed to biopsy each anatomical area 
in turn, taking 4 samples from each area of which 3 go to clinical histopathology 
 a. Prepyloric area
 b. Gastric antrum
 c. Transitional zone
 d. Body
 e. Gastric fundus
 f. Gastric cardia
 Total: Approximately 30 biopsies
5.   Research biopsies: Provided that the patient has given informed consent an addi-
tional biopsy should be taken from focal lesions and each anatomical area.
Endoscopic evaluation of new modalities such as trimodal imaging or confocal microendosco-
py should be done in the context of a research protocol.
Routine Clinical Biopsy processing:
1.  Record position of biopsy by anatomical area and cross sectional circumference (by 
dividing circumference into 4 equal parts: lesser curve, greater curve, anterior wall, 
posterior wall) and give distance in cm from the teeth e.g. gastric body, greater curve 
at 50 cm
2.  All clinical specimens from each anatomical area should be separately labeled and 
sent to the histopathology laboratory with clinical information stating that this is a 
screening procedure to look for microscopic foci of signet ring cells in a patient that 
fulfills the IGCLC criteria for HDGC.
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Supplementary protocol 2. Protocol and reporting of CDH1  
mutation-related gastrectomy specimens
Macroscopic examination and sampling of prophylactic gastrectomies should follow specif-
ic protocols. After painting the margins, dissection of the omentum and retrieval of lymph 
nodes, fresh gastrectomy specimens should be opened along the greater curve and pinned 
onto a cork board. A life size specimen photo should be used as a template to identify the ex-
act location of the tissue blocks. The collection of fresh tissue samples from any macroscopic 
lesion and normal looking mucosa should be considered for research purposes. Overnight 
fixation in buffered formalin is recommended before sampling for routine histopathology, in-
cluding any macroscopically abnormal areas such as pale lesions. Sections of the margins 
should be taken (and labelled) and the remainder of the stomach should be sectioned com-
pletely (each section 2 cm x 0.3 cm, full thickness) and blocked (paraffin embedded). The 
location of each section should be marked on the map of the stomach. Any macroscopic 
lesions identified should be precisely localized within the map. This method usually results 
in 200-300 blocks per stomach. An alternative is to use an adaptive version of the Swiss roll 
technique.103 However, in case a carcinoma of >T1a is discovered unexpectedly, this option 
is suboptimal as it may be difficult to localize the remainder of the tumour or it may be lost 
in the processing. Another technique is to use giant histologic sections with the whole-mount 
technique, also called large-format histology. This method will save time and blocks, as each 
stomach is represented in approximately 25 blocks. The histological examination should be 
made using a checklist focusing on the items listed in Table 2.
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Supplementary figure 1. Mimickers of signet ring cells. (A) Vacuolization of superficial epithelium; (B) Globoid 
cells in hyperplastic epithelium; (C) “Signet cell change”: in ischemic columnar mucosa, cells can lose their 
cohesion, displace into the lumen of glands and resemble signet ring cells; (D) Clear/ glassy cell changes: the 
cytoplasm displays a glassy vacuole that is PAS negative; (E) Cells with clear changes, probably regenerative 
changes; (F) Clear mucous neck cells in the neck region; (G) Detached cells that resemble signet ring cells, 
probably due to fixation effect; (H) Capillaries; (I) Xanthoma.
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Abstract
Gastric cancer is caused by both genetic and environmental factors. A woman who suffered 
from recurrent candidiasis throughout her life developed diffuse-type gastric cancer at the 
age of 23 years. Using whole-exome sequencing we identified a germline homozygous mis-
sense variant in MYD88. Immunological assays on peripheral blood mononuclear cells re-
vealed an impaired immune response upon stimulation with Candida albicans, characterized 
by a defective production of the cytokine interleukin-17. Our data suggest that a genetic de-
fect in MYD88 results in an impaired immune response and may increase gastric cancer risk.
Keywords: MYD88, gastric cancer, Candida albicans, interleukin-17, Th17 response
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Brief report 
Worldwide, the burden of gastric cancer (GC) is very substantial, being the third leading cause 
of death from cancer.1 GC is a multifactorial disease with a low survival rate in which both ge-
netic and environmental factors are involved. Infection with Helicobacter pylori is an import-
ant risk factor for GC.2 Approximately 1-3% of GC cases fulfill the criteria for Hereditary Diffuse 
Gastric Cancer (HDGC; MIM 137215), a cancer predisposition syndrome characterized by 
early-onset diffuse GC. In approximately 14-40% of the families fulfilling the HDGC criteria a 
germline mutation can be found in the CDH1 gene encoding the E-cadherin protein, but in the 
majority of cases the underlying genetic cause remains unknown.3-5 In this study we report 
the case of a young woman with diffuse-type GC, recurrent candidiasis and a novel germline 
homozygous MYD88 variant.
The patient first presented with pain in the left upper abdomen at the age of 22 years. She 
was diagnosed with an H. pylori infection, for which eradication treatment was given. As the 
abdominal pain continued, a gastroduodenoscopy was performed, which revealed a gastric 
ulcer. Histopathological analyses of biopsies showed a signet ring cell carcinoma and mod-
erate chronic active, non-specific gastritis (Figure 1 panel A-C). The patient was treated with 
neoadjuvant chemotherapy resulting in almost complete regression of the gastric tumor at 
the time of surgery (Figure 1 panel D).
Because of the early-onset diffuse GC the patient was referred for genetic counseling. Family 
history revealed distantly related parents of Kurdish descent, six unaffected siblings and no 
other relatives with GC. Her medical history revealed that she lost her fingernails (idiopathic 
onycholysis) at the age of two years. Throughout her life, she suffered from recurrent vagi-
nal Candida albicans infections and recurrent fungal infections, in particular dermatophytic 
onychomycosis, of which at clinical examination pigmented rash could be observed in her 
neck and between her breasts. Her medical history was negative for allergies and pyogenic 
infections.
No germline CDH1 alterations were found by sequencing analysis of the entire open reading 
frame, including intron-exon boundaries, and Multiplex Ligation-dependent Probe Amplifica-
tion (MLPA) of all exons. Therefore, further research on possible underlying genetic aberra-
tions was performed. Copy number profiling using SNP6.0 arrays showed no significant copy 
number variations, but revealed large areas with loss of heterozygous calls, in agreement 
with parental consanguinity. Subsequent whole-exome sequencing (for details see the Sup-
plementary materials) on germline DNA from peripheral blood revealed seventeen infrequent 
homozygous variants of which the missense variant (c.712C>T, p.(Arg238Cys)) in the myeloid 
differentiation primary response 88 (MYD88) gene was considered most relevant. This vari-
ant affects a moderately conserved nucleotide (phyloP 3.76) of a highly conserved amino acid 
in the Toll/interleukin-1 receptor (TIR) homology domain of the gene and is predicted to be 
damaging to protein function using in silico prediction programs. 
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Germline and somatic variation in the coding region of MYD88 is rare with less than 0.5% 
heterozygous missense mutations in about 8,832 individuals (Supplementary Table 2). The 
variant detected in our patient is not present in any of the commonly used control databases 
or in 183 healthy controls from Turkish or Pakistani descent. Only one other heterozygous 
MYD88 variant (c.704G>A, p.(G235D)) was identified by targeted resequencing of the coding 
regions of the gene in 126 additional patients with early-onset and/or familial GC. In silico 
analyses predicted this variant to be benign. These results indicate that variants in MYD88 
are infrequent in both controls and GC patients.
MYD88 plays a central role as a mediator of the innate immune response to infections. The 
infectious phenotype of autosomal recessive MYD88 deficiency (OMIM 612260) is domi-
nated by invasive pyogenic infections and the main bacteria isolated in cases of invasive 
infection are Staphylococcus pneumoniae, S. aureus, and Pseudomonas aeruginosa. Also 
fungal infections, for example caused by the yeast C. albicans, are described in patients with 
MYD88 deficiency.6 In mice it was shown that MYD88 deficiency leads to an early and rapid 
CHAPTER 3
Figure 1. Signet ring cell carcinoma of the patient with the MYD88 variant. Note the typi-
cal spreading of single cells in the gastric glands (A and B) and invasive signet ring cells be-
tween glands in the lamina propria (C). Gastrectomy shows patchy remnants of cancer cells in the 
submucosa (D, Cytokeratin 8.18 stain). (Original magnifications 400x (A, B, C); 50x (D))
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development of H. pylori-induced gastric dysplasia.7 To date only a few MYD88 mutations are 
known8, the variant identified in our patient has, to the best of our knowledge, never been 
described. To assess the functional consequences of this MYD88 variant on the immune 
response against fungi or bacteria, we analyzed the cytokine production of peripheral blood 
mononuclear cells (PBMCs) stimulated with heat-killed C. albicans and H. pylori. As expected 
based on the infections seen in patients with MYD88 deficiency6, a specific defect in the pro-
duction of Th17 cytokine IL-17 (Figure 2, left panel) was observed upon re-stimulation of the 
patients’ PBMCs with C. albicans. In healthy individuals that have been exposed to H.pylori, 
an enhanced IL-17 production is observed after re-stimulation of the PBMCs with this patho-
gen.9 When we performed this assay for the patient, no difference was observed compared 
to controls (Figure 2, right panel). The immune response to TLR stimuli and S. aureus was 
normal (data not shown). 
GC has not been described in twenty-four patients with MYD88 deficiency, of which the old-
est patient was aged 20 at time of publication.6 However, ‘classic’ MYD88 deficiency has a 
high mortality at an early age, and likely too young to develop GC.8 From literature it is known 
that patients with both C. albicans and H. pylori infection have an increased risk of develop-
ing gastric ulcers.10 Therefore, we hypothesize that, in our patient, the partial MYD88 defect 
causes an impaired immune response, resulting in recurrent C. albicans infections and non-
specific gastritis increasing the risk of signet ring cell carcinoma of the stomach wall. Previous 
studies have shown that C. albicans is able to degrade E-cadherin in vitro11, which may be a 
tumor initiating event in the development of gastric signet ring cell carcinoma.12 In line with 
this hypothesis, the co-occurrence of C. albicans and signet ring cell carcinoma of the stom-
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Figure 2. Immunological assays on peripheral blood mononuclear cells (PBMCs) from the patient with the 
MYD88 variant. Assays revealed an impaired immune response upon stimulation with Candida albicans (left 
panel), characterized by a specific defect in production of the Th17 cytokine IL-17. Immune response to Helico-
bacter pylori was normal (right panel). The detection limit for the assay is indicated with the dotted line. Values 
depicted are the means with standard deviation (SD).
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ach was previously described in a patient with acquired immune deficiency syndrome13, who 
as a group have a 1.5-fold increased risk to develop GC.14 Moreover, a 10-fold increased GC 
risk is seen in patients with common variable immunodeficiency disorders (CVIDs).15 Whether 
GC is more frequently diagnosed in patients with recurrent fungal infections remains to be 
elucidated, but will provide more insights into the role of C. albicans in GC development.
In conclusion, we identified a functionally relevant homozygous missense variant in MYD88 
and a defective Th17 response in a patient with recurrent C. albicans infections and early-on-
set gastric cancer. The missense variant in MYD88 is the likely cause of persistent fungal 
infections that ultimately may have led to the development of early-onset gastric cancer in 
this patient. Future research is needed to unravel whether this is a more common genetic risk 
factor for gastric cancer development.
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Supplementary Materials and Methods
Patient and control samples
In our cohort of gastric cancer patients we included 126 patients that meet one of the follow-
ing criteria; one case of gastric cancer below the age of 40, two cases in one family, one below 
the age of 50 or three cases of gastric cancer, regardless of age. Patients were proven to be 
negative for CDH1 mutations. From each family only one patient was included. Furthermore, 
patients were included regardless the histology of the gastric cancer. For the control cohort, 
102 healthy people from Turkish and 81 people from Pakistani descent were included to 
match the ethnicity of our patient as well as possible. This study was approved by the medical 
ethics committee of the Radboud university medical center, reference number 2013/201.
Copy number variation analysis
Genomic DNA was extracted from peripheral blood cells of the patient and hybridized to Affy-
metrix SNP6.0 arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s pro-
tocol. The genotype was generated using the Birdseed analysis software incorporated in the 
Affymetrix Genotyping Console v2.1 (Affymetrix). The detected copy number variants (CNVs) 
were compared to a set of healthy controls, as described previously1, to exclude regions of 
normal variation.
Whole-exome sequencing
In brief, massive parallel whole-exome sequencing of genomic DNA extracted from peripheral 
blood cells of the patient was performed using the 5500XL SOLiD platform (Life Technologies, 
Bleiswijk, The Netherlands). DNA enrichment was performed using the human SureSelect 
50Mb kit (version 2), targeting the coding regions of approximately 21,000 human genes (Agi-
lent Technologies, Santa Clara, CA, United States). Reads were mapped to the hg19 reference 
genome using SOLiD BioScope software (Life Technologies).2
Variant prioritization
All variants were annotated using an in-house annotation pipeline, as described previously.2,3 
Briefly, from our total set of variants we selected high-confidence (≥5 variant reads and/or 
≥20% variant reads) non-synonymous variants with a SNP frequency in dbSNP (v132) below 
1% and that were present not more than one time in our in-house variant database contain-
ing 2,096 exomes (the majority of European ancestry).2 Because the parents were distantly 
related, we next focused on homozygous variants with a variant percentage ≥80% (n=17). 
Protein-truncating variants (n=1), variants resulting in splice site defects (n=0) and putative 
pathogenic missense variants were selected for further validation using Sanger sequencing. 
Missense variants were considered putatively pathogenic when the affected nucleotide was 
highly conserved (PhyloP ≥3.0) and if two of the following three in silico prediction programs 
considered this variant deleterious/damaging: SIFT4, PolyPhen-25 and Align GVGD6 (all in-
corporated in the Alamut 2.0 software package (Interactive Biosoftware, Rouen, France)). In 
total, 6 out of 16 missense variants were considered putatively patogenic, four of them were 
118
validated using Sanger sequencing. To determine recurrency of variants in the five genes in 
which variants were selected, we extracted the number of different truncating and homozy-
gous missense variants for each of the genes from a second in-house dataset (n=2,329) for 
which paired-end exome sequencing data was available. There are no individuals with a sus-
picion of hereditary cancer in this dataset. Also, the number of different truncating variants 
for the gene set was obtained from the Exome Variant Server of the University of Washington 
(EVS, 6,503 individuals of European and African American descent).7 For the list of all vali-
dated variants and occurrence of variation in the corresponding genes, see Supplementary 
Table 1.
Germline and somatic variation in the MYD88 gene in control databases
To assess the variation in MYD88 in control databases, we extracted all the germline variation 
in the coding region from MYD88 from our second in-house dataset (see above) and the EVS.7 
Furthermore, we used The Cancer Genome Atlas (containing 220 gastric adenocarcinomas) 
to determine the amount of somatic variation in the MYD88 gene.8 The data is depicted in 
Supplementary Table 2.
Gastric cancer patient cohort screening
Germline DNA of 126 gastric cancer patients was analyzed for mutations in MYD88 
(NM_001172567.1) using either Sanger sequencing (n=41) or ion semiconductor sequencing 
(n=63) (PGM, Life Technologies) or whole-exome sequencing (n=22, see above). For Sanger 
sequencing the full coding sequence of MYD88, including splice junctions, was amplified 
using polymerase chain reaction (primer sequences and PCR conditions are available on 
request) and screened for mutations using Big-Dye terminator sequencing (BigDye Termina-
tors (v 1.1) Applied Biosystems, USA). Analysis was performed on an ABI 3730 DNA Analyzer 
(Applied Biosystems). Subsequently, data was analyzed for variants using Chromas Lite (Tech-
nelysium, South Brisbane, Australia). Ion semiconductor sequencing was performed using a 
custom designed multiplex Ion AmpliSeqTM PCR primer panel (Life Technologies) according to 
the manufacturer’s protocol. Briefly, for the library preparation, four DNA samples from our 
gastric cancer patient cohort were pooled in equimolar and 10 ng of DNA was used for Am-
pliSeq amplification. Each pool was barcoded with Ion Xpress Barcode adapters (Life Technol-
ogies). Barcoded libraries were purified using Agencourt AMPure XP beads (Beckman Coulter 
Genomics, High Wycombe, UK), pooled and diluted for use in a 200-bp amplification run on 
an OneTouch emulsion PCR system (Life Technologies). Sequencing primer and polymerase 
were added to the final enriched spheres before loading onto the 316 chip. SeqNext (JSI Med-
ical Systems) was used for mapping and analysis of the data. All amplicons were analyzed at a 
coverage of at least 150x. The identified variant was validated in the individual DNA samples 
of the pool using Sanger sequencing as described above.
Control cohort screening for the MYD88 variant c.712C>T
The DNA sequence surrounding the variant was amplified using polymerase chain reaction 
(primer sequences and PCR conditions are available on request) and screened for mutations 
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using Big-Dye terminator sequencing (see above). Analysis was performed on an ABI 3730 
DNA Analyzer (Applied Biosystems). Subsequently, data was analyzed for variants using Chro-
mas Lite (Technelysium). 
Immunological assays
The cytokine production capacity was assessed as previously described.9 Briefly, venous blood 
was collected into EDTA tubes and primary blood mononuclear cells (PBMCs) were isolated by 
density centrifugation of blood diluted 1:1 in PBS over Ficoll-Paque (Pharmacia Biotech AB, 
Uppsala, Sweden). Cells were washed three times with PBS and resuspended in RPMI 1640 
(Dutch modified) supplemented with 50 mg/L gentamicin, 2 mM L-glutamine, and 1 mM 
pyruvate. Cells were counted on a Coulter Counter Z (Beckman Coulter, Mijdrecht, the Nether-
lands) and adjusted to 5 × 106 cells/mL. PBMCs (5 × 105) in a 100μL volume were added to 
round-bottom 96-well plates (Greiner, Alphen a/d Rijn, the Netherlands) and incubated with 
either 100μL of culture medium (negative control) or one of the stimuli described for 24 h 
(TNFα, IL-6), 48 h (IFN-γ) and/or 7 days (IL-17 and IL-22). Cytokine production was tested after 
stimulation of PBMCs with: lipopolysaccharide (LPS) derived from E. coli (10 ng/ml), heat-
killed C. albicans (105 microorganisms/ml), heat-killed H. pylori (107 microorganisms/
ml), heat-killed S. aureus (107 microorganisms/ml), recombinant IL-1 or IL-23 (100 ng/
ml), and recombinant IL-12 or IL-18 (10 ng/ml) after 24 hours and 7 days. 10% human 
pooled serum was added when PBMCs were incubated during 7 days. After incubation the 
supernatants were stored at −20 °C until assay. Experiments were performed in duplicate.
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1This database differs from the database that was used to filter the exome data and contains 
high-coverage paired-end exome sequencing data of 2,329 individuals that are not suspected to have a form 
of hereditary cancer. 2 Reference 7. 3 Reference 8.
Supplementary table 2. Variation in the MYD88 gene in control datasets. 
Database Number of  
samples 
MYD88 variant  
c.712C>T 
present 
Total variants in MYD88 
in this database 
Percentage of 
samples with 
heterozygous 
MYD88 variant 
Second in-house 
database1  
2,329 No Seven heterozygous carriers 
of six different germline 
missense variants 
 
No homozygous germline 
variants 
0.3% 
EVS2 6,503 No Twenty-six heterozygous 
carriers of 19 different 
germline missense variants 
 
No homozygous germline 
variants 
0.4% 
TCGA3 220 No One somatic variant 0.45% 
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Abstract
IL-12Rβ1 deficiency, also known as immunodeficiency 30 (IMD30, OMIM 614891), is a rare 
immunodeficiency syndrome caused by biallelic mutations in IL12RB1. Three second-degree 
relatives of a patient with this syndrome, all women, developed intestinal-type gastric cancer 
(GC). In the Netherlands the incidence of non-cardia GC in women is only 7 per 100,000 
person years. Both relatives that were available for testing proved to be heterozygous for the 
familial IL12RB1 mutation, suggesting there might be a causal relation. Testing 29 index 
patients from families with early onset and/or a familial history of GC for germline mutations 
in both IL12RB1 and IL12RB2, that encodes the binding partner of IL-12Rβ1, did not reveal 
other germline mutations in these genes. Therefore, heterozygous inactivating mutations in 
IL12RB1 and IL12RB2 are unlikely to be frequently involved in GC predisposition. Additional 
research in families with IL12RB1 mutations is required to determine whether carriers of 
IL12RB1 mutations have an increased (gastric) cancer risk. 
Keywords: Gastric cancer, interleukin-12 receptor, genetics, Salmonella infections,  
Mycobacterium infections
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Introduction
IL-12Rβ1 deficiency, also known as immunodeficiency 30 (IMD30, OMIM 614891), is an au-
tosomal recessive disorder caused by biallelic mutations in IL12RB1. To date, 156 patients 
have been described.1,2 Interleukin-12 (IL-12) plays an important role in the interaction be-
tween the innate and adaptive immunity. Phagocytic cells and dendritic cells produce this 
cytokine after an encounter with pathogens. IL-12 is involved in the cytotoxic activities of T 
cells and NK cells and is important for the production of cytokines, especially interferon (IFN) 
gamma.3,4 The receptor for IL-12 on NK- and T-cells is composed of two chains, IL-12 receptor 
beta-1 (IL-12Rβ1) and IL-12 receptor beta-2 (IL-12Rβ2). IL-12Rβ1 is primarily responsible for 
binding, while IL-12Rβ2 is essential for signaling through the JAK–STAT pathway.5,6 Patients 
with biallelic inactivation of IL-12Rβ1 are extremely susceptible to severe infections caused by 
otherwise poorly pathogenic mycobacteria (non-tuberculous mycobacteria or Mycobacterium 
bovis BCG) and Salmonella spp.7,8 
Three relatives of a patient with IL-12Rβ1 deficiency, caused by a homozygous truncating 
mutation in IL12RB18, developed gastric cancer (GC). In the Netherlands, the incidence of 
non-cardia GC is only 14 per 100,000 person years for men and 7 per 100,000 person years 
for women.9 In its early stages GC is often asymptomatic or causes only nonspecific symp-
toms. By the time symptoms occur, the cancer has often reached an advanced stage, which 
is one of the main reasons for the low average 5-year survival.9 
According to the Laurén classification, GC can be roughly divided into three histopathological 
types; diffuse, intestinal and mixed/indeterminate type.10 Another commonly used classifica-
tion of GC is the classification of the World Health Organization (WHO), that recognizes five 
main types of GC, namely tubular, papillary, mucinous, poorly cohesive (including signet-ring 
cell type) and mixed carcinomas.11 Gastric cancer is a multifactorial disease, both genetic 
alterations and environmental factors play a role in GC development. The main environmental 
factor involved is infection with Helicobacter pylori (H. pylori) and this pathogen has been 
recognised as a carcinogen by the WHO in 1994.12,13 
Familial aggregation of GC is estimated to occur in 8-30% of the patients.14-16 The most import-
ant GC susceptibility gene is CDH1, which accounts for 1-3% of all GC.17 CDH1-associated GC 
is mainly of the diffuse-type. The criteria to test patients/families with GC for mutations in this 
gene include: (1) 2 or more GC cases in family, one DGC <50 years; (2) 3 or more DGC cases 
in 1st- or 2nd- degree relatives, regardless of age; (3) DGC <40 years and (4) personal or 
family history of DGC and lobular breast cancer, one diagnosed <50 years.18 CDH1 mutations 
have been encountered in up to 50% of strictly selected families.19-21 The remaining families 
are still genetically unexplained and may carry mutations in other, still to be identified, GC 
susceptibility genes.
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To date, there is no literature on subjects with heterozygous and/or homozygous mutations in 
IL12RB1 and IL12RB2 and gastric cancer. A few studies have been reported about mutations 
in these genes in esophageal cancer. Cardenes et al. reported a subject with a homozygous 
splice site mutation in IL12RB1 who developed esophageal squamous cell carcinoma at the 
age of 25, which is extremely young for this type of cancer. Therefore, the authors speculate 
on the possible role of a defective IL-12Rβ1 protein underlying this malignancy.22 This case is 
also mentioned in an extensive study of 141 patients with IL-12Rβ1 deficiency, in which this 
patient is the only patient who developed cancer. However, it is unclear whether sytemetic 
analysis for the occurrence of tumors was performed.2,22 Tao et al. also reported an associa-
tion between IL12RB1 and esophageal cancer. In their study, they found that the CC genotype 
of a single nucleotide polymorphism (SNP) in IL12RB1 (rs401502, indicated in the article 
as 378 C/G) was associated with increased IL-12p40 levels and protection from esophageal 
cancer susceptibility.23 Airoldi et al. describe the consequence of lack of Il-12 signaling in 
mice, they observed that Il12rb2 homozygous knock-out mice are prone to develop tumors 
of the lung epithelia.24 
 
To determine whether IL12RB1 and IL12RB2 can be considered candidate genes for GC 
susceptibility, we analyzed whether the GC patients in the family with IL-12Rβ1 deficiency 
were carriers of this mutation and tested 29 GC patients that were suspected for a genetic 
predisposition based on their personal and/or familial GC history for germline mutations in 
these genes. 
Materials & Methods
Patient samples
DNA was isolated from peripheral blood samples and formalin-fixed paraffin-embedded tumor 
material of two GC patients from the family with IL-12Rβ1 deficiency to test for the familial 
mutation at the Department of Infectious Diseases of the Leiden University Medical Center, 
Leiden, the Netherlands. 
For mutation analysis of IL12RB1 and IL12RB2, DNA was isolated from peripheral blood 
samples from GC patients who were tested negative for CDH1 mutations at the Department 
of Human Genetics of the Radboud university medical center, Nijmegen after genetic coun-
seling at the Radboud university medical center or the Maastricht University Medical Center, 
Maastricht, both in the Netherlands. Because of the relatively high age of the GC patients in 
the IL12RB1 family, no further selection was made based on age and/or family history. Pa-
tient characteristics, including H.pylori status, can be found in Table 1.
LOH analysis by pyrosequencing
To isolate DNA from formalin-fixed, paraffin-embedded tissue, thin sections were treated by 
initial xylol extraction to remove paraffin. The extracted tissue was incubated overnight at 
37°C in 600 µl nuclei lysis solution (Promega) supplemented with 400 µg pronase, followed 
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Table 1. Characteristics of patients screened for mutations in IL12RB1 and IL12RB2 
Number of patients 29 
Mean age at diagnosis (SD) 54.2 (16.4) 
Gastric cancer classification according to WHOa  
Tubular 
Poorly cohesive (incl. signet-ring cell carcinoma) 
Mixed histology 
No histology available 
 
8 
16 
1 
4 
Tumor classification according to Laurénb 
Intestinal type 
Diffuse 
Mixed 
No histology available 
 
8 
16 
1 
4 
Helicobacter pylori in pathology specimen 
Yes 
No 
Unknown 
 
5 
20 
4 
Chronic gastritis 
Yes 
No 
Unknown 
 
15 
9 
5 
Helicobacter pylori infection in medical history 
Yes 
No 
Unknown 
 
1 
0 
28 
Family history of gastric cancer 
Yes 
No 
Unknown 
 
21 
4 
4 
 
SD: Standard deviation ; aBosman et al.11 ; bLauren10
by addition of protein precipitation solution (Promega), incubation for 5 minutes on ice, and 
centrifugation to remove proteins. Supernatant was incubated on ice with an equal volume 
of isopropanol to precipitate the DNA, the pellet was dissolved in TE and further purified with 
a QIAquick gel extraction kit (Qiagen). PCR and pyrosequencing was essentially performed 
according to the protocol described previously25, primers used for the PCR are ps-F: 5’-CTC-
CCCTCTCCTTCCAGAAC and ps-R: biotine labeled 5’-TTCCAGGCCATTACCCATT. Pyrosequencing 
primer ps-seq: 5’-TGGCSGCCTGTGGT. 
Mutation analysis of IL12RB1 and IL12RB2
The full coding sequence of IL12RB1 (transcript numbers NM_005535.1 and NM_153701.1) 
and IL12RB2 (transcript number NM_001559.2) including splice junctions was amplified us-
ing polymerase chain reaction (PCR) and screened for mutations using Big-Dye terminator 
sequencing (BigDye Terminators (v 1.1) Applied Biosystems, USA) and analysis on an ABI 
3730 DNA Analyzer (Applied Biosystems). Subsequently, data was analyzed for variants using 
the Sequence Pilot software (JSI Medical Systems, Germany). 
Missense variants were analyzed using the Alamut 2.0 software package (Interactive Bio-
software, Rouen, France), which incorporates SIFT26, PolyPhen-227, Align GVGD28 and dbSNP 
(build 135). We used the Exome Variant Server of the University of Washington29, which con-
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tains sequencing data of approximately 6,500 individuals of European and African descent, 
and the database of the GoNL project30 to assess whether variants were present in individu-
als without GC.
Results
Gastric cancer patients from the family with the truncating mutation in IL12RB1
A 73-year old patient (patient A), recently diagnosed with GC, was referred because of a fam-
ily history of GC. One of her sisters had been diagnosed with GC at age 72 (patient B) and 
their mother had died of GC at age 70. Her 62-year old sister was healthy and had a medical 
history of a few rectal polyps (three tubular adenomas with low grade dysplasia and 2 hyper-
plastic). Her niece (daughter of the 62-year old sister) was known to have a biallelic mutation 
(c.1126C>T, (p.(Q376*)) in IL12RB1, inducing a rare inheritable immune disorder (described 
as Patient 2 in the paper by De Jong et al.8 The pedigree of this family is shown in Figure 
1. No information is available for the fathers’ family of the niece with the immune disorder. 
Germline CDH1 mutation analysis of the index patient as well as analysis of her tumor for 
microsatellite instability were negative. 
To elucidate whether an IL12RB1 mutation could underlie the pathogenesis of GC in this 
family, we tested both sisters that developed GC. Both were heterozygous for the IL12RB1 
mutation. No material from their mother was available for testing. 
Histopathological characteristics of gastric tumors 
Material of both sisters with GC was available for histological re-evaluation. In the total gas-
trectomy specimen of the patient A an ulcerating tumor in the gastric body was seen with 
a diameter of 5.4 cm. The tumor invaded the subserosal tissue and was staged as pT3N0. 
Review showed a poorly differentiated intestinal-type adenocarcinoma. The surrounding mu-
cosa showed extensive intestinal metaplasia and chronic active gastritis. No quantitative dif-
ference indicating loss of the wild type IL12RB1 allele was observed in the tumor by quantita-
tive analysis of both alleles by pyrosequencing from blood as well as normal and tumor tissue 
sections (data not shown). Her sister had a 12 cm large polypoid tumor with central ulceration 
in the transitional zone of the stomach. Review of the histology showed an intestinal-type ad-
enocarcinoma, poorly differentiated with focally a few poorly formed glands. According to the 
seventh edition of the TNM classification the tumor is staged as pT4aN3a. The surrounding 
mucosa showed intestinal metaplasia and chronic atrophic inflammation. Loss of heterozy-
gosity analysis could not be performed due to insufficient quality of the material. Helicobacter 
pylori was not identified in the resection specimens of both patients. 
Mutation analysis of IL12RB1 and IL12RB2 in 29 patients with gastric cancer
Twenty-nine patients with GC, that were suspected for genetic predisposition, were screened 
for mutations in the two genes encoding the IL-12 receptor chains, IL12RB1 and IL12RB2. The 
histological characteristics of GC patients in our cohort, including H.pylori status, are shown 
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in Table 1. Several common polymorphisms in both genes (data not shown) and four rare 
heterozygous variants of unknown significance (VUS) in IL12RB1 were identified (c.102G>A, 
c.848G>A, c.1161G>A, c.1619-6C>T), but none of them appear to be pathogenic according to 
various in silico prediction programs (Table 2). The variants were all identified only once and 
in different patients. We conclude that no clear deleterious mutations were found. 
Discussion
In the current study we describe cosegregation of a heterozygous germline defect in IL12RB1 
and GC development in a family with IL-12Rβ1 deficiency. This heterozygosity might lead to 
impaired response of T- and NK-cells to pathogens that increase the risk of GC development. 
Therefore the gene would not act as a tumor-suppressor gene for which loss of the wild type 
allele would drive tumorigenesis. Indeed, the wild type allele was still present in the tumor of 
one of the patients.
The truncating mutation found in the family, (c.1126C>T, p.(Q376*)), probably does not ren-
der a stable protein. However, if a stable truncated protein would be formed, part of the FNIII 
extracellular domains, which are necessary for the IL-12Rβ1-IL-12Rβ2 dimerization would be 
missing, as well as the transmembrane domain required for expression of the protein on the 
THE IMMUNE SYSTEM AND GASTRIC CANCER
Figure 1. Pedigree of the family with an IL-12Rβ1 deficiency and gastric cancer.
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cell surface.31 Although IL-12 can bind with low affinity to IL-12Rβ1 and IL-12Rβ2 separately, 
presence of a heterodimer is necessary for high affinity binding.31
 
To determine whether germline mutations in the IL-12 receptor chains are a common event 
in GC patients, we sequenced these genes in a cohort of GC patients who were suspected for 
genetic predisposition. Although we identified several rare heterozygous variants in IL12RB1, 
none appeared to be deleterious using in silico prediction programs. The variants we identi-
fied were found in patients with both intestinal-type (n=2) and diffuse-type GC (n=1) accord-
ing to the Laurén classification. For one patient in whom we detected a variant the histological 
subtype is unknown. One of these variants, c.848G>A, results in an amino acid substitution 
of an arginine to a glutamine in the FNIII domain of the IL-12Rβ1 protein. This is the domain 
required for IL-12Rβ1-IL-12Rβ2 dimerization. Although this substitution is predicted not to 
affect the function of the protein, only experimental evidence, such as obtained with IL12RB1 
expression constructs32, can determine whether this is indeed the case. 
The results of our study suggest that germline mutations in IL12RB1 and IL12RB2 do not 
play a frequent role in GC predisposition. However, in contrast to the two heterozygous car-
riers with GC of the index family, the majority of patients in our cohort have been diagnosed 
with diffuse-type GC and therefore mutations in IL12RB1 and IL12RB2 may still play a more 
prominent role in intestinal-type GC predisposition. 
Taken together, we found a heterozygous IL12RB1 mutation to segregate with intestinal-type 
GC in one family. No additional mutations were found in 29 families with GC. Since only little 
is known about cancer risks in families with IL12RB1 mutations, the observation in the cur-
rent study may warrant additional research in other families with this deficiency to determine 
whether they are at increased risk for developing (gastric) cancer.
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Abstract
The underlying cause of genetic susceptibility to gastric cancer largely remains to be ex-
plored. In this study, we performed whole exome sequencing on patients with unexplained 
diffuse-type and intestinal-type GC to identify novel GC predisposing candidate genes. As 
young age at diagnosis and familial clusters are hallmarks of genetic tumor susceptibility, we 
selected 23 patients that were diagnosed below the age of 35, eighteen patients from fam-
ilies with two cases of GC at or below the age of 60 and thirteen patients from families with 
three GC cases at or below 70 years of age. All included individuals were tested negative for 
CDH1 mutations. Predicted deleterious variants were further filtered using several indepen-
dent approaches that were based on gene function, and gene mutation burden in controls 
and GC tumors. Using these approaches, several candidate genes for GC predisposition were 
selected for further analysis. The significance of these candidates will be determined by tar-
geted sequencing of these genes in a larger patient cohort, and by cosegregation analysis in 
the families with recurrently affected genes. 
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Introduction
Annually, almost one million people develop gastric cancer (GC) and approximately 723,000 
people die of this disease worldwide. This makes GC the fifth most common malignancy and 
the third leading cause of cancer-related mortality worldwide.1 There is a large difference in 
incidence of GC between and within continents, countries and regions. Over 70 percent of GC 
occurs in developing countries.2 In Western Europe, the incidence of gastric cancer (GC) is 8.8 
per 100,000 persons for men and 4.3 per 100,000 persons for women.1 In The Netherlands, 
the incidence of non-cardia GC has declined during the last century.3 Each year approximately 
1,500 patients are diagnosed with GC, which accounts for 1.5% of all new cancer cases in 
The Netherlands.4
Gastric cancer is a multifactorial disease, both genetic and environmental factors are in-
volved in the development of GC. The main environmental factor is infection with Helicobacter 
pylori. This infection is commonly acquired during childhood and persists unless eradicated.5 
H. pylori infection increases the risk of developing GC about six-fold6 and the World Health 
Organisation (WHO) has classified H. pylori as a class I carcinogen in 1994.7,8
Gastric carcinoma is a heterogeneous disease and can be roughly divided into three main 
types; the diffuse type, the intestinal type and a rest group composed of mixed and indetermi-
nate type.9 Diffuse GC (DGC) consists of poorly cohesive single cells without gland formation. 
Due to the presence of signet ring cells, this type of GC is often referred to as signet ring cell 
carcinoma. Intestinal GC is composed of glandular or tubular components with various de-
grees of differentiation.10 
In low- and high incidence countries, around 8-30% of patients with GC have a family history 
of GC.11-15 CDH1 mutations have been encountered in up to 50% of families16-18 that meet 
strict criteria for Hereditary Diffuse Gastric Cancer (HDGC): two or more GC cases in family, 
one DGC <50 years; three or more DGC cases in 1st- or 2nd- degree relatives, regardless of 
age or DGC <40 years or personal or family history of DGC and lobular breast cancer, one 
diagnosed <50 years.19 The remaining families are still genetically unexplained and may carry 
mutations in other, yet unknown, GC susceptibility genes. Recently, DGC families with muta-
tions in CTNNA120 and MAP3K621 have been described, but the exact contribution of these 
genes to GC predisposition remains unclear until more families with mutations in these genes 
are reported. In families with intestinal type GC exhibiting an autosomal dominant inheritance 
pattern, genetic susceptibility genes may also play a role, but no genes have been associated 
with this type of GC yet. 
The aim of the current study is to identify novel candidate GC susceptibility genes using whole 
exome sequencing of germline DNA of GC patients suspected of genetic predisposition, but 
without CDH1 mutations.
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Materials & methods
Patient selection for exome sequencing
In our exome sequencing cohort, 54 patients from 53 families meeting the following criteria 
were included (Table 1): one gastric cancer diagnosed below the age of 35 years, two GC 
cases diagnosed at or below the age of 60 years (index diagnosed at or below the age of 50 
years) or three cases of GC diagnosed at or below 70 years of age. The majority of the patients 
(n=39) was proven negative for CDH1 mutations. From one family two patients were included, 
from all other families one patient was included. Patient characteristics are shown in Table 2. 
This study was approved by the medical ethics committee of the Radboud university medical 
center, reference number 2013/201.
Exome sequencing
Detailed information on the sequencing statistics of individual samples are available upon re-
quest. Whole exome sequencing of genomic DNA extracted from peripheral blood cells of the 
patient was performed using the 5500XL SOLiD platform (Life Technologies, Bleiswijk, The 
Netherlands) for 26 samples and on the Illumina HiSeq (2x100bp paired end; Illumina) for 
13 samples (BGI, Copenhagen, Denmark.) DNA enrichment was performed using either the 
human SureSelect All Exon 50Mb kit (n=11) or the human SureSelect All Exon V4 kit (n=28), 
targeting the coding regions of approximately 21,000 human genes (Agilent Technologies, 
Santa Clara, CA, United States). Reads were mapped to the Human Genome Reference As-
sembly GRCh37/hg19 using SOLiD LifeScope software (Life Technologies). 
For 15 patients, exome sequencing was performed through the Baylor-Hopkins Center for 
Mendelian Genomics, according to previously described methods.22 In brief, 1 μg of genom-
ic DNA was fragmented in a Covaris sonication system. Whole-exome targeted capture was 
performed using the BCM-HGSC Core design. Sequencing was performed on the Illumina 
HiSeq 2000 platform (Illumina). Subsequently, reads were mapped and aligned to the Human 
Genome Reference Assembly GRCh37/hg19 using the BCM-HGSC Mercury pipeline.23 Variant 
calling was performed with the Atlas224 and SAMtools25 algorithms; variant annotation was 
performed with an intramurally developed annotation pipeline26 based on ANNOVAR27 and 
custom scripts to incorporate multiple databases to inform on identified variants.
Data annotation and variant prioritization
All variants were annotated using an in-house annotation pipeline, as described previous-
ly.28,29 Briefly, from our total set of variants we selected high-confidence (≥5 variant reads 
and/or ≥20% variant reads) non-synonymous variants that present in dbSNP (v132) with 
a frequency below 1% and occurred at most once in our in-house variant database (2,096 
exomes, the majority of which are from European ancestry)28 Missense variants with a PhyloP 
≥3 in selected pathways (see below) were analyzed using the Alamut 2.0 software pack-
age (Interactive Biosoftware, Rouen, France), which incorporates SIFT30, PolyPhen-231, Align 
GVGD32 and dbSNP (build 135). Missense variants which were predicted deleterious/damag-
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Table 1. Inclusion criteria for exome sequencing cohort and extended patient cohort 
Inclusion criteria for exome sequencing cohort (patients can meet more than one 
criterion) 
1. One GC diagnosed <35 years of age or 
2. Two GC cases diagnosed ≤60 years (index diagnosed ≤ 50 years) or  
3. Three cases of GC diagnosed ≤ 70 years 
Inclusion criteria for extended patient cohort 
1. One case of DGC diagnosed below age 40  
2. Two GC cases, one DGC diagnosed below age 50 
3. Three cases of DGC, regardless of age 
4. One case of IGC diagnosed below age 40  
5. Two GC cases, one IGC diagnosed below age 50 
6. Three cases of IGC, regardless of age 
7. One case of mixed-type GC diagnosed below age 40 
8. Two or more cases of GC, both DGC and IGC in one family, 1 diagnosed below age 50 
9. Three or more cases of GC, both DGC and IGC in one family, regardless of age  
10. One case of DGC diagnosed between age 40 and 50 
11. One case of IGC diagnosed between age 40 and 50 
12. One case of mixed GC diagnosed between age 40 and 50 
13. Two or three cases of GC, one DGC 
14. Two or three cases of GC, one IGC 
15. Two or three cases of GC, one, one mixed-type GC 
16. DGC above age 50 and LBC below age 50 in one family 
17. Group of suspicious families not meeting criteria 1-16 
18. Group of less suspicous families not meeting criteria 1-17 
 
ing by at least two of these programs were considered deleterious. In addition, we selected 
all truncating variants that were either significantly enriched compared to a control dataset 
or with a gene function of the gene that could be linked to cancer development (see below).
Variants were prioritized based on gene function using five partially overlapping criteria. The 
first criterion used included variants in known hereditary cancer predisposing genes. For this 
analysis we used an in-house generated list of 113 genes. In addition we assessed the re-
cently described GC predisposing genes CTNNA121 and MAP3K620 for variants. Second, we 
selected genes putatively involved in GC development. A gene list for this category was com-
posed by combining the genes from the KEGG pathways33: regulation of actin cytoskeleton 
(entry 04810), adherens junction (entry 04520), focal adhesion (entry 04510), epithelial cell 
signaling in Helicobacter pylori infection (entry 05120) and pathways in cancer (entry 05200) 
with a list of known tumor-suppressor genes.34. Third, based on previous results (Vogelaar et 
al., see chapter 3.1) we used the Resource of Asian Primary Immuno Deficiencies (RAPID) 
gene list35, an in-house generated candidate gene list and three KEGG pathways (JAK-STAT 
pathway (entry 04630)), NFkB pathway (entry 04064) and TLR pathway (entry 04620)33 to 
select variants known to predispose to immunodeficiencies. As a fourth criterion, we selected 
genes with a high expression in the stomach (based on data from the Tissue-specific Gene 
Expression and Regulation (TiGER) database36). The combined gene list is available upon re-
quest. Finally, we selected genes with recurrent somatic mutations in GC tumors (For specific 
genes see references).37-40 
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The National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP; 6,503 
exomes) database (hereafter referred to as EVS)41, which contains sequencing data of ap-
proximately 6,500 individuals of European and African descent, was used to assess whether 
selected variants were present in individuals without GC. Furthermore, we used a second 
in-house database containing 2,329 exomes with high coverage to exclude common variants.
Enrichment of truncating variants compared to controls
The number of different truncating variants per gene was established for our dataset and the 
in-house database containing 2,329 exomes. Next, Fisher’s exact/Chi square test was used 
to determine whether the number of variants in our set was enriched compared to the control 
dataset. The strict Bonferroni correction was used to correct for multiple testing bases on the 
26 genes. To select only those genes which were highly significant in our dataset, all genes 
with a p-value < 0.01 after correction were included for further analysis. 
Sanger sequencing
The DNA sequence surrounding the variant was amplified using polymerase chain reaction 
(PCR, primer sequences and PCR conditions are available on request) and screened for mu-
tations using Big-Dye terminator sequencing (BigDye Terminators (v 1.1) Applied Biosystems, 
USA). Analysis was performed on an ABI 3730 DNA Analyzer (Applied Biosystems). Subse-
quently, the data were analyzed using Vector NTI advance v 11.0 (Invitrogen Corporations, 
USA) or Chromas Lite (Technelysium, Australia).
Results
Patient cohort and characteristics
Whole-exome sequencing was performed on germline DNA from 54 patients of 53 families. In 
this cohort 23 patients below the age of 35 were included, eighteen patients had two cases 
of GC in the family at or below the age of 60 and thirteen patients were from families with 
three GC cases at or below 70 years of age. The average age at diagnosis of all the patients 
included was 37.9 years.
For fifteen cases we were able to confirm the pathology of the GC; ten patients had diffuse-type 
GC and five patients had intestinal-type GC. For the remaining cases no revision could be per-
formed. According to the pathology reports, eleven patients of this group had diffuse-type GC, 
one patient had signet ring cell carcinoma, three patients had intestinal-type carcinoma, one 
GC was mixed-type, one patient developed glandular type GC, one GC was poorly differenti-
ated and one was mucinous. For twenty patients, no information on histology was available.
Exome sequencing statistics
Three different enrichment kits and two different sequencing platforms were used for ex-
ome sequencing. On average, 5.2 Gb of data aligned to targets was generated per sample 
(range: 2-10.2 Gb), hitting 98.9% of the targets (96-99.98%) with an average coverage of 
CHAPTER 4
145
81.7x (36.8-132x). A coverage of at least 10-fold was reached for 93.3% of the targets (81.1-
99.31%) and 87.7% was covered at least 20-fold (68.9-98.19%). The statistics for individual 
exome sequencing data are available upon request.
Variant prioritization
After the quality filtering steps, approximately 9,300 variants from 54 cases remained (aver-
age 172). Because of the large amount of variants, prioritization was performed based on the 
function and recurrence of the affected genes. 
None of the cases carried pathogenic mutations in CDH1. Also, no variants were found in 
CTNNA1, previously described in a GC family.20 Three variants were identified in MAP3K6; 
two missense variants (p.Y591C and p.L541P) and one amino acid deletion (p.K1125del). 
MAP3K6 has been associated with familial GC21, but based on the number of variants found 
in healthy controls we did not follow up on these variants.
In total, we observed 26 genes with recurrent truncating variants in the patients. For these 
genes we compared the mutation burden of truncating variants in our 54 patients to those 
found in a control exome sequence dataset of 2,329 individuals, resulting in 20 genes (43 
variants) which were significantly enriched for truncating variants (Table 3). Genes in which 
we can validate these variants will be included in a gene panel for resequencing. 
To select additional variants which may be involved in GC predisposition, we created a gene 
list composed 1899 genes. Our exome data were then filtered for variants in these genes. In 
total, 269 putative pathogenic variants were identified using this approach. To test our quality 
settings, we performed Sanger sequencing on a subset of these variants and found that we 
were able to confirm 93% of the variants. The number of variants in the individual pathways 
and databases can be found in Table 4 (excluding variants that were not confirmed after vali-
dation using Sanger sequencing, variant details are available upon request).
Twenty-three variants were identified in known cancer predisposing genes (Table 4, variant 
details are available upon request). Five of these variants were identified in the ATM gene, 
previously associated with a small increased GC risk (RR = 3.39, 95% CI = 0.86 to 13.4)42 This 
gene was also found significantly enriched for truncating mutations (see above). 
Four additional genes of particular interest came out of the analyses. The first one is ARH-
GEF12, a known tumor-suppressor gene that is involved in the regulation of the actin cyto-
skeleton, in which we identified two missense variants in two unrelated patients. ARHGEF12 
functions upstream of RHOA in the RHoA pathway, which is frequently mutated in diffuse-type 
GC.39 The second one is a known tumor-suppressor gene (TSGene list, details are available 
upon request), RB1CC1. This gene plays an important role in the RB1 pathway and has been 
found to act as a tumor-suppressor in breast cancer.43. Another tumor-suppressor gene that 
came from this analysis is also found to be mutated somatically in GC, FAT4.38 Patient 531A 
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1 See reference 33; 2 See reference 36; 3 See reference 35; 4 See reference 34
Table 4. Number of potential deleterious variant calls in different pathways 
Pathway / gene list 
(number of genes in pathway) 
Total number of 
variants  
KEGG Actin cytoskeleton (151)1 18 
KEGG Adherens junction (73)1 20 
KEGG Focal adhesion (205)1 49 
KEGG Helicobacter pylori (68)1 4 
KEGG JakSTAT pathway (158)1 3 
KEGG NFkB signaling (92)1 12 
KEGG TLR pathway (106)1 7 
KEGG Pathways in cancer (327)1 49 
TiGER database (207)2 18 
Asian Primary ImmunoDeficiencies (247)3 42 
In-house generated gene list of genes predisposing to immunodeficiencies (271) 41 
In-house generated gene list of genes predisposing to hereditary cancer (113) 23 
Human TSGene (716)4 120 
Total 406 
 
carries two missense variants in this gene that are predicted to be pathogenic. Since the vari-
ants are located at a large distance from each other, it was not possible to determine whether 
they are on different alleles. FAT4 is a protocadherin that may be involved in planar cell polar-
ity. However, in control databases germline FAT4 variants are quite frequent, arguing against 
a role for this gene in GC predisposition. Furthermore, we found a variant in STAT3 in patient 
119A, who showed an immune phenotype in addition to GC. However, segregation analysis 
revealed that the variant was inherited from the mother, who was asymptomatic. Therefore, it 
is unlikely that this is the causative variant in this patient.
Discussion
In the current study, whole-exome sequencing was performed on germline DNA from 54 GC 
patients from 53 families with the aim to identify novel GC susceptibility genes. Even though 
we identified over 9,300 rare variants, we did not find obvious candidate genes in multiple 
patients. Therefore, it is necessary to test a selection of candidate genes in a larger study 
cohort, which is currently in preparation. 
There are several reasons for the fact that we did not find clear candidate genes in the current 
study. The main reason is the heterogeneous patient group that we included in this study. Pa-
tients with both diffuse-type and intestinal-type GC were included, both at young age and with 
a family history of GC. It may be very well possible that performing whole-exome sequencing 
in a more stringently selected patient cohort may allow for improved detection of candidate 
genes. Also, it may seem reasonable that the predisposing mutations are in our dataset, but 
that because of the large amount of variation we do not recognize them as such. Furthermore 
we performed exome sequencing, whereas predisposing variants may also be in non-coding 
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parts of the genome, currently not analyzed. Finally, there is also a possibility that some of the 
patients we included developed cancer because of chance and occasional familial clustering.
Mutations in CDH1 were not detected in the 15 cases for which no CDH1 mutation analysis 
had been performed prior to our study. The coverage of the CDH1 gene was good, except for 
the first exon of this gene, which was poorly covered. Therefore, it may theoretically be possi-
ble that we have missed a mutation, but since CDH1 mutations are found in only a minority 
of the patients and the gene has no mutational hotspots44, this chance is rather small. Ma-
jewkski et al. identified a germline mutation in CTNNA1 in a large family with GC.20 This gene 
is in the same pathway as E-cadherin, making it a plausible candidate gene. In our dataset of 
54 patients no mutations in this gene were found, which indicates that mutations in CTNNA1 
probably do not explain a large proportion of the families that are CDH1 negative. 
Gaston et al. report on the MAP3K6 gene in familial GC.21 We have also observed variants in 
this gene, but we do not consider this gene a strong candidate gene for two reasons. First,  the 
gene was identified in a large family, but the variant does not completely segregate with the 
disease.21 Furthermore, the variant that was identified occurs quite frequent in the EVS. This 
argues against its pathogenicity, simply because it is not expected that a variant that occurs 
so frequently in a database would cause this relatively rare form of hereditary cancer. 
The observation that frequently occurring variants are reported as candidate genes for GC 
development stresses the importance to determine the frequency of variants in candidate 
genes in local and public control datasets in addition to assessment of functional relevance. 
In the current study, we have used two datasets (in addition to the one used in the bio-infor-
matics pipeline) to compare our exome data with. The first one is the database of The Nation-
al Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP; 6,503 exomes)41, 
which contains sequencing data of approximately 6,500 individuals of European and African 
descent. The second one is an in-house database containing 2,329 exomes sequenced with 
high coverage. These datasets allowed for more stringent filtering of the data. 
In our dataset we found multiple truncating variants in a number of genes. For 20 of them, 
this number was enriched compared to the control dataset. No association can be found at 
this moment between the histology of the GC and the genes in which the mutations are found 
(Table 3). However, the numbers are relatively small. When in future research additional mu-
tations in these genes are found, it might be possible to determine an association. One of the 
genes in which we found an enrichment is ATM. Mutations in ATM are associated with a small 
increased risk of GC.42 Mutations in this gene have been found in various exome-sequencing 
studies so far, it is therefore remarkable that we have found an enrichment compared to con-
trols. Future research will have to reveal whether the enrichment can be confirmed in larger 
cohort studies.
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In our cohort we included two first-degree relatives (UPN059A and UPN059B). Even though a 
large number of shared variants were found, there was no real candidate gene identified. Also 
the copy number variation analysis that we performed based on the exome data did not reveal 
shared aberrations that may be causal. This indicates that either the variant is not present in 
the exome, or that more relatives have to be sequenced to unravel the genetic cause of GC 
in this family. In the study of Majewski, identifying the CTNNA1 gene, more family members 
were included, ultimately leading to the identification of the gene.20 Therefore, if possible, in 
the near future additional family members of our family 059 should be sequenced.
To confirm the role for the selected genes as (gastric) cancer predisposing genes, several ad-
ditional steps have to be performed. The genes in our gene panel (the 20 genes in which we 
identified an enrichment of truncating variants as well as the genes found with the candidate 
gene list approach) will be sequenced in an additional cohort of GC patients suspected for 
genetic predisposition, using targeted next generation sequencing. We will use the Molecular 
Inversion Probe (MIP) technology for the targeted enrichment of our gene set.45 Furthermore, 
segregation analysis will have to be performed, as well as assessment of cancer risk in these 
families. Also, it is important that our results are validated in other GC cohorts to determine 
whether the variants we identified are specific for the European population or not. In the cur-
rent study, a rather heterogeneous group of patients was included, with both diffuse-type and 
intestinal type GC, at an early age as well as families with multiple cases of GC. By screening 
larger cohorts, we might be able to determine which genes are relevant for GC predisposition 
in which groups of patients. The exclusion of variants in the selected genes in healthy con-
trols is important. This can be achieved by sequencing the controls using MIP technology, or 
by using whole-exome data from controls. The latter can only be done if the coverage of the 
specific genes is sufficient.
Taken together, we performed exome sequencing in 54 CDH1 mutation-negative patients 
from 53 families. Using different analyses candidate genes were identified. Genes in which an 
enrichment of (different) truncating variants was observed, as well as several genes identified 
using a gene function-based filtering approach will be further evaluated for their role in GC 
predisposition.
Acknowledgements
The authors would like to thank Lilian Vreede, Hanna Feunekes, Eveline Kamping and Neeltje 
Arts from the Radboud university medical center for excellent technical assistance.
GENETIC PREDISPOSITION TO GASTRIC CANCER
152
References
1.  Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Par-
kin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mor-
tality Worldwide: IARC CancerBase No. 11 (Internet). International Agency for 
Research on Cancer, 2013 (http://globocan.iarc.fr)
2.  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA 
Cancer J Clin 2011, 61:69-90.
3.  Dassen AE, Dikken JL, Bosscha K, Wouters MW, Cats A, van de Velde CJ, Coebergh 
JW, Lemmens VE: Gastric cancer: decreasing incidence but stable survival in the 
Netherlands. Acta Oncol 2014, 53:138-142.
4.  IKNL: (http://www.cijfersoverkanker.nl/) 
5.  Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa 
L, Guha N, Freeman C, Galichet L, et al: A review of human carcinogens-Part B: 
biological agents. Lancet Oncology 2009, 10:321-322.
6.  Webb PM, Law M, Varghese C, Forman D, Yuan JM, Yu M, Ross R, Limberg PJ, Mark 
SD, Taylor PR, et al: Gastric cancer and Helicobacter pylori: a combined analysis 
of 12 case control studies nested within prospective cohorts. Gut 2001, 49:347-
353.
7.  Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994, 
61:177-240.
8.  Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002, 
347:1175-1186.
9.  Lauren P: The two histological main types of gastric carcinoma: diffuse and so-
called intestinal-type carcinoma. An attempt at a histo-clinical classification. 
Acta Pathol Microbiol Scand 1965, 64:31-49.
10.  Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of 
the Digestive System, 4th edition. IARC, Lyon, France; 2010.
11.  Han MA, Oh MG, Choi IJ, Park SR, Ryu KW, Nam BH, Cho SJ, Kim CG, Lee JH, Kim YW: 
Association of family history with cancer recurrence and survival in patients with 
gastric cancer. J Clin Oncol 2012, 30:701-708.
12.  Bernini M, Barbi S, Roviello F, Scarpa A, Moore P, Pedrazzani C, Beghelli S, Marrelli 
D, de Manzoni G: Family history of gastric cancer: a correlation between epidemi-
ologic findings and clinical data. Gastric Cancer 2006, 9:9-13.
13.  Kawasaki K, Kanemitsu K, Yasuda T, Kamigaki T, Kuroda D, Kuroda Y: Family history 
of cancer in Japanese gastric cancer patients. Gastric Cancer 2007, 10:173-175.
14.  La Vecchia C, Negri E, Franceschi S, Gentile A: Family history and the risk of stom-
ach and colorectal cancer. Cancer 1992, 70:50-55.
15.  Roviello F, Corso G, Pedrazzani C, Marrelli D, De Falco G, Suriano G, Vindigni C, Be-
rardi A, Garosi L, De Stefano A, et al: High incidence of familial gastric cancer in 
Tuscany, a region in Italy. Oncology 2007, 72:243-247.
16.  Oliveira C, Seruca R, Carneiro F: Genetics, pathology, and clinics of familial gastric 
CHAPTER 4
153
cancer. Int J Surg Pathol 2006, 14:21-33.
17.  Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van 
Manen L, Gilpin C, et al: Founder and recurrent CDH1 mutations in families with 
hereditary diffuse gastric cancer. JAMA 2007, 297:2360-2372.
18.  Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten 
J, Fitzgerald R, Vogelsang H, et al: Germline CDH1 deletions in hereditary diffuse 
gastric cancer families. Hum Mol Genet 2009, 18:1545-1555.
19.  Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, 
Norton J, Ragunath K, Van Krieken JH, et al: Hereditary diffuse gastric cancer: 
updated consensus guidelines for clinical management and directions for future 
research. J Med Genet 2010, 47:436-444.
20.  Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, Hansford S, Hogervorst 
FB, Bosma AJ, Hofland I, et al: An alpha-E-catenin (CTNNA1) mutation in hereditary 
diffuse gastric cancer. J Pathol 2013, 229:621-629.
21.  Gaston D, Hansford S, Oliveira C, Nightingale M, Pinheiro H, Macgillivray C, Kaurah P, 
Rideout AL, Steele P, Soares G, et al: Germline mutations in MAP3K6 are associat-
ed with familial gastric cancer. PLoS Genet 2014, 10:e1004669.
22.  Lupski JR, Gonzaga-Jauregui C, Yang Y, Bainbridge MN, Jhangiani S, Buhay CJ, Kovar 
CL, Wang M, Hawes AC, Reid JG, et al: Exome sequencing resolves apparent inci-
dental findings and reveals further complexity of SH3TC2 variant alleles causing 
Charcot-Marie-Tooth neuropathy. Genome Med 2013, 5:57.
23.  Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, New-
sham I, Reid JG, Fink JK, Morgan MB, Gingras MC, et al: Whole-genome sequencing 
for optimized patient management. Sci Transl Med 2011, 3:87re83.
24.  Shen Y, Wan Z, Coarfa C, Drabek R, Chen L, Ostrowski EA, Liu Y, Weinstock GM, 
Wheeler DA, Gibbs RA, Yu F: A SNP discovery method to assess variant allele prob-
ability from next-generation resequencing data. Genome Res 2010, 20:273-280.
25.  Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, 
Durbin R, Genome Project Data Processing S: The Sequence Alignment/Map for-
mat and SAMtools. Bioinformatics 2009, 25:2078-2079.
26.  Gonzaga-Jauregui C, Lotze T, Jamal L, Penney S, Campbell IM, Pehlivan D, Hunter JV, 
Woodbury SL, Raymond G, Adesina AM, et al: Mutations in VRK1 associated with 
complex motor and sensory axonal neuropathy plus microcephaly. JAMA Neurol 
2013, 70:1491-1498.
27.  Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants 
from high-throughput sequencing data. Nucleic Acids Res 2010, 38:e164.
28.  Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, van Lier B, Arts 
P, Wieskamp N, del Rosario M, et al: A de novo paradigm for mental retardation. 
Nat Genet 2010, 42:1109-1112.
29.  de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, Vreede 
L, Kamping EJ, Verwiel ET, Hahn MM, et al: Germline mutations in the spindle as-
sembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. 
GENETIC PREDISPOSITION TO GASTRIC CANCER
154
Gastroenterology 2013, 145:544-547.
30.  Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous vari-
ants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081.
31.  Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov 
AS, Sunyaev SR: A method and server for predicting damaging missense muta-
tions. Nat Methods 2010, 7:248-249.
32.  Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, 
Zharkikh A, Thomas A: Comprehensive statistical study of 452 BRCA1 missense 
substitutions with classification of eight recurrent substitutions as neutral. J Med 
Genet 2006, 43:295-305.
33.  KEGG: Kyoto Encyclopedia of Genes and Genomes (http://www.genome.jp/kegg/
kegg2.html) 
34.  Zhao M, Sun J, Zhao Z: TSGene: a web resource for tumor suppressor genes. Nu-
cleic Acids Res 2013, 41:D970-976.
35.  Keerthikumar S, Raju R, Kandasamy K, Hijikata A, Ramabadran S, Balakrishnan 
L, Ahmed M, Rani S, Selvan LD, Somanathan DS, et al: RAPID: Resource of Asian 
Primary Immunodeficiency Diseases. Nucleic Acids Res 2009, 37:D863-867.
36.  Liu X, Yu X, Zack DJ, Zhu H, Qian J: TiGER: a database for tissue-specific gene ex-
pression and regulation. BMC Bioinformatics 2008, 9:271.
37.  Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, 
et al: Exome sequencing identifies frequent mutation of ARID1A in molecular 
subtypes of gastric cancer. Nat Genet 2011, 43:1219-1223.
38.  Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, 
Heng HL, Deng N, Gan A, et al: Exome sequencing of gastric adenocarcinoma iden-
tifies recurrent somatic mutations in cell adhesion and chromatin remodeling 
genes. Nat Genet 2012, 44:570-574.
39.  Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsu-
no K, Katoh H, Watanabe Y, et al: Recurrent gain-of-function mutations of RHOA in 
diffuse-type gastric carcinoma. Nat Genet 2014, 46:583-587.
40.  Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, et al: 
Whole-genome sequencing and comprehensive molecular profiling identify new 
driver mutations in gastric cancer. Nat Genet 2014, 46:573-582.
41.  Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA 
(http://evs.gs.washington.edu/EVS/) 
42.  Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, 
Easton DF: Cancer risks and mortality in heterozygous ATM mutation carriers. J 
Natl Cancer Inst 2005, 97:813-822.
43.  Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S: Truncating mutations of RB-
1CC1 in human breast cancer. Nat Genet 2002, 31:285-288.
44.  Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F: Frequency of CDH1 germline 
mutations in gastric carcinoma coming from high- and low-risk areas: metanaly-
sis and systematic review of the literature. BMC Cancer 2012, 12:8.
CHAPTER 4
155
45.  O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, 
Lee C, Ankenman K, et al: Multiplex targeted sequencing identifies recurrently 
mutated genes in autism spectrum disorders. Science 2012, 338:1619-1622.
GENETIC PREDISPOSITION TO GASTRIC CANCER

CHAPTER 5
Lynch syndrome and the 
MisMatch Repair genes

CHAPTER 5.1
Somatic mutations in MLH1 and 
MSH2 are a frequent cause of 
mismatch-repair deficiency 
in Lynch syndrome - like tumors
Arjen R. Mensenkamp*, Ingrid P. Vogelaar*, Wendy A. G. van Zelst–Stams, 
Monique Goossens, Hicham Ouchene, Sandra J. B. Hendriks–Cornelissen, 
Michael P. Kwint, Nicoline Hoogerbrugge, Iris D. Nagtegaal, 
and Marjolijn J. L. Ligtenberg
Gastroenterology 2014; 146: 643-646
160
CHAPTER 5
Abstract
Lynch syndrome is caused by germline mutations in the mismatch repair (MMR) genes. Tu-
mors are characterized by microsatellite instability (MSI). However, a considerable number of 
MSI-positive tumors have no known molecular mechanism of development. By using Sanger 
and ion semiconductor sequencing, 25 MSI-positive tumors were screened for somatic mu-
tations and loss of heterozygosity in mutL homolog 1 (MLH1) and mutS homolog 2 (MSH2). 
In 13 of 25 tumors (8 MLH1-deficient and 5 MSH2-deficient tumors), we identified 2 somatic 
mutations in these genes. We conclude that 2 acquired events explain the MMR-deficiency in 
more than 50% of the MMR-deficient tumors without causal germline mutations or promoter 
methylation.
Keywords: Genetic, colorectal cancer, mismatch repair deficiency, Lynch-like syndrome
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LYNCH SYNDROME AND THE MMR GENES
Brief report
Lynch syndrome is the most frequent cause of hereditary colorectal cancer (CRC). This au-
tosomal-dominant disease is caused by germline mutations affecting the mismatch repair 
(MMR) genes.1 Lynch syndrome mutation carriers have a lifetime risk of up to 80% to develop 
CRC.2 In addition, Lynch syndrome carriers are at high risk to develop endometrial cancer (EC) 
and several other cancer types.3 Inactivation of the MMR system results in frequent aberra-
tions in microsatellite repeat sequences known as microsatellite instability (MSI), which is a 
hallmark of Lynch syndrome. In a subset of patients with an MSI-positive tumor, no molecular 
explanation for the MMR-deficiency was found. Although their risk for CRC may be much lower 
than for Lynch syndrome mutation carriers and extracolonic cancer risk may not be increased, 
relatives of patients with an unexplained MSI tumor are advised to undergo surveillance sim-
ilar to Lynch syndrome patients. This includes colonoscopy once every 1–2 years starting at 
age 25, as well as surveillance for extracolonic cancers.4 
In the current study we determined to what extent somatic mutations in mutL homolog 1 
(MLH1) and mutS homolog 2 (MSH2) can explain CRC or EC with MMR-deficiency in patients 
suspected of having Lynch syndrome. Of the 232 MSI-positive tumors detected in patients 
counseled in our center between 1997 and 2011, the underlying molecular cause of the 
deficiency was established in 181 tumors (Table 1). By using a combined approach of Sanger 
and ion semiconductor sequencing, we analyzed whether somatic mutations in the suspect-
ed MMR gene could explain the MSI phenotype in a subset of the unexplained MLH1- and 
MSH2-deficient cases from whom sufficient high-quality DNA was available and permission 
could be obtained (patient characteristics are shown in Table 2). In 17 of 18 MLH1-deficient 
(94%) and 6 of 7 MSH2-deficient tumors (86%), somatic events were detected (Table 2 and 
Supplementary Table 1). In 8 MLH1- and 2 MSH2-deficient tumors, loss of heterozygosity 
(LOH) was detected (Supplementary Tables 2 and 3). In 8 MLH1- and 5 MSH2- deficient tu-
mors, 2 at least likely pathogenic hits (class 4 or 5) were identified, which were considered 
to explain the MMR-deficient phenotype. In an additional 3 patients with an MLH1-deficient 
tumor and 1 patient with an MSH2- deficient tumor, a combination of a variant of unknown 
significance (class 3) and either a pathogenic mutation or LOH were identified. As yet, it is 
unclear whether these combinations explain the MSI phenotype. In 8 MLH1- deficient tumors 
and 2 MSH2-deficient tumors, the LOH results were not informative. 
The age at diagnosis of the tumors with 2 somatic events was not statistically significantly 
higher than that of Lynch syndrome-associated tumors caused by MLH1 or MSH2 germline 
mutations (P = .055). Still, it was significantly lower than the age at diagnosis of MMR-defi-
cient tumors with MLH1 promoter hypermethylation (P < .0001). This suggests that the inci-
dence of biallelic somatic events other than MLH1 promoter methylation does not increase 
with age, as has been shown for tumors with MLH1 promoter hypermethylation.5 
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Table 1. Summary of the cause of MMR-deficiency of MSI-positive colorectal and endometrial  
tumors of patients counseled in the outpatient clinic between 1997 and 2011 
Cause of MMR deficiency Number Mean age at diagnosis, y, mean±SD 
(range) 
MLH1 deficient   
MLH1 germline mutation 30 41±11 (22-65) 
MLH1 promoter hypermethylation 61 57±10 (34-75) 
Unexplaineda 26 47±9 (26-69) 
Not analyzed 2  
Total 119 50±12 (22-75) 
   
MSH2 deficient   
MSH2 germline mutation 36 42±10 (16-63) 
EPCAM germline mutation 5 43±6 (34-50) 
MSH6 germline mutation 2 51±11 (43-58) 
Unexplaineda 15 45±11 (30-64) 
Total 58 43±10 (16-64) 
   
Only MSH6 deficient   
MSH2 germline mutation 1 32 
MSH6 germline mutation 26 49±10 (36-70) 
Unexplained2 4 53±11 (37-61) 
Total 31 49±10 (32-70) 
   
Only PMS2 deficient   
MLH1 germline mutation 5 42±9 (27-52) 
PMS2 germline mutation 15 47±8 (36-60) 
Unexplained2 4 50±19 (26-71) 
Total 24 46±11 (26-71) 
 
EPCAM, epithelial cellular adhesion molecule; PMS2, post-meiotic segregation increased, S. 
Cerevisiae, 2. aNot explained by a germline MMR gene mutation or hypermethylation of the 
promoter
In our cohort, 2 somatic events in either MLH1 or MSH2 cause the MMR-deficiency in more 
than half (52%) of the MMR-deficient tumors that previously had tested negative for germline 
MMR gene mutations and somatic MLH1 promoter methylation. In a previous study by Sour-
rouille et al.6, 2 putative biallelic, somatic mutations in MMR genes were detected in 4 of 18 
unexplained MMR-deficient tumors. In our cohort, the incidence of putative biallelic somatic 
mutations was higher than in the study by Sourrouille et al.6, as well as in other studies (see 
Zhang et al.7 for a meta-analysis), which resulted from the addition of analysis for LOH in the 
current study. LOH of MLH1 represented a high proportion of somatic events being detected 
in 8 of 15 tumors. In 10 tumors the LOH analysis was not informative, indicating that the 
number of cases with LOH in our study could be underestimated. A biallelic event is proven 
formally only in tumors with a combination of a point mutation and loss of the wild-type allele, 
resulting in LOH, because most of the somatic point mutations reside on different polymerase 
chain reaction (PCR) products. This nonhereditary cause of MMR-deficiency explains earlier 
observations that relatives of patients with MMR- deficient tumors, that are not explained by 
detectable germline mutations in MMR genes or hypermethylation of the MLH1 promoter, 
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have a lower risk of developing colorectal cancer than relatives of Lynch syndrome patients.8,9 
Nonetheless, our results do not rule out that other hereditary factors might play a role in 
tumor development.
In a subset of both the MLH1- and MSH2-deficient tumors only a single somatic event was 
detected, indicating technical shortcomings in detecting an additional mutation that can be 
present in either the germline10 or could have occurred during tumorigenesis. In the near fu-
ture, targeted next-generation sequencing will allow both more sensitive analyses of the cod-
ing region and exploration of the intronic regions and putative regulatory elements. Because 
Lynch syndrome still is a plausible diagnosis for these patients, they remain to be considered 
as Lynch-like with matched surveillance advice. In a couple of Lynch-like patients, not a sin-
gle somatic event could be detected. This might be owing to the aforementioned technical 
limitations or to a completely different genetic event that leads to the down-regulation of 
either MLH1 or MSH2. Recently, deletions affecting genes that regulate MSH2 degradation 
were shown to lead to MMR deficiency and undetectable levels of MSH2 protein.11 Moreover, 
cells lacking the H3K36 trimethyltransferase SET domain containing 2 (SETD2) display MSI 
owing to the loss of an epigenetic histone mark that is essential for the recruitment of the 
MSH2-MSH6 complex. Whether these mechanisms lead to MSH2-deficient colorectal cancer 
remains to be shown.12
Taken together, we identified somatic events as an underlying cause for mismatch repair 
deficiency in more than half of the MMR-deficient CRCs and ECs that could not yet be attribut-
ed to a germline MMR gene mutation or hypermethylation of the MLH1 promoter. Patients 
with these tumors no longer need to be considered as Lynch-like and thus the surveillance 
regimen for these patients and their relatives can be based on their family history. This most 
often reduces the frequency and starting age of colonoscopies and eliminates the need for 
surveillance for extracolonic Lynch syndrome–associated tumors.
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Supplementary Materials and Methods
Patients
The study cohort consisted of patients with an MSI-positive colorectal or endometrial tumor 
who visited the outpatient clinic of the Department of Human Genetics of the Radboud uni-
versity medical center (Nijmegen, The Netherlands) between 1997 and 2011. MSI positivity 
was determined either as part of the counseling procedure because of a suspicion of Lynch 
syndrome or as part of the routine pathologic diagnostic process in patients diagnosed before 
age 50 or with multiple Lynch-associated tumors at younger than age 70.
MSI, immunohistochemistry, and MLH1 and MSH2 hypermethylation
MSI analysis and immunohistochemistry were performed essentially as described previous-
ly.1 Analysis of hypermethylation of the MLH1 and the MSH2 promoter was performed on DNA 
isolated from normal and tumor tissue using a methylation-sensitive multiplex ligation-depen-
dent probe amplification (kit ME011; MRC-Holland, Amsterdam, The Netherlands) according 
to the manufacturer’s instructions, essentially as described by Ligtenberg et al.2
Germline mutation analysis
Germline analysis of MLH1 (NM_000249.3), MSH2 (NM_000251.2), and MSH6 
(NM_000179.2) was performed by Sanger sequencing. For the detection of large deletions 
or duplications of the MLH1, MSH2, MSH6, and EPCAM genes, multiplex ligation-dependent 
probe amplification was performed using kits P003 and P072 (MRC-Holland) according to the 
manufacturer’s instructions. Analysis of exons 1–10 of PMS2 was performed using primers 
specific for the reference sequence of PMS2 (NM_000535.5). Analysis of exons 11–15 was 
performed by long-range PCR followed by nested PCR and sequencing of the target exons, 
essentially as described by Vaughn et al.3 Multiplex ligation-dependent probe amplification 
of PMS2 was performed as previously described using kits P008-B1 or P008-A2 (MRC-Hol-
land).4
Somatic mutation analysis
No germline mutation or promoter hypermethylation could be identified in 41 cases with 
MLH1- or MSH2- deficiency. In 16 cases, insufficient high-quality DNA was available or no 
permission could be obtained. Somatic mutation analysis of MLH1 was performed on the 
remaining MLH1-deficient tumors without somatic hypermethylation of the MLH1 promoter 
from patients without a detectable germline mutation in MLH1 or PMS2. Somatic mutation 
analysis of MSH2 was performed on MSH2-deficient tumors without somatic hypermethyla-
tion of the MSH2 promoter from patients without a detectable germline mutation in MSH2, 
MSH6, or the 3’ end of EPCAM.
Somatic mutations in MLH1 and MSH2 genes were analyzed using tumor DNA isolated from 
formalin-fixed, paraffin-embedded tissues. Small PCR fragments were obtained by specifically 
designed primers (see Supplementary Tables 4 and 5) and analyzed by Sanger sequencing. 
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All detected mutations also were tested on DNA isolated from normal tissue. For patients from 
whom sufficient material was available, mutations were confirmed in both tumor and normal 
tissue using ion semiconductor sequencing (Ion Torrent PGM, Life Technologies, Bleiswijk, 
The Netherlands) according to the manufacturer’s protocol. In short, 200 bp amplicons were 
generated by PCR, followed by barcode and adapter ligation. The fragments were amplified 
and DNA was purified with Agencourt AMPure XP beads (Beckman Coulter Genomics, High 
Wycombe, UK). The library was diluted to 12 pmol/L. Emulsion PCR was performed using the 
OneTouch 200 Template kit (Life Technologies). Sequencing primer and polymerase were 
added to the final enriched spheres before loading onto the 316 chip. NextGene software 
(SoftGenetics LLC, State College, PA) was used for mapping and analysis of the data. All am-
plicons were analyzed at a coverage of at least 500x.
LOH analysis
In parallel with somatic mutation detection, SNPs at the MLH1 locus (rs9852378, rs4647215, 
rs1540354, rs1799977, and rs9876116) and MSH2 locus (rs10191478, rs6753135, 
rs6544990, rs3764960, and rs11684737) were genotyped in normal and tumor tissue using 
ion semiconductor sequencing according to the manufacturer’s protocol (Life Technologies, 
see earlier). The PCR primers used for this assay can be found in Supplementary Table 6.
In silico prediction tools and mutation interpretation
Missense variants and putative splice-site variants were analyzed using the Alamut 2.1 
software package (Interactive Biosoftware, Rouen, France), incorporating Align GVGD5, Poly-
Phen26, SIFT7, SpliceSiteFinder-like8, MaxEntScan9, NNSPLICE10, Human Splicing Finder11, 
and dbSNP (build 137). In addition, detailed mutation database and literature searches were 
performed. Combining all available information allowed us to categorize the variants quali-
tatively on a scale of 1–5, in line with previous publications and the Association for Clinical 
Genetic Science/Vereniging Klinisch Genetische Laboratoriumdiagnostiek (ACGS [UK]/VKGL 
[The Netherlands]) guidelines.12-14 MLH1- or MSH2-deficiency likely was explained by the 
identified somatic events if 2 events were classified as pathogenic (class 5 or LOH) or likely 
pathogenic (class 4). MLH1- or MSH2-deficiency was probably explained when one hit was 
classified as pathogenic (class 5 or LOH) and the other hit was classified as class 3 (unknown 
significance). MLH1- and MSH2-deficient was not explained in case no genetic events, or only 
a single genetic event, was detected.
Statistical analysis
The nonparametric Mann–Whitney U test, incorporated in SPSS version 20 (IBM Corporation, 
Armonk, NY), was used to compare the average age at diagnosis of the different groups in our 
study cohort. In this test, P < .05 was required for statistical significance.
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Supplementary table 4. Primers and amplicons used for MLH1 analysis  
on DNA isolated from paraffin-embedded tissues.  
Exon 
Forward / 
Reverse 
Primer sequence 5’ – 3’ Amplicon size 
1 
  
Forward GAGGTGATTGGCTGAAGGC 272 
 Reverse GCGGCCCGTTAAGTCGTAG 
2 
  
Forward ATGTACATTAGAGTAGTTGCAG 238 
 Reverse GGTCCTGACTCTTCCATGAAG 
3 
  
Forward TGGGAATTCAAAGAGATTTGG 260 
 Reverse TGACAGACAATGTCATCACAGG 
4 
  
Forward TGAGGTGACAGTGGGTGAC 254 
 Reverse GACAGGATTACTCTGAGACC 
5 
  
Forward TTCCCCTTGGGATTAGTATC 303 
 Reverse TATACAAACAAAGCTTCAAC 
6 
  
Forward CGCTTTTGCCAGGACATC 264 
 Reverse GACAAATCTCAGAGACCCAC 
7 
  
Forward GCTCTGACATCTAGTGTGTG 225 
 Reverse CCTTATCTCCACCAGCAAAC 
8 
  
Forward ATGATGTTTCAGTCTCAGCC 274 
 Reverse GTGATGGAATGATAAACCAAG 
9 
  
Forward GTAATGTTTGAGTTTTGAG 284 
 Reverse GTGGATTTCCCATGTGGTTC 
10 
  
Forward CACCTGTGACCTCACCCCTC 
284 
Reverse CCTTGTGAGTCTTGGTTGAG 
11a 
  
Forward CACCACATACACCATATGTG 
274 
Reverse CCTGACCTGGGTGAAGTAC 
11b 
  
Forward GGAGAGCATCCTGGAGCGGG 
216 
Reverse GGCACATTTCAAAGGCCCCAG 
12a 
  
Forward CTTATTCTGAGTCTCTCCAC 
257 
Reverse AATGCATCAAGCTTCTGTTCC 
12b 
  
Forward CTTCTACTTCTGGAAGTAGTG 
298 
Reverse GAAGTCCSCTTTGTTGTATCC 
12c 
  
Forward AGCAAGATGAGGAGATGCTT 
241 
Reverse AAAGCCAAAGTTAGAAGGCAG 
13a 
  
Forward GCTCCTCCAAAATGCAACC 
277 
Reverse TACGTACCCTCATGTCCCTG 
13b 
  
Forward GATTCTGATGTGGAAATGGTG 
222 
Reverse AACCTTGGCAGTTGAGGCCC 
14 
  
Forward TGCTTTGGTCAATGAAGTGG 
286 
Reverse TTGTGCCTGTGCTCCCTGG 
15 
  
Forward TTCTCCCATTTTGTCCCAAC 
245 
Reverse TGGAGAGCTACTATTTTCAGAAACG 
16a 
  
Forward CATTTGGATGCTCCGTTAAAG 
269 
Reverse AGAATGGCTGTCACACCTC 
16b 
  
Forward TAGGAGCCAGCACCGCTC 
283 
Reverse ATTACAGCCATGAGCCACC 
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NOTE. All forward primers contained an M13F tag: TGTAAAACGACGGCCAGT. All 
reverse primers contained a M13R tag: CAGGAAACAGCTATGACC.
Supplementary Table 4 continued 
Exon 
Forward / 
Reverse 
Primer sequence 5’ – 3’ Amplicon size 
17 
  
Forward CCTGGGAAAGCACTGGAG 262 
 Reverse TCCAGCACACATGCATGTAC 
18 
  
Forward TGATCTCCGTTTAGAATGAGAATG 275 
 Reverse GATTGTATGAGGTCCTAGTCC 
19a 
  
Forward GGACACCAGTGTATGTTGGG 264 
 Reverse TAACACCTCTCAAAGACTTTG 
19b 
  
Forward GCCTCCTAAACATTTCACAG 257 
 Reverse ATCAGAAGGCAAGTATAAGTC 
 
 
Supplementary table 5. Primers and amplicons used for MSH2 analysis  
on DNA isolated from paraffin-embedded tissues.  
Exon 
Forward / 
Reverse 
Primer sequence 5’ – 3’ Amplicon size 
1a 
  
Forward GGGAAACAGCTTAGTGGGTG 182 
 Reverse CGGCATGCCCTGAAAGAAG 
1b 
  
Forward GTGAGGAGGTTTCGACATG 255 
 Reverse CCCATGTACTTGATCACCC 
1c 
  
Forward CTTCTTTCAGGGCATGCCG 
260 
Reverse ACTCTCTGAGGCGGGAAAG 
2a 
  
Forward CAGCTAATACAGTGCTTGAAC 
276 
Reverse TATGCCAAATACCAATCATTC 
2b 
  
Forward GTAAAAGATCTTCTTCTGGTTC 
280 
Reverse CATTCTACTATCACAATCTAC 
3a 
  
Forward ACAGAGCAAGACTTCATCTC 
268 
Reverse CATTTTAACACCCACAACACC 
3b 
  
Forward GTTTGAAGACATTCTCTTTGG 
289 
Reverse TCTCAGTTTCCCCATGTCTC 
3c 
  
Forward GGTGTTGTGGGTGTTAAAATG 
302 
Reverse TAAAGAGCCTTTCCTAGGCC 
4a 
  
Forward CTTATTCCTTTTCTCATAGTAG 
294 
Reverse AATCCATGTACCTGATTCTCC 
4b 
  
Forward TTGAAAGGCAAAAAGGGAGAG 
211 
Reverse GAGATAAATATGACAGAAATATCC 
5a 
  
Forward CTTTAGAACTGGATCCAGTGG 
323 
Reverse GCTCTGACTGCTGCAATATC 
5b 
  
Forward GGTAATCAAGTTTTTAGAACTC 
248 
Reverse GCTTCTTCAGTATATGTCAATG 
6a 
  
Forward TGGCGTAGTAAGGTTTTCAC 
217 
Reverse TCTTATCCATGAGAGGCTGC 
6b 
  
Forward GGTTCTGTTGAAGATACCAC 
228 
Reverse ATCATGTGGGTAACTGCAGG 
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Supplementary Table 5 continued 
Exon 
Forward / 
Reverse 
Primer sequence 5’ – 3’ Amplicon size 
7a 
  
Forward GAGACTTACGTGCTTAGTTG 
250 
Reverse AACAATCTTGTAAGTTTGCTGC 
7b 
  
Forward ACTTCGTCGATTCCCAGATC 
246 
Reverse TATGAGGACAGCACATTGCC 
8a 
  
Forward TGATGCTTGTTTATCTCAGTC 
187 
Reverse GTCAGAACGAAGATCAGTAAG 
8b 
  
Forward CTTTCTTTTAGGAAAACACCAG 
223 
Reverse CTTTCTTAAAGTGGCCTTTGC 
9a 
  
Forward GTCTTTACCCATTATTTATAGG 
217 
Reverse GTTGACTGCATCTTCTTTTCC 
9b 
  
Forward ACCATGAATTCCTTGTAAAACC 
215 
Reverse CTATACAGTGTATAGACAAAAG 
10a 
  
Forward GGTAGTAGGTATTTATGGAATAC 
210 
Reverse GGACTTTTTCTTCCTTACAGG 
10b 
  
Forward GATTAAACTGGATTCCAGTGC 
229 
Reverse CATCATGTTAGAGCATTTAGG 
11 
  
Forward GTACACATTGCTTCTAGTACAC 
188 
Reverse GTTACCAAAAGCCAGGTGAC 
12a Forward ATTATTCAGTATTCCTGTGTAC 
239 
Reverse GAACAGGTGCTCCATTTGAC 
12b Forward AGCTAGATGCTGTTGTCAGC 
240 
Reverse CAGTAATGATGTGGAACATCTG 
12c Forward ATTGCATTTATTCCTAATGACG 
211 
Reverse GAACTGGGAATTTTCTCCATC 
13a Forward ACAATCCATTTATTAGTAGCAG 
214 
Reverse TCCACAATGGACACTTCTGC 
13b Forward ACAAACTGGGGTGATAGTAC 
258 
Reverse CAGGACAGAGACATACATTTC 
14a Forward TTTTGTATGTGTATGTTACCAC 
180 
Reverse CATCTAACCCAAATCCATC 
14b Forward CTTCAGGTCTGCAACCAAAG 
216 
Reverse GGTATCTGATTGGCCAAGGC 
14c Forward CATTGCAACAAAGATTGGTGC 
236 
Reverse GTTTCCCATTACCAAGTTCTG 
15a Forward AATTGCTGTCTCTTCTCATGC 
205 
Reverse TCCAATATACTGAAACTCCTC 
15b Forward TTCCCTAAGCATGTAATAGAG 
237 
Reverse ACCTTCATCTTAGTGTCCTG 
16a Forward TTTGTCACTGTCTAACATGAC 
209 
Reverse GCTATTACTTCAGCTTTTAGC 
16b Forward GGTGAAACAAATGCCCTTTAC 
225 
Reverse CTATTACAGACAATAGCTTATC 
 
NOTE. All forward primers contained an M13F tag: TGTAAAACGACGGCCAGT. 
All reverse primers contained a M13R tag: CAGGAAACAGCTATGACC.
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Supplementary table 6. Primer sequences for LOH analysis on SNPs  
by ion semiconductor sequencing. 
SNP 
Forward / 
Reverse 
Primer sequence 5’ – 3’ Amplicon size 
rs1540354 Forward CATGGCCTCCTGGAGTCTTC 187 
Reverse TAAAACTGGGTAACAGCAGAACC 
rs13320360 Forward TCCTTGATTCTATCAGCAACCT 180 
Reverse TGGAGTTGAGTAATCTAAACAAAGG 
rs4647215 Forward TTTTTAGAGGCAAGGTCTCACTCT 174 
Reverse AGGCCCTATTTCTACAAAAACAAA 
rs9852378 Forward CTATCAAGGAGGCCAGTTTGTC 220 
Reverse TGTCCTGCTATTTTCCACACAG 
rs1799977 Forward TCAGCCATGAGACAATAAATCCT 218 
Reverse AAGGTTCCAAAATAATGTGATGG 
rs9876116 Forward TCTGTCTCATCCATGTTTCAGG 224 
Reverse TTTTCAGAAACGATCAGTTGAA 
rs10191478 Forward CCCAAAATCAACAACAACAAAA 197 
Reverse CTTGCAAATTACCCAGTCCTTC 
rs6544990 Forward GTTTGGCTCACCTCTCAGATTC 179 
Reverse TTTGCACAATGGTACATCAGTAAA 
rs11684737 Forward GTCCTGGAAACATGTACTGCAA 153 
Reverse TTAGGCTCAAAAACCATACACA 
rs6753135 Forward TGATTAAGGCCTATTGCACTGA 175 
Reverse GCTATGACAGCCTTTGACTGTG 
rs3764960 Forward TTGGTAACAGAAGAAAAATCATGA 222 
Reverse GGCCCTAGTGTTTCCTTTCC 
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CHAPTER 5.2
The MLH1 c.-27C>A and c.85G>T 
variants are linked to dominantly 
inherited MLH1 epimutation 
and are borne on a European 
ancestral haplotype
Chau-To Kwok*, Ingrid P. Vogelaar*, Wendy A. van Zelst-Stams, Arjen R. Mensenkamp, 
Marjolijn J.L. Ligtenberg, Robert W. Rapkins, Robyn L. Ward, Nicolette Chun, James M. 
Ford, Uri Ladabaum, Wendy C. McKinnon, Marc S. Greenblatt and Megan P. Hitchins
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Abstract
Germline mutations of the DNA mismatch repair genes MLH1, MSH2, MSH6 or PMS2, and 
deletions affecting the EPCAM gene adjacent to MSH2, underlie Lynch syndrome by predis-
posing to early-onset colorectal, endometrial and other cancers. An alternative but rare cause 
of Lynch syndrome is constitutional epimutation of MLH1, whereby promoter methylation and 
transcriptional silencing of one allele occurs throughout normal tissues. A dominantly trans-
mitted constitutional MLH1 epimutation has been linked to an MLH1 haplotype bearing two 
single-nucleotide variants, NM_000249.2: c.-27C>A and c.85G>T, in a Caucasian family with 
Lynch syndrome from Western Australia. Subsequently, a second seemingly unrelated Cau-
casian Australian case with the same MLH1 haplotype and concomitant epimutation was 
reported. We now describe three additional, ostensibly unrelated, cancer-affected families 
of European heritage with this MLH1 haplotype in association with constitutional epimuta-
tion, bringing the number of index cases reported to five. Array-based genotyping in four of 
these families revealed shared haplotypes between individual families that extended across 
≤2.6–≤6.4 megabase regions of chromosome 3p, indicating common ancestry. A minimal 
≤2.6 megabase founder haplotype common to all four families was identified, which encom-
passed MLH1 and additional flanking genes and segregated with the MLH1 epimutation in 
each family. Our findings indicate that the MLH1 c.-27C>A and c.85G>T variants are borne 
on a European ancestral haplotype and provide conclusive evidence for its pathogenicity via 
a mechanism of epigenetic silencing of MLH1 within normal tissues. Additional descendants 
bearing this founder haplotype may exist who are also at high risk of developing Lynch syn-
drome-related cancers. 
Keywords: Lynch syndrome, MLH1, epimutation, founder haplotype
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Introduction
Lynch syndrome, characterized by the development of colorectal, endometrial and additional 
cancers below 50 years of age1,2, is caused by dominantly inherited heterozygous mutations 
within one of the DNA mismatch repair genes, MLH1, MSH2, MSH6 or PMS2.3 Germline 
deletions of the EPCAM gene, which give rise to dominantly inherited epimutations of MSH2, 
have been identified in a proportion of cases.4 An acquired functional loss of the remaining 
wild-type allele of the affected gene within somatic tissues gives rise to cancers exhibiting mi-
crosatellite instability (MSI).5 A diagnosis of Lynch syndrome is confirmed by the identification 
of a causative mutation, allowing for accurate genetic counselling of families and targeted 
clinical surveillance of mutation carriers with a high risk of cancer development.2 However, 
a significant proportion of families with putative Lynch syndrome either have no identifiable 
mismatch repair mutation, or have missense ‘variants of uncertain significance’, which con-
founds diagnosis and genetic counselling.3 Classification of such variants as pathogenic or 
benign is based upon a compilation of clinical, genetic and epidemiological factors, as well 
as functional analyses.6 A cluster of sequence variants within the promoter regions of the 
mismatch repair genes has also been identified in cancer-affected families7-10; however, the 
pathogenic significance of most of these has remained largely uninterpreted.
A subset of mutation-negative patients has been identified with an MLH1 epimutation, char-
acterized by soma-wide methylation of one allele of the promoter and transcriptional loss 
from this allele.11 These cases have tended to be sporadic due to the spontaneous origination 
of the epimutation in carriers and its subsequent eradication in the germline.12-15 However, a 
handful of familial cases with an MLH1 epimutation have been reported in which transmis-
sion of the epimutation between generations has been shown to occur in both non-Mende-
lian14 and autosomal dominant patterns, with the latter linked to localized cis-acting genetic 
anomalies.16,17 
In a Caucasian family from Western Australia (WA Family 16), dominant transmission of a 
mosaic MLH1 epimutation was demonstrated through three successive generations linked 
to a particular haplotype bearing two single-nucleotide variants (SNVs) in tandem; promoter 
substitution c.-27C>A and missense variant c.85G>T (p.A29S) (according to coding reference 
sequence NM_000249.2).17 The mosaic nature of the epimutation was observed as variable 
levels of somatic methylation and partial allelic losses of transcription among different tis-
sues and carriers in the family.17 Two other index cases have also been reported as carriers 
of the MLH1 c.-27C>A and c.85G>T SNVs.7,10 In the first familial case ever reported (Fam-
ily 1744)7, no methylation or allelic expression studies were performed and so this allele 
was not linked to constitutional epimutation at the time. Instead, that study focused on the 
potential role of the c.85G>T SNV as the disease-causing mutation in this family. However, 
comprehensive functional assays of the p.A29S protein variant encoded by this SNV showed 
normal protein activity, suggesting it is neutral.7 The subsequent link between the c.[-27C>A; 
85G>T] haplotype and MLH1 epimutation in WA Family 1617, and thereafter the identification 
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of another index case (Proband H) with this haplotype and concomitant MLH1 epimutation10, 
strongly suggests this haplotype confers cancer susceptibility through its propensity for so-
ma-wide epigenetic silencing. The concurrence of both SNVs in distinct cases also raises the 
question of whether they are borne on a founder haplotype.
Through a follow-up study of members from Family 1744, herein designated USA Family 1, as 
well as two newly identified canceraffected families carrying the same c.-27C>A and c.85G>T 
SNVs, we provide definitive evidence that these variants are located on an ancestral haplo-
type and that it is associated with a mosaic, dominantly heritable form of MLH1 epimutation.
Materials and methods
Patients and specimens
Patients and their family members were recruited to this study following referrals from Family 
Cancer Clinics due to a clinical suspicion of Lynch syndrome and the prior identification of het-
erozygous MLH1 SNVs c.-27C>A and c.85G>T in a family member(s) during germline screen-
ing of the mismatch repair genes for mutations. USA Family 1 was referred from the Vermont 
Family Cancer Clinic by WCM and MSG. The two siblings provided fresh samples of peripheral 
blood, but no sample was available from their deceased parents. USA Family 2 was referred 
from the Stanford Family Clinic by UL and NC. The four siblings and their father each provided 
fresh samples of saliva, buccal mucosa and hair follicles. A formalin-fixed paraffin-embed-
ded (FFPE) block containing a biopsy of normal oesophageal tissue was available for the 
deceased mother. Netherlands Family 3 was diagnosed at the Radboud University Medical 
Centre by W.A.vZ-S. DNA samples from peripheral blood were obtained from members of the 
second and third generations of this family with help from F.H.M. from the VU University Med-
ical Centre after counselling two siblings, but no samples were available from the deceased 
members of the first generation. Study approval was granted by the Human Research Ethics 
Committees from the South Eastern Sydney Local Health District, the University of New South 
Wales, the Radboud University Medical Centre, Stanford University and the University of Ver-
mont. All subjects provided their written consent.
Genomic DNA and total RNA were extracted from peripheral blood lymphocytes (PBL) using 
standard procedures. DNA was extracted from buccal mucosa and hair follicles using the Epi-
centre BuccalAmpTM DNA extraction kit. Genotek Oragene saliva kits were used to extract DNA 
and RNA from saliva samples. The Qiagen QIAamp DNA Mini Kit was used to extract genomic 
DNA from FFPE tissue. 
Specific mutation testing
All MLH1 sequence variants are annotated according to coding reference sequence 
NM_000249.2. Testing for the MLH1 c.-27C>A and c.85G>T SNVs was performed by PCR 
amplification and direct sequencing of a fragment encompassing MLH1 exon 1 as previous-
ly described, irrespective of prior genetic testing of the individuals.18 Exons 7, 13 and 14 
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of the MUTYH gene were PCR amplified and sequenced to detect the c.536A>G (p.Y179C), 
c.1187G>A (p.G396D) and c.1437_1439del (p.E480del) mutations (according to coding ref-
erence sequence NM_001128425.1), as previously described.19 
Methylation analyses 
For Netherlands Family 3, initial methylation testing was performed by methylation-specific 
multiplex ligation-dependent probe amplification (MS-MLPA) using the ME011 MS-MLPA kit 
(MRC Holland, Amsterdam, The Netherlands). Methylation testing was performed on DNA de-
rived from the CRC, adjacent normal colorectal mucosa and PBL of the proband (F3-II3) and 
from PBL of other contributing family members.
For USA Families 1 and 2, and for confirmatory testing in four members of Netherlands Family 
3, methylation detection was performed by CpG pyrosequencing across five CpG sites, as 
previously described.20 First, genomic DNA (1 μg) was sodium bisulphite converted using the 
EZ methylation Gold kit (Zymo Research, Irvine, CA, USA), and 100–200 ng was used as PCR 
template. To determine allelic methylation patterns, fragments within the MLH1 CpG island 
encompassing either c.-27C>A or both SNVs were amplified using the forward primer (5’-3’) 
GGTATTGAGGTGATTGGTTGAAGG in combination with either reverse primer ATTCACCACTATCT-
CRTCCAAC (124 bp product) or CTATACATACCTCTACCCRAACAA (316 bp product), respectively 
(Figure 2a). Amplification products were cloned using the pGEMTeasy vector system (Prome-
ga, Madison, WI, USA) and the plasmid inserts from 24 individual bacterial colonies were 
sequenced.
 
Allelic expression analyses
The relative levels of transcripts derived from the two MLH1 alleles were quantified at the 
r.85g>u variant site in carriers of the c.[-27C>A; 85G>T] haplotype, or at the r.655a>g site in 
subjects heterozygous for the benign c.655A>G SNP (both according to coding reference se-
quence NM_000249.2), using previously described allele quantification (AQ) pyrosequencing 
assays.17,21 AQ data from mRNA was normalized to AQ data from parallel assays of genomic 
DNA to produce an allelic expression ratio: (allele 1mRNA/allele 2mRNA)/(allele 1DNA/allele 2DNA).
Haplotyping and copy number variant analysis using the Affymetrix SNP6.0 array
Genomic DNA from five carriers of the c.[-27C>A; 85G>T] haplotype (F1-II2, F2-II1, F2-II3, 
F3-II2 and F3-II3) was hybridized to Affymetrix SNP6.0 arrays. The data were combined with 
those from prior Affymetrix SNP6.0 arrays of five carriers from WA Family 16, publicly avail-
able from the Gene Expression Omnibus (GEO) databank, accession number GSE3034817, 
representing a total of 10 carriers from four distinct families. Genotypes were generated using 
Birdseed analysis software implemented in the Affymetrix Genotyping Console version 4.0. 
Subsequently, regions across the entire genome that were shared by all carriers of the two 
MLH1 SNVs were determined by defining the longest stretches of SNP genotypes that showed 
concordance between one or both alleles. A linkage disequilibrium plot of the chromosome 
3p22 region that exhibited haplotype sharing among carriers of the MLH1 SNVs was gener-
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ated using the Haploview software.22 Copy number analysis was performed using the Nexus 
Copy Number 6.1 software (BioDiscovery, El Segundo, CA, USA). The Affymetrix SNP6.0 array 
data from the three new families has been deposited in the GEO database (accession number 
GSE45149).
Results
Identification of distinct cancer-affected families bearing the MLH1 c.-27C>A and c.85G>T 
single-nucleotide substitutions
Three Caucasian families whose proband had previously undergone selective genetic screen-
ing of the mismatch repair genes due to a clinical suspicion of Lynch syndrome, and in whom 
the two SNVs c.-27C>A and c.85G>T had been identified within MLH1, were included in this 
study. Pedigrees are shown in Figure 1.
‘USA Family 1’ (Figure 1a) represents members of the family previously reported as ‘Family 
1744’7, who met the Amsterdam I criteria for Lynch syndrome.1 The female proband (F1-II2) 
and her older brother (F1-II1), who had both developed CRC exhibiting MSI and dual loss of 
MLH1 and PMS2 at the ages 36 and 51 years, respectively, were both carriers of the c.-27C>A 
and c.85G>T SNVs (Figure 1a). Their deceased father had also developed Lynch syndrome-re-
lated cancer, but no sample was available to confirm his carrier status. 
‘USA Family 2’ had raised a clinical suspicion of Lynch syndrome (Figure 1b). The male pro-
band (F2-II3) and his three siblings had undergone colonoscopic surveillance due to a pos-
itive family history of cancer. Their deceased mother (F2-I2) had developed CRC at the age 
of 59 years and the family also reported that their maternal grandmother had died of an 
‘abdominal cancer’ at 47 years of age. Colonoscopies conducted on the proband had led to 
the identification of a 2-mm sessile adenoma at the age of 42 years and a 15 mm flat ade-
noma with high-grade dysplasia at the age of 44 years. Consistent with an early Lynch syn-
drome-related neoplastic lesion, molecular pathology testing of his second adenoma showed 
it had lost MLH1 and PMS2 expression but retained MSH2 and MSH6, and was negative 
for the BRAF NM_004333.4: c.1799T>A (p.V600E) mutation.23 Based on these findings, tar-
geted germline screening of the MLH1 gene was performed, which revealed the c.-27C>A 
and c.85G>T SNVs. Testing of archival normal tissue from his mother showed she had also 
been a carrier. Clinical surveillance in his three siblings had led to the identification and re-
moval of one adenoma in his older brother at the age of 51 years, two adenomas of <5mm 
in his sister at the ages of 41 and 46 years, and two adenomas in his younger brother at 41 
years of age. The MLH1 c.-27C>A and c.85G>T SNVs were found in the older brother (F2-II1), 
whose adenoma was not examined by immunohistochemistry, but not in the other two sib-
lings (F2-II2 and F2-II4) who had also both developed adenomas. Immunohistochemistry of 
one adenoma from the youngest brother (F2-II4) showed retention of all four mismatch repair 
proteins. This raised concerns that an independent genetic mutation may have contributed 
to the phenotype in this family and so we additionally tested the four siblings and their father 
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Figure 1. Pedigrees of three families harbouring the MLH1 c.-27C>A and c.85G>T single-nucleotide variants. 
Pedigrees are shown for three cancer-affected families in which some members carry the variant (V) haplotype 
of MLH1 bearing the c.-27C>A and c.85G>T SNVs (according to reference sequence NM_000249.2) in tandem. 
(a) ‘USA Family 1’, (b) ‘USA Family 2’, (c) ‘Netherlands Family 3’. Alleles are shown as vertical lines; red, the 
variant (V) c.[-27C>A; 85G>T] haplotype identified in heterozygous carriers; grey, wild-type alleles. Segregation 
of constitutional MLH1 promoter methylation with the variant haplotype is indicated (Me). NT, not tested for 
the presence of methylation. Allele types are shown only for those relatives whose carrier status for the c.-
27C>A and c.85G>T SNVs could be tested. Circles, females; squares, males; black-filled, affected by a Lynch 
syndrome-type cancer; grey-filled, either affected by a cancer unlikely to be associated with Lynch syndrome, or 
diagnosis with a precursor lesion that could be Lynch syndrome-related. The type of neoplastic lesion and age 
of diagnosis in years (y) is given. HF, hepatic flexure.
188
Figure 2. Acquired loss of heterozygosity of the normal allele in the colorectal carcinoma of the 
proband from Netherlands Family 3. Sequence electropherograms across the MLH1 NM_000249.2: 
c.-27C>A (left) and c.85G>T (right) variants are shown for proband F3-II3, indicated by *. (a) Normal 
tissue shows heterozygosity for both variants. (b) CRC showing a significant reduction in the levels 
of the wild-type alleles, indicating somatic loss of heterozygosity of the normal, functional allele.
for the NM_001128425.1: c.536A>G (p.Y179C), c.1187G>A (p.G396D) and c.1437_1439del 
(p.E480del) mutations within the MUTYH gene, which have been associated with polyposis 
and an increased risk of CRC particularly among Caucasians.19 All were negative for these 
common MUTYH mutations.
‘Netherlands Family 3’ met the Amsterdam I criteria for Lynch syndrome (Figure 1c). The male 
proband (F3-II3) had presented with colorectal and kidney cancers at the age of 41 years. 
Molecular pathology testing of his CRC revealed MSI and dual absence of MLH1 and PMS2 
expression. Selective germline screening of MLH1 and PMS2 for mutations uncovered the 
MLH1 c.-27C>A and c.85G>T SNVs and his CRC demonstrated loss-of-heterozygosity (LOH) 
of the wild-type allele (Figure 2). Targeted screening for the two SNVs in family members 
identified them in both of his cancer-affected brothers, including a non-identical twin. The 
twin sisters were not carriers. Although one (F3-II4) had developed melanoma at a young 
age, this is likely to represent a sporadic cancer unrelated to Lynch syndrome. Both parents, 
now deceased, had developed CRC, which could have been Lynch syndrome-related in either 
parent. However, no samples were available to test their carrier status. One family member 
in the third generation (F3-III1), who was asymptomatic at 19 years of age, also carried the 
MLH1 SNVs (Figure 1c).
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Absence of MLH1 c.-27C>A and c.85G>T among healthy individuals suggests they are rare 
variants
In a previous study, we did not find either the MLH1 c.-27C>A or the c.85G>T SNV in a screen 
of 304 Australian healthy control subjects.17 To determine if these variants are represented on 
a wider population basis, we mined the genetic variation database generated from the 1092 
subjects enrolled in the ‘1000 Genomes Project’, which included 379 individuals of European 
ancestry.24 The power to detect SNVs present at a frequency of 1% in this study population 
was estimated to be at least 99.3%.24 Neither variant was found, suggesting they occur in 
<1% of the general population. 
The haplotype bearing the c.-27C>A and c.85G>T variants is linked to constitutional methyl-
ation and transcriptional repression in all three families
The variant MLH1 c.-27C>A and c.85G>T alleles were linked as a haplotype in each family 
(Supplementary Figure 1). Members from the three additional families were then tested for 
the presence of MLH1 methylation within normal tissues (n=15 subjects) and tumour tissue 
(n=1 proband) by MS-MLPA and/or CpG pyrosequencing. MLH1 methylation levels ranged 
from 17–32% within the normal tissues from all testable carriers of the variant MLH1 hap-
lotype, whereas all family members with the wild-type sequence were negative for MLH1 
methylation (Table 1; Supplementary Figure 2). Thus, substantial methylation of the MLH1 
promoter in normal somatic tissues segregated with the MLH1 c.[-27C>A; 85G>T] haplotype 
in all three families (Figure 1). In Netherlands Family 3, high levels of MLH1 methylation were 
first found by MS-MLPA in the CRC of the proband (F3-II3), consistent with the finding of LOH 
of the wild-type MLH1 allele, and subsequently in his normal colorectal mucosa and PBL (Ta-
ble 1). Notably, constitutional MLH1 methylation was found in two generations of this family, 
with passage from the proband’s twin brother (F3-II2) to his daughter (F3-III1), consistent with 
dominant transmission of the epimutation linked to this haplotype.
Allelic bisulphite sequencing across the c.-27C>A or both SNVs was performed in each 
proband and an additional methylation positive subject from each family (Figure 3a). This 
showed that methylation was linked specifically to the haplotype bearing the variant c.-27C>A 
and c.85G>T alleles. Furthermore, the methylation patterns showed some copies of this hap-
lotype were completely or partially methylated, while others were entirely unmethylated, con-
sistent with a mosaic epimutation (Figure 3b; Supplementary Figure 3).
Quantitative allelic expression analyses were performed at the r.85g>u site in carriers of the 
c.[-27C>A; 85G>T] haplotype (n=5) to determine if the epimutation was associated with the 
loss of expression from the affected allele within normal tissues (Figure 3a). A partial, but 
significant reduction in the levels of mRNA transcripts derived from the variant allele was 
observed in each of the carriers tested, ranging from 19 to 63% relative to the wild-type allele 
(Figure 3c; Table 1; Supplementary Figure 3). By contrast, near equivalent levels of expres-
sion from each MLH1 allele were observed at the r.655a>g site in a member of USA Family 
2 (F2-II4) who was informative for the benign c.655A>G SNP but did not carry the variant c.[-
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Table 1. MLH1 methylation and relative allelic expression levels in normal tissues from family 
members and unrelated healthy controls 
Subject 
 
c.[-27C>A; 
85G>T] carrier 
status 
Methylation levels 
(%) 
AER u:g at 
r.85g>u 
AER a:g at 
r.655a>g 
USA F1 
F1-II1 sibling 
F1-II2 proband 
 
Carrier 
Carrier 
PBL 
20 
32 
PBL 
0.40 
0.19 
 
USA F2 
F2-I1 father 
F2-I2 mother 
F2-II1 sibling 
F2-II2 sibling 
F2-II3 proband 
F2-II4 sibling 
 
Non-carrier 
Carrier 
Carrier 
Non-carrier 
Carrier 
Non-carrier 
Saliva; hair bulb 
1; 1 
NT 
17; 19 
1; 1 
29; 30 
1; 0 
Saliva 
 
 
0.63 
 
0.22 
 
Saliva 
 
 
 
 
 
1.06 
Netherlands F3 
F3-II1 sibling 
F3-II2 sibling 
F3-II3 proband 
F3-II4 sibling 
F3-II5 sibling 
F3-III1 niece 
F3-III2 daughter 
F3-III3 daughter 
 
Carrier 
Carrier 
Carrier 
Non-carrier 
Non-carrier 
Carrier 
Non-carrier 
Non-carrier 
PBL; NCM; CRC 
30* 
21*/23 
23/30*; 31*; 86* 
< 1* 
< 1* 
35* 
1/1* 
1/1* 
PBL 
 
 
0.31 
 
 
Unrelated 
Healthy control 1 
Healthy control 2 
 
Non-carrier 
Non-carrier 
PBL 
0 
1 
 
 
 
 
Abbreviations: CRC, colorectal cancer; F, family; PBL, peripheral blood lymphocytes; NCM, normal colorectal 
mucosa; NT, not tested due to lack of sample availability. The levels of constitutional methylation and allelic 
expression of MLH1 are shown in relation to the carrier status of the NM_000249.2: c.[-27C>A; 85G>T] 
haplotype among the members from three families. Methylation levels shown are the average across five CpG 
sites assayed by pyrosequencing within the C-region of the MLH1 promoter, or by MS-MLPA (*). A background 
signal of 1% methylation was considered negative, since this was also found in healthy controls. CpG 
pyrosequencing traces are given in Supplementary Figure 2. The high level of methylation detected in the CRC 
of F3-II3 was consistent with loss of heterozygosity of the unmethylated wild-type allele. The allelic expression 
ratio (AER) shows the normalized relative levels of MLH1 transcripts derived from the two alleles at expressed 
sequence variants NM000249.2: r.85g>u or r.655a>g in heterozygous individuals. Values are derived from 
allele quantification pyrosequencing data shown in Figure 3, and Supplementary Figures 3 and 4. An AER of 
1.0 indicates an exactly equal level of expression between the two MLH1 alleles, whereas an AER significantly 
below 1.0 for the variant allele at the r.85g>u site indicates a significant loss of expression from the variant 
c.85G>T allele. The source of normal tissue from which constitutional DNA or RNA was extracted is indicated.
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Genotyping reveals an extensive shared ancestral haplotype across chromosome 3p22 be-
tween four families bearing the MLH1 c.-27C>A and c.85G>T SNVs
USA Families 1 and 2 had immigrated to the USA, but were self-reported to be of Scottish 
descent and mixed German and UK heritage, respectively. Netherlands Family 3 was of mixed 
Dutch and Australian heritage. Thus these three families and the two previously reported 
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Australian cases were of European origin.10,17 The occurrence of two distinct SNVs on the 
same MLH1 haplotype in association with MLH1 epimutation in five ostensibly unrelated can-
cer-affected European families raised the question of whether they share common ancestry. 
If so, the carriers in each family would be predicted to share a larger founder haplotype on 
chromosome 3 extending beyond MLH1 itself.
Genome-wide array-based genotyping performed in 10 carriers of the MLH1 c.[-27C>A; 
85G>T] haplotype from among the three families and WA Family 1617 revealed shared gen-
otypes among 883 consecutive SNPs across chromosome 3p22. The shared genotypes 
spanned nearly 2.6 Mb and encompassed the ARPP21, miRNA128-2, STAC, DCLK3, TRANK1, 
EPM2AIP1, MLH1, LRRFIP2, GOLGA4 and ITGA9 genes (Supplementary Figure 5; Figure 4a). 
This region stretched across 89 consecutive haplotype blocks (Figure 4b), indicating a very 
high likelihood that the degree of genotype concordance in these families did not occur by 
chance. Additional shared haplotypes spanning large genomic regions were found on other 
chromosomes as well (data not shown). These findings strongly support our hypothesis that 
the four families share a common genetic lineage and that the c.-27C>A and c.85G>T MLH1 
variants are indeed borne on a founder haplotype.
Using WA Family 16 as the reference, pair-wise genotype comparisons were made between 
the carriers from each of the other three families individually, to determine the degree of hap-
lotype sharing between them. This revealed even more extensive regions of genetic overlap 
spanning 5.5–6.3 Mb between USA Families 1 and 2 and the WA Family 16, whereas the WA 
and Dutch families shared the same minimal ≤2.6 Mb region of overlap that was common to 
all four families (Figure 4a).
To confirm the extended ancestral haplotype segregated with the variant MLH1 c.[-27C>A; 
85G>T] haplotype and the epimutation itself, the same 3p22 SNP and STS microsatellite 
markers previously used to identify the epimutation-associated haplotype in WA Family 1617, 
were genotyped in both carrier and non-carrier members from the three families. Alleles seg-
regating with the presence of constitutional methylation within each pedigree were compiled 
into haplotypes and compared with the ‘reference’ haplotype from WA Family 16 (Table 2). 
The epimutation-associated haplotypes were identical between the four families within the 
minimally shared 2.6 Mb region, and were also consistent with the distinct larger regions of 
overlap found between individual families (Table 2). The Dutch family and WA Family 16 were 
found to share an allelotype at one STS marker (D3S1277) located upstream of the ≤2.6 Mb 
region they both shared. However, this may simply reflect chance allelotype sharing at this 
particular marker, or a double-recombination event between this upstream locus and the 
proximal end of their shared region.
Dominant inheritance of the MLH1 epimutation with the c.[-27C>A; 85G>T] haplotype strong-
ly implicates a cis-acting genetic basis to this epimutation. To investigate whether any large 
deletions or duplications are present within the minimally shared 2.6 Mb region of chromo-
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Figure 3. MLH1 promoter methylation and transcriptional repression are linked to the c.[-27C>A; 85G>T] 
variant haplotype of MLH1. (a) Maps of assays used to detect allelic methylation patterns and measure 
the relative levels of allelic expression at the c.85G>T or r.85g>u sites, respectively. The promoter region of 
MLH1 to exon 2 is depicted, with grey rectangles indicating exons as numbered. Narrow rectangles indicate 
5’ untranslated sequence and wide rectangles show translated sequence. The major transcription initiation 
site is indicated by a large arrow. The translation start site is located at +1. Individual CpG dinucleotides are 
shown as lollipops, with those assessed for the presence of methylation filled in grey. The locations of the 
MLH1 NM_000249.2: c.-27C>A and c.85G>T substitutions are indicated by vertical red lines. Horizontal black 
lines indicate PCR amplification fragments incorporating the c.-27C>A or both SNVs and a number of flanking 
CpGs for allelic bisulphite sequencing. The allele quantification pyrosequencing assay to determine allelic 
expression levels, shown in blue, has been previously published.17 (b) Allelic methylation patterns are shown for 
the proband from each family for each normal somatic tissue type tested. PBL, peripheral blood lymphocytes. 
Horizontal lines represent single molecules of the DNA fragments. Circles show individual CpG sites, numbered 
according to the map, with black as methylated and white as unmethylated. The SNVs are indicated as shapes; 
with variant alleles in red. Only one representative wild-type (W-T) allele is shown for each proband as these 
were uniformly unmethylated. Methylation was confined to the variant haplotype, but did not affect every single 
copy of it, indicating methylation mosaicism. (c) Pyrogram traces showing the relative levels of each allele at 
the c.85G>T site in genomic DNA or r.85g>u in mRNA samples. Yellow shading highlights the peaks of the two 
nucleotides at the c.85g>u site (measured in reverse complement as c>a), from which the relative level of each 
allele is derived and given as a percentage of the two above. The normalized allelic expression ratios from the 
variant T allele relative to the W-T G allele are provided. A consistent reduction in expression from the variant 
allele was observed in each proband.
LYNCH SYNDROME AND THE MMR GENES
some 3p22, copy number variation analysis was performed in the five carriers from the three 
families. Similar to previous findings in WA Family 1617, no copy number changes within this 
region were consistently detected among the carriers (data not shown).
Discussion
We have shown in three cancer-affected families that the MLH1 haplotype bearing the c.-
27C>A and c.85G>T SNVs is linked to a mosaic form of constitutional epimutation, which 
manifested as variable levels of promoter methylation accompanied by significant transcrip-
tional loss from this haplotype within normal tissues. This study brings the number of inde-
pendent cases harbouring this MLH1 haplotype with a concomitant epimutation to five. Ver-
tical transmission of the epimutation with this haplotype was observed in one of our families 
(Netherlands Family 3), consistent with the prior finding of its dominant inheritance of in WA 
Family 16.17 In the other two families, sample availability from the parental generation was 
restricted, but segregation of the MLH1 epimutation with the c.[-27C>A; 85G>T] haplotype 
was nevertheless clearly demonstrated among siblings.
These families provide collective evidence that the c.[-27C>A; 85G>T] MLH1 haplotype is 
associated with a heritable MLH1 epimutation, which in turn, confers a high risk of develop-
ment of Lynch syndrome-related cancers. Four of the cases reported to date (USA Family 1, 
Netherlands Family 3, WA Family 16 and Proband H) met the Amsterdam I criteria due to a 
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The locations of STS markers are shown with respect to the MLH1 translation initiation site. The genotypes 
of chromosome 3p22 SNP and STS markers that segregated with the MLH1 NM000249.2: c.-27C>A and 
c.85G>T SNVs and MLH1 methylation within each of four families (F) are tabulated. The epimutation-
associated haplotypes shown in each column were compiled from the diplotypes of the two affected siblings in 
USA Family 1 (F1-II1 and F2-II2), all members of USA Family 2, and two carriers (F3-II2 and F3-II3) and two non-
carriers (F3-III2 and F3-III3) of Netherlands Family 3, by independent segregation analyses at each individual 
marker. Highlighted in bold are the haplotypes shared with the reference haplotype previously reported for WA 
Family 16.17 All four families shared a common haplotype spanning at least 700 kb (from D3S1561 to LRRFIP2 
rs10849), located within the 2.6 Mb region identified by array-based genotyping. USA Family 1 shared a larger 
haplotype with WA Family 16 extending ~1.8 Mb downstream of MLH1 to include D3S1100. USA Family 2 and 
Netherlands Family 3 shared a more extensive haplotype >2.4 Mb upstream of MLH1 to include D3S1277. 
The Dutch family and WA Family 16 share an allelotype at D3S1277 located upstream of the ≤2.6 Mb region 
they both shared. This may simply reflect chance allelotype sharing at this particular marker, or a double-
recombination event between this upstream locus and the proximal end of their shared region. NT, not tested.
Table 2. Chromosome 3p22 SNP and STS haplotypes segregating with the  
MLH1 c.-27C>A and c.85G>T variants and epimutation in four families. 
Location Marker WA F16  USA F1 USA F2 Dutch F3 
-2,438,039 bp D3S1277 264 272 264 264 
-609,919 bp D3S1561 240 240 240 240 
TRANK1 3’ UTR rs4789:A>G G G G G 
EPM2AIP1 3’ UTR rs9311149:C>A A A A A 
MLH1 promoter rs1800734:G>A G G G G 
MLH1 5’UTR c.-27C>A A-Me A-Me A-Me A-Me 
MLH1 exon 1 c.85G>T T-Me T-Me T-Me T-NT 
MLH1 intron 3 rs4647224:G>A A A A NT 
MLH1 exon 8  rs1799977:A>G or 
c.655A>G 
G G G G 
MLH1 intron 9 rs4647277:A>G G G G G 
LRRFIP2 3’ UTR rs10849:G>A A A A A 
+1,785,165 bp D3S1100 178 178 180 166 
 
significant family history of syndromal cancers that included CRC below 50 years of age in at 
least one member. Of the cancers tested, both herein and previously10,17, MSI and MLH1 loss 
were consistently observed. Furthermore, the finding of LOH as the ‘second hit’ in the CRCs 
from the Dutch and WA probands17 is consistent with the c.[-27C>A; 85G>T] germline hap-
lotype serving as the ‘first hit’. The role of this haplotype in disease causation in USA Family 
2 is less clear. Although this family did not meet formal clinical criteria for Lynch syndrome2, 
this was likely precluded by the lack of histopathology testing in the mother’s CRC and clinical 
intervention in the proband and siblings that may have altered their disease course. Never-
theless, absence of MLH1 was observed in the tested large adenoma from the proband, con-
sistent with a precursor lesion with the potential to progress to Lynch-type adenocarcinoma. 
Furthermore, the cancer-affected mother was also a carrier. Nevertheless, the detection of 
adenomas in the two siblings who did not carry the variant MLH1 haplotype is of concern. A 
second genetic mutation may be present in this family that has contributed to their pheno-
type. Immunohistochemistry of one adenoma from the younger brother showed normal mis-
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match repair status and hence we screened for common mutations within the MUTYH gene, 
but did not find them. Genetic studies in this family are ongoing.
The lack of representation of the MLH1 c.-27C>A and c.85G>T variants among healthy sub-
jects from the general population, most pertinently among Europeans, suggests they are rare 
and provides further epidemiological support for the pathogenicity of this haplotype. These 
two nucleotide substitutions most likely comprise ‘private’ disease-linked variants, as op-
posed to ‘polymorphisms’.
The five families identified with the MLH1 c.[-27C>A; 85G>T] haplotype are all of European 
ethnicity. We showed that carriers from four of these families share a large common haplo-
type that extends well beyond the two SNVs, spanning ≤2.6 Mb of chromosome 3p22 and 
encompassing the MLH1 gene neighbourhood. These findings provide strong evidence that 
these families are descended from a common ancestor. Indeed, paired comparisons between 
WA Family 16 from and each of the other three families individually showed haplotype sharing 
across even larger regions of chromosome 3 between the Australian and USA families, sug-
gesting they are more closely related to one-another than the Dutch family.
We confirmed that the extended founder haplotype segregated with the c.-27C>A and 
c.85G>T SNVs and the MLH1 epimutation. This finding has two important implications. The 
first relates to the identification and diagnosis of Lynch syndrome in other carriers. The exis-
tence of additional descendants of the ancestor in whom these SNVs arose seems likely and 
they may be disseminated across the globe through migration. We proffer that the identifica-
tion of these germline SNVs during standard mutation screening provides a firm molecular 
diagnosis of Lynch syndrome. In addition, any Lynch syndrome-like cases identified as carriers 
of a constitutional MLH1 epimutation should be investigated for these two SNVs, since their 
presence indicates a 50% risk of transmission of the epimutation to offspring. The second im-
plication is in discerning the mechanism by which this particular genetic haplotype underlies 
the high-penetrance epigenetic inactivation of MLH1 throughout the soma. Faithful dominant 
inheritance of the MLH1 epimutation with this genetic haplotype provides clear evidence that 
its epigenetic manifestations are caused by a genetic defect located on this haplotype. How-
ever, the candidate region within which the causative genetic defect is presumably located, 
is now defined by the ≤2.6 Mb minimal region of haplotype overlap between the four fami-
lies. We found no evidence for large copy number changes within this region; however, this 
does not rule out more subtle alterations. The c.-27C>A variant remains the prime candidate 
underlying the MLH1 epimutation on this haplotype. In support of this, artificial promoter re-
porter assays have shown this substitution results in significantly diminished transcriptional 
output.10,17 However, a clear mechanistic link between this SNV and epigenetic modification 
of the MLH1 promoter remains to be demonstrated. Irrespective of the precise molecular 
mechanism via which the MLH1 epimutation is induced on this founder haplotype, or wheth-
er the c.-27C>A variant is indeed responsible, the c.-27C>A and c.85G>T SNVs can serve as 
markers for this disease-causing genetic haplotype.
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Supplementary Figure 1. The c.-27C>A and c.85G>T variants within MLH1 exon 1 
are located in tandem on the same haplotype. Representative sequence electrophero-
grams of MLH1 exon 1 are shown for the proband from one family (USA Family 1), who 
was a carrier of the germline heterozygous single nucleotide variants c.-27C>A and 
c.85G>T (top panel). Resequencing of individual DNA strands following cloning of the 
PCR products show the variant c.-27A and c.85T alleles are linked on a single haplo-
type (middle panel). The other haplotype is wild-type, bearing the c.-27C and c.85G 
alleles (bottom panel). 
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Supplementary Figure 2. Measurement of MLH1 promoter methylation in 
constitutional tissues.
LYNCH SYNDROME AND THE MMR GENES
USA Family 1
F1-II2: Proband (MLH1 c.-27C>A and c.85G>T carrier)
Peripheral blood lymphocytes, mean methylation: 32.2%
F1-II1: Affected brother (MLH1 c.-27C>A and c.85G>T carrier)
Peripheral blood lymphocytes, mean methylation: 20.0%
USA Family 2
F2-II3: Proband (MLH1 c.-27C>A and c.85G>T carrier)
Saliva, mean methylation: 29.2%
Hair bulb, mean methylation: 30.0%
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Supplementary Figure 2 continued
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F2-I1: Father
Saliva, mean methylation: 1.2% (negative)
Hair bulb, mean methylation: 0.6%
F2-II1: Older brother (MLH1 c.-27C>A and c.85G>T carrier)
Saliva, mean methylation: 17.0% 
Hair bulbs, mean methylation: 18.6%
203
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F2-II2: Older sister (non-carrier)
Saliva, mean methylation: 1.2% (negative)
Hair bulbs, mean methylation: 1.4% (negative)
F2-II4: Younger brother (non-carrier)
Saliva, mean methylation: 1.2% (negative)
Hair bulb, mean methylation: 0.4% (negative)
Supplementary Figure 2 continued
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Netherlands Family 3
F3-II3 Proband (MLH1 c.-27C>A and c.85G>T carrier)
Peripheral blood lymphocytes, mean methylation: 22.6%
F3-II2 Non-identical twin brother (MLH1 c.-27C>A and c.85G>T carrier)
Peripheral blood lymphocytes, mean methylation: 23.2%
F3-III2 Daughter (non-carrier)
Peripheral blood lymphocytes, mean methylation: 1.2% (negative)
F3-III3 Daughter (non-carrier)
Peripheral blood lymphocytes, mean methylation: 0.8% (negative)
Supplementary Figure 2 continued
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CpG pyrosequencing traces are shown in the “Deng-C” region of the MLH1 promoter for members of families 
in which the MLH1 c.-27C>A and c.85G>T single nucleotide variants had been identified, plus healthy control 
individuals. Subjects are labeled with identifiers according to Figure 1. Their carrier status of the variant MLH1 
haplotype and tissue-type(s) tested are indicated. Methylation levels were measured at five consecutive CpG 
sites (peaks within grey shaded regions), with the percentage of methylation detected at each given in blue 
boxes above. The final percentage methylation score was the mean across the five sites, given above each 
pyrogram. Quality control cytosine sites ensuring complete conversion of genomic DNA with sodium bisulphite 
(and hence rule out false-positives) are highlighted by green shading.
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Healthy Control 1 (non-carrier)
Peripheral blood lymphocytes, mean methylation: 0.4% (negative)
Healthy Control 2 (non-carrier)
Peripheral blood lymphocytes, mean methylation: 1.4% (negative)
Supplementary Figure 2 continued
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Supplementary figure 3. Constitutional methylation and reduced expression of the MLH1 variant haplotype 
in family members. See main Figure 3 for legend.
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Supplementary Figure 4. Equal levels of expression of the two MLH1 alleles at the benign c.655A>G SNP in 
a heterozygous family member who does not carry the c.[-27C>A; 85G>T] haplotype. Allele quantification py-
rosequencing traces are shown at the c.655A>G SNP site within MLH1 exon 8 for subject F2-II, who does not 
carry the variant c.-27C>A and c.85G>T MLH1 haplotype. The top trace shows heterozygosity for the neutral 
c.655A>G SNP in his genomic DNA. The lower trace shows the relative levels of expression at the informative 
r.655a>g site in his mRNA. The normalized allelic expression ratio (AER) showed near equivalent levels of ex-
pression between the two alleles, consistent with normal MLH1 transcription.
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USA Family 2 individual II-4 (non-carrier)
Saliva DNA
Saliva mRNA
Allelic expression ratio (AER) = (48.7/51.3)/(50.2/49.8) = 1.06
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Supplementary Figure 5. Regions of shared chromosome 3 SNP genotypes among carriers of the MLH1 c.-
27C>A and c.85G>T variants from four unrelated families. SNP genotype concordance plot across chromo-
some 3 generated from Affymetrix SNP6.0 array data by comparing the genotypes from 10 carriers of the MLH1 
c.-27C>A and c.85G>T haplotype from four families (WA Family 16, USA Families 1 and 2, and Netherlands 
Family 3). Vertical black bars show concordance was found between one or both alleles of consecutive SNPs 
between all individuals within the group comparison. A large block of genotype concordance between 883 
consecutive SNPs spanning 2,581,068 bp from chromosome 3 position 35281232-37862300 was found 
among the 10 carriers (horizontal blue bar). The location of MLH1 within this region is indicated by a blue arrow.
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CHAPTER 6
General discussion
Knowledge about the genetic cause of gastric- and colorectal cancer is important in order to 
identify individuals at risk at an early stage (before the cancer develops) to be able to apply 
appropriate surveillance strategies, thereby reducing the mortality related to these two types 
of cancer. The aim of this thesis was to add to this knowledge, with a focus on the improved 
recognition of CDH1 mutation carriers (at risk for Hereditary Diffuse Gastric Cancer) and the 
identification of novel genes underlying early-onset and familial gastric cancer. Furthermore, 
we have examined genetic aberrations in patients suspected of Lynch syndrome. 
Improved recognition of HDGC and Lynch syndrome
Recognition of HDGC in daily practice
In 1998, Guilford et al. identified germline mutations in the CDH1 gene as a cause for hered-
itary diffuse gastric cancer (HDGC).1 CDH1 mutation carriers have a high risk of developing 
gastric cancer of approximately 80% by age 80 and women have an additional lifetime risk of 
developing lobular breast cancer of approximately 60%.2 Since diffuse GC is difficult to detect 
at an early and treatable stage3, there is a great need to recognize mutation carriers prior to 
their disease. One of the approaches to achieve this is the use of guidelines with criteria for 
families in which CDH1 mutations occur. The last guideline in 2010 broadened the clinical 
criteria to select patients eligible for CDH1 mutation analysis. These revised criteria are: (1) 
one diffuse gastric cancer case below age 40, (2) two gastric cancer cases in a family, one 
confirmed diffuse gastric cancer below the age of 50, (3) three confirmed diffuse gastric can-
cer cases in 1st or 2nd degree relatives independent of age or (4) personal or family history of 
diffuse gastric cancer and lobular breast cancer, with one diagnosis below age 50.2
The detection rate of CDH1 mutations using the guidelines from 19994 was reported to be 
25-50%. Since CDH1 was identified in 1998 as HDGC susceptibility gene, it seems reason-
able that there is a bias of large and highly suspected families in the initial studies that re-
ported these percentages. Also, we know that the detection rate is considerably higher in the 
New Zealand Māori population, in which CDH1 was originally identified and is likely higher in 
the Newfoundland population, where a founder mutation has been described.5
In the Netherlands, the Radboud university medical center is the reference laboratory for 
CDH1 mutation analysis. In chapter 2.1, the criteria to predict germline CDH1 mutations 
in Hereditary Diffuse Gastric Cancer as they were set in 2010 were evaluated by combining 
the CDH1 mutation analysis results with clinicopathological data of 499 families screened 
between 1999 and 2014. Of these families, 118 met the HDGC criteria and in this group, 
16 pathogenic CDH1 mutations were identified (14%). Two additional mutations were found 
in the remaining families, who either did not meet the criteria or from whom the data was 
incomplete (Van der Post et al. 2014, submitted). No mutations were identified in the group 
of patients with intestinal-type GC, indicating that considering the histological subtype is very 
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important when selecting patients eligible for CDH1 mutation screening. In six out of the 
eighteen CDH1-positive families there were breast cancer cases. In two of them, the breast 
cancer case was the index patient and in one case the index patient had both gastric and 
breast cancer. There were no CDH1 mutations in families with LBC (without GC), in contrast 
to what has been described for other patient cohorts.6-9
The criteria had a sensitivity of 89%, which means that using the 2010 HDGC criteria, 11% of 
the families would be missed. The first patient that did not meet the criteria had DGC at age 
45. This patient was the only affected individual in the family and was diagnosed with DGC at 
an age five years above the upper age limit for single cases in a family. The second family did 
not meet the 2010 criteria because the index patient had DGC at age 59 with a first degree 
relative with GC at age 32 from whom no histology was available. Based on these results and 
the results of others6, the International Gastric Cancer Linkage Consortium (IGCLC) has up-
dated these criteria in the new international guideline (chapter 2.3). The new criteria (taking 
into account first- and second-degree relatives) are: families with two gastric cancer patients 
at any age, one confirmed diffuse gastric cancer, or individuals with diffuse gastric cancer 
before the age of 40 years and, third, families with diagnoses of both DGC and LBC (one 
diagnosis before the age of 50). One of the families that previously did not meet the criteria 
does now, thereby increasing their sensitivity. Of course, broadening the criteria means that 
the number of families to be tested will also increase. This was also discussed during the 
IGCLC meeting, but given the fact that the costs of sequencing are decreasing rapidly, we do 
not consider this a problem. 
Identification of germline mutations in CDH1 in patients with orofacial clefts
The current criteria for HDGC2 focus on the occurrence of gastric and lobular breast cancer in 
families. However, besides these two types of cancer, the presence of patients with orofacial 
clefts (OFC) in CDH1 families also has been described, first by Frebourg et al.10 and later this 
association was confirmed by Kluijt et al.11 OFC are among the most common birth defects 
worldwide.12 Examining the role of CDH1 as a candidate gene seemed reasonable since the 
fusion of the palate is the result of complex cell–cell interactions13 and E-cadherin is ex-
pressed during the critical stages of lip and palate development.10 
Functionally relevant mutations in CDH1 had not yet been described in an unselected cohort 
of non-syndromic OFC patients prior to our study, although several studies have focused on 
common SNPs at the CDH1 locus. Letra et al. found borderline significance between two 
intronic SNPs in CDH1 and OFC.14 For another variant, rs16260, located upstream of the 
transcriptional start site, there seem to be differences in populations studied. This SNP did 
not show significance in a Polish study.15 Song et al. found that in a Chinese Han population, 
this polymorphism was associated with cleft palate only.16 In people from Iran, there is an 
association between the AC and AA genotypes of this SNP and all forms of OFC.17 
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Identifying CDH1 mutation carriers in a group of unselected OFC patients would provide a 
perfect opportunity to perform interventions to prevent GC and LBC, since OFC is already 
apparent very early in life. In our cohort of 81 children with non-syndromic OFC, we identified 
heterozygous CDH1 missense variants in four out of 81 (5%) patients (chapter 2.2). Assess-
ing the putative pathogenicity of missense variants is a challenge. We used a combined ap-
proach of sequencing data of control cohorts not enriched for cancer, in silico analyses and in 
vitro analyses to classify the variants. The in vitro assays confirmed the functional relevance 
of the missense variants. 
The data obtained in our study supports the hypothesis that germline CDH1 mutations in-
crease the risk of non-syndromic OFC. Two additional studies besides the studies of Frebourg 
et al. and Kluijt et al.10,11 have been published in which the relation between OFC, DGC and 
CDH1 mutations was further supported. Benusiglio et al. described a 17-year old patient 
with DGC and OFC, who was confirmed to be carrier of a truncating mutation in CDH1.18 And 
recently, in a study among 55 unselected families with OFC, Bureau et al. found a truncating 
CDH1 mutation in three second cousins from an Indian family. Interestingly, this is the first 
truncating CDH1 mutation found in a cohort of unselected OFC patients. There was no further 
information on family history other than the cleft cases.19 The variant is not described in DGC/
LBC families thus far.6,20 (Van der Post et al. 2014, submitted)
Currently, it is not known whether the mutation carriers that we identified in the OFC cohort 
are at increased risk of developing GC and LBC. There is a possibility that the variants we 
identified might be relevant for OFC risk, but not for gastric cancer risk. In most of the pub-
lished studies on GC and LBC risk, missense variants have been left out of the analysis be-
cause of the difficulties with determining their putative pathogenicity. Systematic calculation 
of the cancer risks among carriers of functionally relevant missense CDH1 mutation carriers 
is needed to determine whether CDH1 missense mutation carriers should opt for prophylactic 
gastrectomy, which is the only intervention to prevent the development of GC. If our results 
are confirmed in a larger cohort of OFC patients and risk assessment of CDH1 missense 
variants show that carriers of germline CDH1 missense mutations indeed have an increased 
of developing GC and/or LBC, our results may be highly relevant for the diagnostic work-up of 
patients with OFC as well as DGC families. Not every clinical geneticist may be aware of the 
association between OFC and germline CDH1 mutations, so there may be an underestimation 
of the number of OFC cases in CDH1 families reported to date. 
Based on our results in the OFC cohorts and the results of other groups that have observed an 
association between OFC and CDH1 mutations and variants10,11,18, there has been a revision 
of CDH1 testing criteria of the international guideline for CDH1 mutation carriers (chapter 
2.3). In this revised guideline, additional criteria have been included based on observations 
for which insufficient data is yet available to make cancer risk assessments. In total there are 
three of such criteria, one of them is that patients with DGC who have a personal or family his-
tory of OFC are eligible for CDH1 mutation testing. The addition of this criterion will hopefully 
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lead to more awareness among clinical geneticists about the occurrence of OFC in families 
suspected of HDGC and furthermore the addition of the criterion will provide more insight in 
the role of CDH1 mutations in OFC predisposition. 
CDH1 mutation carriers identified by gene panel sequencing
Another reason why it is important to investigate cancer risks for CDH1 missense mutation 
carriers is the implementation of next-generation sequencing (NGS) based gene panels, in 
research as well as in diagnostic settings. In these panels, CDH1 alterations (either truncating 
or missense) may be found in patients with or without a personal or family history of (gastric) 
cancer.21,22 In the new IGCLC guideline (chapter 2.3) it is advised to be very careful with the 
identified variants regarding clinical follow-up, especially if the CDH1 variant does not lead to 
a premature stop codon. For example, in a large study conducted in the United States, 141 
women with personal or family history of breast cancer were screened for 42 genes with can-
cer risk associations, including CDH1.22 One woman without personal history of breast cancer 
but an extensive family history with several breast cancer cases was found to carry the c.532-
18C>T variant in CDH1. Based on this finding, this healthy carrier was advised to consider 
annual breast MRIs, as well as frequent endoscopic gastroduodenoscopy (once every one to 
two years).22 However, other studies already revealed that this is a common variant without 
functional consequences on protein level.23,24 Furthermore, this variant was also identified 
several times in our studies on germline CDH1 mutations in families meeting the HDGC cri-
teria as well as in the study on CDH1 variants in OFC patients (chapters 2.1 and 2.2). Based 
on the predicted absence of pathogenicity of the variant, we consider this presymptomatic 
screening unnecessary and not of benefit to the carrier of the variant.
Based on the study by Johnston et al., the pathogenicity of one of the CDH1 missense vari-
ants has been re-assessed.21 The c.892A>G (p.Ala298Thr) variant was previously reported by 
Brooks-Wilson et al.25 and it was shown using in vitro studies that this variant impacts E-cad-
herin function25,26, after which the variant was considered pathogenic. However, Johnston 
et al. found this variant in two individuals without a family history of gastric and/or breast 
cancer.21 Therefore, this variant, which was also found in a Dutch HDGC family (chapter 2.1), 
is now considered a variant of unknown significance instead of a pathogenic mutation. As a 
consequence of this altered interpretation, carriers of this variant are no longer advised to 
undergo prophylactic gastrectomy.
Currently, there is no international database containing all germline CDH1 mutations and 
variants identified to date. During the workshop of the 2014 IGCLC meeting in Nijmegen this 
has been extensively discussed, since this database can aid both clinicians and researchers 
in determining whether a given CDH1 mutation may be deleterious and likely causative or not. 
The database is now under construction (chapter 2.3). Exchanging knowledge about the vari-
ants will benefit patient care. The database will aid in cancer risk assessment of pathogenic 
CDH1 mutation and VUS carriers, which is not only important for GC families, but may also aid 
in the identification of other individuals at risk, like e.g. OFC patients or breast cancer patients 
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screened with gene panels that include CDH1. Since the database will also contain identified 
VUS that are as yet not considered pathogenic, its use will most likely prevent unnecessary 
interventions in carriers of these specific CDH1 variants. Inclusion of the database in the new 
CDH1 guideline and publically available databases (e.g. Leiden Open Variation Database, 
LOVD) will hopefully create awareness among clinicians and improve decision making in indi-
viduals that have been tested (chapter 2.3).
Somatic mutations in MLH1 and MSH2 in Lynch syndrome - like tumors
Lynch syndrome is caused by heterozygous germline mutations in the MMR genes, for exam-
ple MLH1 and MSH2. Mutation carriers are at high risk of developing CRC and other cancers. 
Patients suspected of Lynch syndrome, who meet the clinical criteria and have an MSI-posi-
tive tumor, but in whom no germline (epi-)mutation in the MMR genes (including a 3’ EPCAM 
deletion) can be identified, are referred to as ‘Lynch-like syndrome patients’, or simply ‘Lynch-
like’.27 There are three possible reasons why cancers from Lynch-like patients are MSI-H de-
spite the absence of germline mutations. The first is a germline defect in an as yet unknown 
gene which, by indirect deregulation of an MMR gene, leads to MSI. Second, it is possible 
that germline variants in the MMR genes are not found with the techniques currently used. 
And third, it could be possible that genetic events in the tumor cause cancers to exhibit MSI.28 
Using next generation sequencing technologies, the second and third possibility can now be 
examined. Sequencing not only the coding exons of a gene but also the introns and regulatory 
elements in the vicinity of the gene, now far less laborious than with conventional Sanger se-
quencing, will most likely identify new mutation carriers, especially since several case reports 
already described intronic aberrations predisposing to Lynch syndrome.29-31 In chapter 5.1, 
we have used a combination of conventional Sanger sequencing and ion semiconductor se-
quencing to examine whether two somatic mutations could be underlying the MMR deficiency 
in part of the tumors of Lynch-like patients. Using the read percentages obtained with the ion 
semiconductor sequencing, we were able to perform detailed LOH analysis using only a small 
amount of SNPs, which was not possible with Sanger sequencing or marker analysis. In our 
cohort, two somatic events in either MLH1 or MSH2 cause the MMR-deficiency in more than 
half (52%) of the MMR-deficient tumors that previously had tested negative for germline MMR 
gene mutations and somatic MLH1 promoter methylation. Patients with two somatic hits in 
their tumor no longer need to be considered as Lynch-like and thus the surveillance regimen 
for these patients and their relatives can be based on their family history, which is also done 
in patients with MSS tumors.
The concept of two somatic mutations underlying MSI-H tumors in Lynch-like patients had 
been described prior to our study. Sourrouille et al. reported two putative biallelic, somatic 
mutations in MMR genes in four of 18 unexplained MMR-deficient tumors (22%).32 Due to 
the addition of LOH analysis in our study, the somatic mutation percentage we observed was 
higher. In eight MLH1- and two MSH2-deficient tumors the LOH analysis was not informative, 
so it is very well possible that the number of cases with LOH in our study is underestimated. 
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This especially holds for the eight MLH1 tumors, since in MLH1-deficient tumors, LOH was a 
major contributor to the MMR deficiency. 
Our results are confirmed in two other recent studies where somatic mutation analysis was 
performed in Lynch-like patients. The first study sequenced the microsatellite-unstable tu-
mors of 40 Lynch-like patients for somatic mutations in the four MMR genes (regardless of 
IHC results). In five of the 40 tumors (13%), two pathogenic mutations were identified and in 
an additional 16 tumors (40%) one (likely) pathogenic mutation was identified in combination 
with LOH. Specifically for the MLH1- and MSH2-deficient tumors, 21/36 (58%) tumors had 
two somatic and (likely) deleterious aberrations, which is comparable to our results. In our 
study, 5/25 (20%) of the tumors showed two pathogenic mutations and 8/25 (32%) showed 
a combination of a (likely) pathogenic mutation and LOH. The percentage of cases that we 
observed with LOH is slightly lower than the results presented by Geurts-Giele et al. (44%), 
most likely because in ten of the cases of our study, the LOH analysis was not informative.33 
In a second comparable study, somewhat higher percentages have been observed when 32 
patients with an MMR-deficient colorectal or endometrial cancer were sequenced for somatic 
mutations in the MMR genes, as well as in POLE and POLD1. Two somatic mutations were 
found in twenty-two of the 32 patients (69%). Of the ten remaining tumors, three had one 
somatic mutation in a MMR gene, with possible loss of heterozygosity that could lead to MMR 
deficiency as a second hit and one had only a single mutation in a MMR gene and remained 
unexplained.34
One remarkable finding in all three studies is that in MLH1-deficient tumors with two somatic 
aberrations, LOH as a second somatic event was far more common compared to MSH2-de-
ficient tumors, in which two mutations were more common. LOH was also observed in the 
Dutch family described in chapter 5.2 (see above). Copy-neutral LOH is a well-known phe-
nomenon in cancer, from the results described above one may argue that MLH1 is more 
sensitive to this type of event than MSH2, something that future research could focus on. 
Another observation that needs clarification is the overlap between the mutations identified 
in the studies described above. Performing somatic mutation analysis in larger patient groups 
will provide more insight into whether these variants are mutational hotspots, providing more 
insight in the underlying mechanism leading to MMR deficiency in these patients or whether 
this is solely coincidence.
In our cohort, the age at diagnosis of the tumors with 2 somatic events was not significant-
ly higher than that of Lynch syndrome-associated tumors caused by MLH1 or MSH2 germ-
line mutations (P = 0.055). In fact, it was significantly lower than the age at diagnosis of 
MMR-deficient tumors with MLH1 promoter hypermethylation (P < 0.0001), indicating that 
the incidence of biallelic somatic events other than MLH1 promoter methylation does not 
increase with age. This is striking, because until now it was assumed that patients with two 
somatic events would have a higher age of onset of their cancer than patients with germline 
mutations. Therefore, it was expected that young patients with an MSI-H tumor without MLH1 
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hypermethylation were carriers of an unidentified germline defect. 
The fact that we have observed two somatic mutations explaining the MMR deficiency does 
not exclude genetic predisposition to cancer, although it is less likely. Five out of the eight 
patients with a likely explained MLH1-deficient tumor and two of the five patients with a likely 
explained MSH2-deficient have a family history of cancer. Based on the family history of the 
family, genetic testing for other syndromes could be considered. For example, the three fami-
lies in which polyps were found in first-degree relatives of the patients could be tested for one 
of the polyposis syndromes or Peutz-Jeghers syndrome. 
Recently, germline biallelic MUTYH mutations have been described as the underlying cause 
of the MMR-deficient tumors in patients suspected of Lynch syndrome, but without germline 
MMR gene mutations. Morak et al. reported on a patient suspected of Lynch syndrome based 
on personal and family history of Lynch-syndrome associated tumors. The patient (who had 
rectal cancer, urothelial carcinoma and a sebaceous gland carcinoma) was found to be a 
biallelic carrier of the p.(Tyr179Cys) mutation. In the sebaceous gland tumor, two somatic mu-
tations in MSH2 were identified, in agreement with the MSI-H and MSH2–MSH6 deficiency on 
IHC in this tumor.35 In another study investigating 178 families meeting the Lynch syndrome 
criteria but without associated germline mutations, a prevalence of 3.9% of MAP syndrome 
was found, in total in seven patients with various tumors, including CRC, gastric cancer and 
endometrial cancer. The authors therefore conclude that inclusion of germline MUTYH muta-
tion analysis in the diagnostic work-up for Lynch syndrome-suspected patients is justified.36 
Somatic mutations in the MMR genes have also been described in patients with a germline 
variant in the proofreading domain of the DNA polymerase POLε (encoded by POLE).37
Since biallelic germline MUTYH mutations may underlie CRC predisposition with MSI-H tu-
mors, additional research into the possibilities to identify biallelic MUTYH mutation carriers 
is warranted. In one of the studies on extracolonic cancers in MAP patients, eleven breast 
cancer patients were identified. Two of the eleven breast cancers were described as having 
intracystic papillary histological subtype38, a rare subtype accounting for less than 1% of the 
total amount of breast cancer cases.39,40 We therefore examined whether papillary carcino-
mas of the breast could be used as a hallmark to recognize patients with MAP by analyzing 
the prevalence of germline biallelic MUTYH mutations in an unselected patient group with 
papillary breast cancer. No germline mutations were identified which indicates that papillary 
carcinomas of the breast cannot be used to recognize patients with MUTYH-associated polyp-
osis (data not included in this thesis, see Boesaard et al.41).
Founder haplotype harboring an MLH1 epimutation: known gene, 
novel type of mutation
Hypermethylation of MLH1 in CRC is a common event and is associated with sporadic cancer 
that develops at an older age. Depending on the age of onset of the studied cohort, these pa-
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tients make up approximately 50 percent of the total group of MLH1-deficient tumors. There 
is, however, a (small) group of patients that have a germline MLH1 epimutation, which caus-
es variable levels of hypermethylation of MLH1 already in normal tissues of these patients. 
When the second allele is inactivated somatically, for example by LOH, they can develop tu-
mors. Thus in essence, these germline MLH1 epimutations predispose to Lynch syndrome.
In chapter 5.2 we describe three families with a constitutional MLH1 epimutation. As a result 
of this epimutation, the patients display variable levels of promoter methylation, accompa-
nied by transcriptional loss from this allele within their normal tissues. Not only do these 
families share the same two variants in MLH1 (c.-27C>A and c.85G>T), they in fact share a 
haplotype of approximately 2.6 Mb on chromosome 3p22, indicating common ancestry. In 
total there are now five families with this MLH1 haplotype. Four of these families met the Am-
sterdam-I criteria. The tumors tested in the different families were MSI-H and showed loss of 
MLH1.42,43 The fifth family did not meet the Amsterdam criteria, since missing pathology files 
made it impossible to obtain a complete family history. 
The shared ancestry between the families indicated that there are additional carriers of these 
SNVs. The families described in chapter 5.2 had spread all over the globe. The fact that 
they are all of European descent does not mean that this haplotype does not occur on other 
continents. Therefore, it seems reasonable that, when during mutation analysis the c.85G>T 
variant is found, also the variant at c.-27 is examined, since they are good markers for the 
haplotype. During standard sequencing protocols the latter variant might be missed, as it is 
located 27 nucleotides upstream of the translational start codon. Also, if hypermethylation in 
normal tissue is observed during hypermethylation analysis, which is indicative of a constitu-
tional MLH1 epimutation, these patients should be investigated for these two SNVs. 
One of the questions that remained unanswered after this study is the mechanism by which 
this haplotype underlies the epigenetic inactivation of MLH1. The c.-27C>A variant remains 
the prime candidate underlying the MLH1 epimutation. Promoter reporter assays have shown 
that this substitution results in significantly decreased transcriptional output.42,43 However, 
based on the haplotype data, there is a shared 2.6 Mb region between the epimutation carri-
ers that may harbor additional mutations explaining the hypermethylation observed in these 
patients. In this region, there are nine genes, apart from MLH1: ARPP21, miRNA128-2, STAC, 
DCLK3, TRANK1, EPM2AIP1, LRRFIP2, GOLGA4 and ITGA9. Previous research in Lynch syn-
drome patients with MSH2-deficient tumors revealed that deletions of the 3’ end of the EP-
CAM gene, located upstream of MSH2, can cause methylation of the MSH2 gene.44 A similar 
mechanism as found in the MSH2-deficient tumors is not expected here, since the gene 
located upstream of MLH1 is in the antisense direction. 
The SNP 6.0 arrays used in this study to determine the haplotypes of the patients also include 
CNV probes that we used to exclude the presence of large CNVs in these patients. However, 
small deletions of a few exons could still be present. With the reducing costs of targeted 
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resequencing and the possibility to perform detailed CNV analysis using these platforms45, it 
may be interesting to investigate the 2.6 Mb region for deletions or insertions of a few base 
pairs or SNVs in the near future. Collecting more families with this particular MLH1 epimuta-
tion may allow for further reduction of the length of the haplotype, making this an even less 
significant undertaking. 
Germline mutations in immune system components in gastric cancer 
development: known genes, new phenotype
In the majority of gastric cancer families fulfilling the 2010 HDGC criteria no germline CDH1 
mutation is found and they remain genetically unexplained. This has major consequences for 
these families. Without a known genetic defect and concomitant cancer risks it is not pos-
sible to perform adequate surveillance and pre-symptomatic interventions in these families. 
Mutations in other GC susceptibility genes, which still have to be discovered, may underlie GC 
predisposition in these families. 
In some cases the phenotype of the GC patients and/or their relatives may provide addition-
al directions in order to unravel the underlying genetic mutations. In chapter 3.2 we report 
on three second-degree relatives of a patient with IL-12Rβ1 deficiency.46 These relatives, all 
women, developed intestinal-type gastric cancer (GC). This is remarkable, because in the 
Netherlands, the incidence of non-cardia GC is only seven per 100,000 person years for 
women.47 From two of these patients we had tumor material available. They both had a poor-
ly differentiated, intestinal-type GC with intestinal metaplasia in the surrounding mucosa. 
Furthermore, chronic active gastritis was seen in one of the sisters and in the other, chronic 
atrophic inflammation was observed. Based on this observation we considered IL12RB1 and 
its binding partner IL12RB2 reasonable candidate genes for GC predisposition. Mutations in 
these genes would have an indirect effect on cancer predisposition: immune cells are less 
capable to recognize pathogens, which can therefore reside longer in the stomach without 
being eradicated and the damage they bring to the cells could ultimately lead to cancer devel-
opment. We sequenced the genes in 29 additional GC patients, the majority with diffuse-type 
GC, but did not identify any additional mutations. These results indicated that mutations in 
these genes are not a frequent cause of GC in the families that remained unexplained after 
CDH1 mutation analysis. Since the patients with the IL12RB1 mutation developed intesti-
nal-type GC, these genes could still be underlying intestinal-type GC predisposition, but this 
remains unclear until larger cohorts are screened for these genes (for example with exome 
sequencing). Nonetheless, it seems logical to systematically review the (gastric) cancer cases 
in families with IL-12Rβ1 deficiency, both in homozygous and heterozygous mutation carriers. 
The phenotypic description of patients and the knowledge obtained from the study men-
tioned above facilitated variant prioritization of exome sequencing data (see below) of the 
patient described in chapter 3.1. In this chapter we describe a patient with early-onset gastric 
cancer and recurrent Candida albicans infections. Whole-exome sequencing of this patient 
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revealed a homozygous missense variant in MYD88, thus far not described in literature. This 
gene plays a central role as a mediator of the innate immune response to infections, and in-
fections with C. albicans have been described in patients with MYD88 deficiency.48 Therefore, 
even though we identified several other variants in this patient, this specific variant seemed to 
most logical candidate gene. To assess the functional relevance of this variant, we stimulated 
the patients’ peripheral blood mononuclear cells with C. albicans and observed a defect in 
production of Th17 cytokine IL-17, confirming a partial defect of the protein caused by the 
variant. 
From literature it is known that patients with both C. albicans and H. pylori infection have an 
increased risk of developing gastric ulcers.49 We hypothesize that the partial MYD88 defect 
causes an impaired immune response, resulting in recurrent C. albicans infections and non-
specific gastritis increasing the risk of signet ring cell carcinoma of the stomach wall. Previous 
studies have shown that C. albicans is able to degrade E-cadherin in vitro50, which may be a 
tumor initiating event in the development of gastric signet ring cell carcinoma.51 The logical 
next step would be to perform immunohistochemistry for E-cadherin on the biopsy and tumor 
remnants of this patient. Staining of the biopsies of the patient revealed normal E-cadherin 
staining. Unpublished research from our group however, has shown that the staining pattern 
of E-cadherin is not reliable, since the staining does not correlate to presence or absence of 
CDH1 mutations. (Van der Post et al., unpublished data) Based on these results, no conclu-
sions were drawn from the staining performed for the patient with the MYD88 variant. 
Prior to identifying the MYD88 variant in a patient with recurrent C. albicans infections and 
early-onset diffuse gastric cancer it was known that gastric cancer could be caused by H. 
pylori and a few other pathogens. Our study shows for the first time that a genetic defect pre-
disposing to impaired host response after infections with C. albicans may also be underlying 
gastric cancer predisposition. This would imply that there is a large group of patients with 
immunodeficiencies at increased risk for (gastric) cancer. Indeed, patients with common vari-
able immunodeficiency, the most common primary immunodeficiency amongst adults, have 
a 10-fold increased risk of developing gastric cancer.52 Interestingly, it was recently shown 
that this group also has a decreased production of interleukin-17.53 Lower production of IL-17 
and infections with C. albicans have also been shown in patients with STAT3 deficiency and 
IL-12Rβ1 deficiency54, but only a single case of esophageal cancer is reported in a patient 
with IL-12Rβ1 deficiency. Future research should include a systematic analysis of cancer cas-
es and calculate cancer risks for patients with the aforementioned immunodefiencies and 
their relatives, as well as in patients with STAT1 deficiency, CARD9 deficiency and patients 
with defective IL-17 receptors55 and their relatives. In families with STAT1 deficiency, leading 
to chronic mucocutaneous candidiasis, cases of esophageal cancer have already been de-
scribed.56 If indeed an enrichment of (gastric) cancer cases is found in these families, surveil-
lance strategies for patients with immune deficiencies and their relatives can be developed to 
prevent them from developing (gastric) cancer.
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Unraveling the genetic predisposition of early-onset and familial 
gastric cancer
As mentioned previously, in the majority of patients that meet the HDGC criteria, no germ-
line CDH1 mutations can be found. The introduction of next generation sequencing opens 
new possibilities for gene discovery. Sequencing the exome or genome of large series of 
GC patients, or multiple members of large HDGC families will most likely identify new candi-
date genes for GC susceptibility. Using these techniques, however, it is reasonable to assume 
that not all patients and families will be explained. There are several reasons for this. First, 
whole-exome sequencing targets only part of the genome (the exome), and other genomic 
regions, like the introns and gene regulatory sequences, are left out of the analysis. As a con-
sequence, mutations predisposing to cancer might be missed. Second, there is currently not 
enough knowledge about variation in the genome of healthy individuals to identify all caus-
ative variants in the large list of variants obtained for each patient. And third, even though 
our cohort consists of highly suspicious families and early-onset cases, indicative of a genetic 
component involved in the etiology of the disease, it is not possible to rule out chance or the 
influence of environmental factors in these cases. Using stringent criteria for the selection of 
our patient, we expect to minimize this effect in our cohort.
Since mutated E-cadherin is involved in the development of DGC, mutated β- and γ-catenin 
(which are in the same pathway) were considered candidate genes for DGC predisposition.57 
We assessed the β-catenin gene (CTNNB1) in 40 families with positive history of GC from the 
Netherlands, but could not identify any mutations. (Vogelaar et al., unpublished data) Recent-
ly, a DGC family with a germline truncating mutation in CTNNA158 has been described. Exome 
sequencing was performed on six patients and a germline truncating variant in α-catenin 
(CTNNA1) was identified which was present in two family members with invasive diffuse gas-
tric cancer and four family members with intramucosal signet ring cells (which were detected 
during endoscopic surveillance).58 Since E-cadherin and α-catenin are in the same complex, 
this gene is an excellent candidate DGC predisposition gene. This is further supported by the 
fact that there is only one truncating variant in the EVS database.59 We expect that more fam-
ilies with germline mutations in this gene will be identified in the near future. 
Another candidate gene for familial gastric cancer has been identified (also using exome 
sequencing) in a large family from Canada. In this family, a germline variant (p.P946L) in 
MAP3K6 was found. Based on conservation, the putative pathogenicity of the variants and 
a known role of the gene in cancer predisposition, the authors consider MAP3K6 a strong 
candidate, also because this same variant and four additional variants were found in a cohort 
of 115 additional families.60 However, variants in this gene are very frequently observed in 
control cohorts not enriched for cancer. The p.P946L variant, for example, is present 38 times 
in a European American cohort (n=4,300) reported in the Exome Variant Server. One of the 
other variants, p.D200Y, is present in 35 individuals from the same cohort.59 It seems very 
unlikely that variants in a gene predisposing to familial gastric cancer, an infrequent disease, 
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would be present in so many non-cancerous controls. This stresses the importance of imple-
menting appropriate control databases in the exome sequencing variant analysis pipeline. 
Furthermore, the variant described in the paper of Gaston et al. does not fully segregate with 
the disease, also arguing against this variant being the causative one.60 So, even though we 
also found variants in MAP3K6 in our cohort of GC patients (see below), the role of these 
variants in GC predisposition is highly questionable.
Patient selection for exome sequencing
In approximately two-third of DGC families, the putative genetic cause is unknown. Also for 
intestinal-type GC (IGC) no susceptibility genes have been identified. We performed exome 
sequencing on a group of 54 patients from 53 families with a suspicion of familial gastric 
cancer, but without CDH1 mutations. Families were included based on the criteria set by the 
IGCLC in 2010, regardless of histology. Also, we established an extended patient cohort that 
met less stringent criteria, also with both DGC and IGC, in which we can evaluate the findings 
from the whole-exome sequencing cohort. 
Whole-exome sequencing variant analysis
Performing whole-exome sequencing on a group of more than 50 patients with such a hetero-
geneous disease as gastric cancer generates a bulk of data, with a large number of potential-
ly interesting variants. There are different approaches to prioritize these variants into a list of 
candidate genes that will be sequenced in a larger patient cohort. In our dataset, we focused 
on pathways that may play a role in (gastric) cancer development and selected variants in 
those pathways. Furthermore, we prioritized variants based on patient phenotype, which is 
described in chapter 3.1 and chapter 3.2. Next, we examined genes in which we observed an 
enrichment of truncating variants compared to controls and on genes in which we identified 
truncating variants with a focus on gene function. Finally, we made a comparison with genes 
that are somatically mutated in cancer, since they may also provide clues to candidate genes.
For all the analyses mentioned above, we have used control databases that contain exome 
sequencing data from individuals without a known history of hereditary cancer. This allows 
for rigorous filtering of the identified variants. Based on its function, a certain gene may seem 
the perfect candidate for GC predisposition. However, when this same variant or variants in 
the same gene are observed in controls that do not have cancer, this argues strongly against 
a role for this gene and/or variant in GC development. In chapter 4, we have used two in-
house databases; one containing approximately 2,100 exomes was used for initial filtering of 
the variants and the second one, containing 2,329 exomes sequenced with high coverage, 
was used for further filtering and to determine the enrichment of truncating variants. Further-
more, we have used data from The National Heart, Lung, and Blood Institute (NHLBI) Exome 
Sequencing Project59, containing 6,503 exomes. 
In our analyses of the exome data, we have used different KEGG pathways that can be func-
tionally linked to gastric cancer development. For example, the KEGG pathway on adherens 
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contains the genes CDH1 and CTNNA1, whereas the JAK-STAT pathway gene list contains 
amongst others IL12RB1 and IL12RB2. Based on the results described in chapter 3.1, we 
also included the genes for the Toll-like Receptor pathway (including MYD88) in our analysis. 
Even though we identified almost 400 variants that may be relevant for GC development us-
ing this approach, it did not reveal any clear candidate genes. 
As a next step in the data-analysis, we decided to focus on the truncating variants in the data-
set. First, we examined the function of the genes in which we identified variants. This was a 
quite laborious approach, since it was difficult to establish what makes a gene a cancer gene. 
In our analysis, we included genes already described as tumor-suppressor gene or oncogene, 
genes involved in cell cycle, genes involved cell adhesion and genes involved in chromosome 
stability. However, using this approach, we found a truncating variant in RB1CC1. This gene 
can be functionally linked to cancer and the variation in controls in this gene is very limit-
ed. Subsequently, we focused on genes with more than one truncating variant, providing a 
stronger indication the gene may be linked to GC predisposition. An enrichment of truncating 
variants was found for 20 genes compared to the control dataset. We could not determine an 
association between the histological subtypes of the patients and specific genes that were 
affected. Future research will have to provide further clues for this, although it may be possi-
ble that we identified mutations in genes that predispose to both histological subtypes of GC.
The genes in which we found the truncating variants will be sequenced in a cohort of GC 
patients meeting less stringent criteria than the cohort used for identification of novel GC pre-
disposing genes. By performing this cohort screening, the contributions of the different genes 
in GC predisposition can be explored. However, there is a fair chance that we will not find as 
many additional mutations as one might expect based on the results described above. In the 
current study, only highly suspected families, meeting very stringent criteria, are included. 
Therefore, we might have an ascertainment bias in our cohort. For this reason we have a large 
number of criteria for inclusion of the resequencing cohort. Patients/families are stratified in 
the first criterion they meet of a set of 18 criteria; the first criteria in this list are still relatively 
strict, while the final criteria are relatively loose. Using this approach for our resequencing, 
we can determine in what patient groups these genes might be relevant. In parallel, coseg-
regation analysis and cancer risk assessments have to be performed. In a future diagnostic 
setting, a panel of genes could be sequenced in families based on the family history, like is 
the case for CDH1.
Somatic mutations as a tool to select genes for gastric cancer predisposition
Variants reported somatically in GC can indicate specific genes and/or pathways that are 
involved in GC development and therefore this data can be used for variant prioritization of 
whole-exome data. Several research groups have published their work on somatic mutations 
in gastric cancers in the previous years. For example, the study by Wang et al. in 2011 re-
vealed that the ARID1A gene is recurrently affected in 22 gastric cancer samples. ARID1A is 
a chromatin modifier and it was observed that the percentage of samples in which this gene 
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was mutated differs between different subgroups of GC, with the MSI-H GC carrying indel 
mutations in this gene being the most frequent. Tumors harbouring ARID1A mutations did 
not have TP53 mutations, a gene commonly mutated in a large number of tumor types.61 
By sequencing 15 gastric adenocarcinomas (3 DGC) and matched normal DNA, Zang et al. 
found frequent mutations in TP53, PIK3CA, and again ARID1A. Furthermore, mutations were 
found in the gene FAT4, which is a member of the cadherin family, like CDH1. The authors 
concluded that since FAT4 and ARID1A showed tumor-suppressor activity in vitro, somatic 
inactivation of these genes could be important in the development of GC.62 Kakiuchi et al. 
performed whole-exome sequencing on 30 DGC cases and found recurrent RHOA nonsyn-
onymous mutations. Their observations were validated in an additional cohort and RHOA 
mutations were observed in 25.3% of DGCs. Also, this study identified mutational hotspots 
in this gene.63 Mutations in RHOA appear to be specific for diffuse-type GC, as was confirmed 
by another study sequencing 100 gastric tumors and their matched normal tissues. RHOA 
aberrations were found exclusively in a subset of the 29 DGCs that were part of this study.64
In the most comprehensive study so far, carried out as part of The Cancer Genome Atlas 
project, 295 primary gastric cancers were sequenced. Based on the obtained data, a molec-
ular classification was proposed, which divides GC in four distinct groups. The first group is 
comprised of EBV-positive tumors, which have, amongst other mutations, recurrent PIK3CA 
mutations. The second group are the MSI-H tumors, which show elevated mutation rates. The 
third group includes genomically stable tumors, in which mutations of RHOA or fusions involv-
ing RHO-family GTPase-activating proteins are found. The last group is formed of tumors with 
chromosomal instability.65 Stratifying the tumors in different groups based on their somatic 
mutation profile will allow for development of improved and more efficient therapies.
In the patient cohort we performed exome sequencing on, there was one patient who carries 
two heterozygous missense variants in the FAT4 gene. Variation in the FAT4 gene occurs quite 
frequently in our in-house dataset of 2,329 exomes, which contains 14 different homozygous 
missense mutations in this gene. Therefore, we think it is less likely that germline variants in 
this gene predispose to GC.
Based on the paper by Kakiuchi et al.63, we examined our dataset for variants in the RHOA 
gene and other genes in this pathway. Two unrelated patients in our cohort carry a heterozy-
gous missense variant in the ARHGEF12 gene, which functions upstream of RHOA. The fact 
that they developed diffuse-type GC is in agreement with the fact that RHOA mutations are 
exclusively found in this type of GC.63,64 The variants that we identified in these patients are 
both present once in the EVS database, and in our in-house dataset there are two different 
homozygous missense variants. Given this limited amount of variation in controls and the fact 
that ARHGEF12 has previously been described as a tumor-suppressor in breast cancer and 
colorectal cancer66, we still consider this interesting for future follow-up studies.
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Future perspectives 
The research described in this thesis provides numerous directions for future research to fur-
ther elucidate the molecular alterations underlying genetic predisposition to gastrointestinal 
cancer. 
Using next-generation sequencing approaches, like whole-exome sequencing but also gene 
panel sequencing, large numbers of missense variants will be identified. Improving the in-
terpretation of these variants is very important for future research studies as well as for 
diagnostics. In studies using NGS, a lot of missense variants are identified, but in most cases 
their definite pathogenicity cannot be assessed. Improving the interpretation will take away 
this uncertainty, thereby facilitating easier data-analysis, which ultimately may lead to im-
proved identification of candidate genes. Also for diagnostics, the improved interpretation 
is important. For example, screening of breast cancer patients with gene panels instead of 
single genes will most likely identify a lot more carriers of CDH1 variants and it is important 
that proper cancer risk assessments can be done, so patients can be offered the appropriate 
type of surveillance or intervention.
There are currently several indications that patients with an immunodeficiency are at in-
creased risk for gastric cancer. Therefore, a systematic review of the risk of developing gastric 
cancer, but also other types of cancer, in patients with an immunodeficiency and their rela-
tives should be performed. So far, this has been performed for patients with common variable 
immunodeficiency (CVID) and AIDS patients, but for other immunodeficiencies this data is not 
available yet. If these patients and relatives are indeed at increased risk of developing cancer, 
they can be offered surveillance and interventions to prevent GC development. Our results 
indicate that individuals at risk may not present as classic immunodeficiency patients and 
may not be recognized as such. To confirm this, clinical geneticists should ask for history of 
infections during their consults. In case this is positive, it will provide additional directions in 
which to look for the predisposing genetic defect. Furthermore, performing somatic exome or 
genome sequencing on the gastric cancers of patients with an immunodeficiency will provide 
additional insights into the development of GC in this patient group and may provide options 
for development of novel therapies.
In this thesis, exome sequencing on 54 patients from 53 unexplained GC families was per-
formed. Several candidate genes were identified, but larger cohorts of patients are required 
to determine the relevance of these mutations. Establishing international research groups 
which combine patient cohorts and share data to determine frequency of variants in certain 
genes will provide additional proof for their role in GC predisposition. In my opinion, it is 
important that complete variant lists (so not only candidate gene lists) are shared between 
groups, since every research group will use their own approach to filter for potentially interest-
ing genes and data needs to be analyzed uniformly. Combining data from different research 
groups will allow for a meta-analysis which may lead to additional recurrently affected genes. 
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Furthermore, increasing the number of patients will allow for stratification of the cohort, for 
example based on histology or family history. Ultimately, this will allow for cancer risk assess-
ments for certain gene mutations in both the patients and their relatives, ultimately improving 
prognosis and cancer prevention in mutation carriers. 
In the group of CRC patients in whom we identified two somatic mutations in the tumor, the 
underlying cause of the mismatch repair deficiency has been found. However, a number of 
these families have a positive family history, indicating there may be an underlying germline 
defect that ultimately leads to the somatic mutations in MLH1 and/or MSH2. Determining the 
genetic defect will help to assess what the appropriate surveillance for them and their rela-
tives will be. Unraveling this defect can be done by exome sequencing, but it will be important 
to include multiple relatives from one family to find variants that segregate with the disease. 
With the costs of whole-genome sequencing decreasing, this will even be a better approach, 
since this has the advantage of examining all coding regions of the genome, increasing the 
yield of putative pathogenic mutations in these families.
The suggestions mentioned above contribute to obtaining more insight into the development 
of gastrointestinal cancers and may ultimately lead to improvement of therapies and reduced 
mortality from these diseases.
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Summary of the thesis
Cancer is a genetic disease that is caused by the step-wise acquisition of specific alterations 
in the DNA. Two types of genes in which mutations can drive tumorigenesis exist; oncogenes 
and tumor-suppressor genes. Germline mutations in certain tumor-suppressor genes and on-
cogenes cause cancer predisposition. Carriers of these germline mutations are at increased 
risk of cancer, because the mutation that contributes to cancer formation is already present 
in every cell of their body. Characteristic features of individuals with hereditary cancer predis-
position are the early age of onset compared to individuals with sporadic forms, the occur-
rence of multiple tumors, and the presence of a positive family history of cancer (chapter 1).
This thesis will focus on novel and known genetic factors associated with predisposition to 
gastric- (GC) and colorectal cancer (CRC). Even though great progress has been made in iden-
tifying genetic causes for these two types of cancer, only a small proportion of the early-onset 
and/or familial cases can be explained thus far. Identification of genetic causes underlying 
GC or CRC predisposition will provide more insight into the mechanisms by which tumors 
develop and may also provide opportunities for prevention and the development of novel 
therapies. For patients it is important to understand what has caused their disease and what 
the risk of developing new primary tumors will be, for themselves as well as their relatives. 
Furthermore, the clinical management of mutation carriers may change based on the muta-
tion that they have (chapter 1).
Familial aggregation of gastric cancer occurs in approximately 8-30% of cases. Mutations in 
the CDH1 gene have been identified as a cause of hereditary diffuse gastric cancer (HDGC), 
a cancer predisposition syndrome with a high lifetime risk of developing diffuse-type gastric 
cancer and lobular breast cancer. Criteria have been developed to predict germline CDH1 mu-
tations in hereditary diffuse gastric cancer. In chapter 2.1 we evaluated the criteria as they 
were set in 2010 by combining the CDH1 mutation analysis results with clinicopathological 
data of 499 families screened in The Netherlands. Sixteen pathogenic mutations were iden-
tified in a group of 118 families that met the HDGC criteria (14%). Two additional mutations 
were found in the remaining families, who either did not meet the criteria or from whom the 
data was incomplete. The criteria had a sensitivity of 89%, which means that using the 2010 
HDGC criteria, 11% of the CDH1 families in the Netherlands would be missed (chapter 2.1). 
Mutations in the CDH1 gene have been associated with a high lifetime risk of developing 
diffuse-type gastric cancer and lobular breast cancer. However, the presence of patients with 
orofacial clefts (OFC) in CDH1 families also has been described. OFC are among the most 
common birth defects worldwide, and identifying CDH1 mutation carriers in a group of unse-
lected OFC patients would allow for interventions to prevent GC and LBC, since OFC is already 
apparent very early in life. We performed CDH1 mutation analysis in a cohort of patients with 
non-syndromic OFC and identified heterozygous CDH1 missense variants in 4 out of 81 (5%) 
of the OFC patients. The functional relevance of these variants was confirmed using in vitro 
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assays. It is not known whether the variant carriers that we identified in the OFC cohort are at 
increased risk of developing GC and LBC. There is a possibility that the variants we identified 
might be relevant for OFC risk, but not for gastric cancer risk (chapter 2.2). 
In March 2014, an international, multidisciplinary workshop was organized by the Depart-
ments of Pathology and Human Genetics of the Radboudumc to discuss genetic testing, 
surgery, surveillance strategies and pathology reporting for individuals suspected of and 
confirmed with a CDH1 mutation, as well as the patient’s perspective on multiple aspects, 
including diet post-gastrectomy. Based on the results described in chapter 2.1 and the re-
sults of others, the International Gastric Cancer Linkage Consortium has updated the CDH1 
testing criteria in a new guideline (chapter 2.3). The new criteria (taking into account first- and 
second-degree relatives) are: (1) families with two gastric cancer patients at any age, one 
confirmed diffuse gastric cancer, (2) individuals with diffuse gastric cancer before the age 
of 40 years and (3) families with diagnoses of both DGC and LBC (one diagnosis before the 
age of 50). Furthermore, three additional criteria have been set, for which more evidence is 
required of incidence of CDH1 mutations before cancer risks can be assessed. One of them is 
that patients with DGC, who have a personal or family history of OFC are now eligible for CDH1 
mutation screening. In this way more data concerning the role of germline CDH1 mutations 
in risk of OFC, as well as the risk of developing GC and/or LBC for OFC patients with germline 
CDH1 mutations can be obtained. Also patients with bilateral LBC at young age or those who 
have multiple close relatives with LBC can be tested for CDH1 mutations. Furthermore, in 
cases where in situ signet ring cells and/or pagetoid spread of signet ring cells in the stomach 
are detected, genetic testing should also be considered (chapter 2.3).
In the majority of gastric cancer families fulfilling the 2010 HDGC criteria no germline CDH1 
mutation is found and they remain genetically unexplained. Without a known genetic de-
fect and concomitant cancer risks it is not possible to perform adequate surveillance and 
pre-symptomatic interventions in these families. In some cases the phenotype of the GC 
patients and/or their relatives may provide additional directions to unravel the underlying 
genetic mutations. In a 23 year old patient with diffuse-type gastric cancer and recurrent Can-
dida albicans infections, we identified a germline homozygous missense variant in MYD88. 
Since infections with C. albicans have been described in patients with MYD88 deficiency, 
this seemed a very logical candidate gene explaining the phenotype of the patient. In vitro 
assays with the patients’ cells indicated a partial functional defect of the variant protein. Our 
study shows for the first time that a genetic defect predisposing to impaired host response 
after infections with Candida albicans may also be underlying gastric cancer predisposition 
(chapter 3.1). 
In another family, three relatives of a patient with a biallelic IL12RB1 mutation developed 
GC. Based on this observation we considered IL12RB1 and its binding partner IL12RB2 rea-
sonable candidate genes for GC predisposition. The genes were sequenced in 29 additional 
GC patients, the majority with diffuse-type GC, but no additional mutations were found. This 
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indicated that mutations in these genes are not a frequent cause of GC in the families that 
remained unexplained after CDH1 mutation analysis. Since the patients with the IL12RB1 
mutation developed intestinal-type GC, these genes could still be underlying intestinal-type 
GC predisposition (chapter 3.2). 
The most recent technological development in disease gene identification is the introduc-
tion of next-generation sequencing methods, such as whole-exome sequencing (WES) and 
whole-genome sequencing (WGS). We performed exome sequencing on a group of 54 pa-
tients from 53 families with a suspicion of familial gastric cancer, but without CDH1 muta-
tions. In our dataset, we focused on genes in which we observed an enrichment of truncating 
variants compared to controls, on pathways that can be implicated in GC development, on 
genes in which we identified truncating variants with a focus on gene function and we also 
prioritized variants based on patient phenotype. Finally, we made a comparison with genes 
that are somatically mutated in cancer, since they may also provide clues to candidate genes. 
Using these approaches, several candidate genes were found, which need to be evaluated in 
other studies in GC patients (chapter 4). 
As is the case with gastric cancer, the majority of colorectal cancer cases are sporadic; familial 
CRC occurs in approximately 20% of cases. Lynch syndrome, caused by germline mutations 
in the mismatch-repair (MMR) genes (for example MLH1 and MSH2), is the most common 
hereditary form of CRC and is characterized by microsatellite-instable (MSI-H) tumors. Lynch 
syndrome mutation carriers have a lifetime risk of up to 80% to develop CRC. In addition they 
are at high risk to develop endometrial cancer (EC) and several other cancer types (chapter 
1 and chapter 5.1). 
There is a group of patients with MSI-H tumors who are not carriers of germline mutations 
in the MMR genes, called ‘Lynch-like’ patients. To examine whether two somatic mutations 
could be underlying the MMR deficiency in (part of) this group of patients, we have used a 
combination of conventional Sanger sequencing and ion semiconductor sequencing to per-
form mutation analysis and LOH analysis. In our cohort, 2 somatic events in either MLH1 
or MSH2 cause the MMR-deficiency in more than half (52%) of the MMR-deficient tumors. 
Patients with two somatic hits in their tumor no longer need to be considered as Lynch-like 
and thus the surveillance regimen for these patients and their relatives can be based on their 
family history (chapter 5.1). 
Hypermethylation of MLH1 in CRC is a common event and is associated with sporadic, MSI-H 
cancer that develops at an older age. In chapter 5.2 we describe three families with a con-
stitutional MLH1 epimutation. These families share a haplotype of approximately 2.6 Mb on 
chromosome 3p22, indicating common ancestry. On this haplotype, there are two variants in 
MLH1 (c.-27C>A and c.85G>T), which are associated with variable levels of MLH1 promoter 
methylation accompanied by transcriptional loss from this allele within their normal tissues. 
These variants can be used as marker to identify additional carriers of this haplotype, who are 
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at risk of Lynch syndrome-associated cancers (chapter 5.2).
In chapter 6 the results presented in this thesis are discussed in detail and suggestions for 
further research are given. In my opinion, it is very important that the interpretation of mis-
sense variants is improved, since it is important to determine whether a certain missense 
variant is pathogenic, both in research and diagnostic setting. The role of immunodeficiencies 
in gastric cancer appears to be important, this should be further examined by a systematic 
review of the risk of developing cancer in patients with an immunodeficiency and their rela-
tives. During the genetic testing process of these families, it will be essential that immuno-
deficiencies are taken into account. By establishing international research cohorts additional 
GC predisposing genes can be identified. 
In tumors of part of the group of ‘Lynch-like’ patients, two somatic mutations explain the 
MMR-deficiency. Some of these patients also have a positive family history, indicating they 
might have a predisposition to hereditary cancer. For these patients it will be relevant to iden-
tify the underlying mutation, in order to assess what the appropriate surveillance for them 
and their relatives will be. 
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Samenvatting van het proefschrift
Kanker is een genetische ziekte die wordt veroorzaakt door een opeenstapeling van speci-
fieke veranderingen in het DNA. Er zijn twee typen genen waarin mutaties kunnen bijdragen 
aan tumorgenese; oncogenen en tumor-suppressorgenen. Kiembaan veranderingen in be-
paalde tumor-suppressorgenen en oncogenen geven een predispositie voor kanker. Dragers 
van deze kiembaan mutaties hebben een verhoogd risico op kanker, omdat de mutatie die 
bijdraagt aan de groei van de tumor aanwezig is in elke cel van hun lichaam. Predispositie 
voor erfelijke kanker is te herkennen aan het voorkomen van kanker op jongere leeftijd in 
vergelijking met sporadische vormen van kanker, het voorkomen van meerdere tumoren, en 
een positieve familieanamnese (hoofdstuk 1).
Dit proefschrift richt zich op de genetische predispositie voor maag- en darmkanker. Hoewel 
er een enorme vooruitgang is gemaakt in het ontrafelen van genetische oorzaken voor deze 
twee vormen van kanker, is de genetische oorzaak in slechts een klein deel van de families 
bekend. Het vinden van nieuwe genetische oorzaken geeft meer inzicht in het mechanisme 
waarmee tumoren zich ontwikkelen en geeft mogelijk aanknopingspunten voor preventie en 
het ontwikkelen van nieuwe therapieën. Voor patiënten is het belangrijk om te begrijpen hoe 
hun ziekte is ontstaan en wat het risico op het ontwikkelen van nieuwe tumoren is, zowel voor 
henzelf als voor hun familieleden. Verder kan de behandeling van mutatiedragers worden 
aangepast afhankelijk van de mutatie die zij dragen (hoofdstuk 1).
Ongeveer 8-30% van alle patiënten met maagkanker is familiair. Mutaties in het CDH1 gen 
zijn een oorzaak van ‘Erfelijk Diffuus maagkanker’, een kanker predispositiesyndroom met 
een hoog risico op het ontwikkelen van diffuus-type maagkanker en lobulair borstkanker. Er 
zijn criteria ontwikkeld voor het opsporen van dragers van CDH1 mutaties. In hoofdstuk 2.1 
evalueren wij deze criteria uit 2010 door het combineren van de resultaten van de CDH1 
mutatie-analyse met de klinisch-pathologische data van 499 families die getest zijn in Neder-
land. Er werden 16 pathogene mutaties gevonden in een groep van 118 families die voldeden 
aan de criteria (14%). Twee additionele mutaties werden gevonden in families die niet aan de 
criteria voldeden, of van wie de data niet compleet was. De criteria hadden een sensitiviteit 
van 89%, wat betekent dat, als de criteria uit 2010 gebruikt worden, 11% van de CDH1 fami-
lies in Nederland zou worden gemist (hoofdstuk 2.1).
Mutaties in CDH1 geven een hoog risico op het ontwikkelen van diffuus-type maagkanker 
en lobulair borstkanker. Er zijn echter ook patiënten met schisis beschreven in families met 
CDH1 mutaties. Schisis is één van de meest voorkomende aangeboren afwijkingen wereld-
wijd. Aangezien schisis al op vroege leeftijd zichtbaar is, biedt het vinden van een CDH1 muta-
tie in deze groep patiënten de mogelijkheid voor interventies om maag- en borstkanker te 
voorkomen. Wij hebben CDH1 mutatie-analyse uitgevoerd in een cohort van niet-syndromale 
schisispatiënten en vonden CDH1 missense varianten in 4 van de 81 patiënten (5%). Het 
functionele effect van deze varianten werd bevestigd met behulp van in vitro assays. Het is 
239
niet bekend of de dragers van de varianten die wij gevonden hebben ook een verhoogd risico 
op het ontwikkelen van maag- en borstkanker hebben. Het is mogelijk dat de varianten die 
wij gevonden hebben wel de onderliggende oorzaken van de schisis zijn, maar geen kanker 
veroorzaken (hoofdstuk 2.2).
In maart 2014 is er een internationale, multidisciplinaire workshop georganiseerd door de af-
delingen Pathologie en Genetica van het Radboudumc om de mutatie-analyse, operatie, sur-
veillance en pathologische verslaggeving van individuen verdacht van en met CDH1 mutaties, 
alsmede het patiëntenperspectief op bijvoorbeeld het dieet na een gastrectomie, te bespre-
ken. Naar aanleiding van de resultaten beschreven in hoofdstuk 2.1 en de resultaten van 
anderen heeft het International Gastric Cancer Linkage Consortium de inclusiecriteria voor 
het testen van CDH1 mutaties aangepast in de nieuwe richtlijn. De nieuwe criteria (uitgaande 
van eerste- en tweedegraads familieleden) zijn: (1) families met twee maagkankerpatiënten 
ongeacht leeftijd, waarvan één bevestigd diffuus-type maagkanker is, (2) patiënten die voor 
hun 40e jaar diffuus-type maagkanker ontwikkelen en (3) families met zowel diffuus-type 
maagkanker als lobulair borstkanker, met één diagnose voor het 50e jaar. Daarnaast zijn er 
drie additionele criteria gemaakt, waarvoor meer onderzoek nodig is om kankerrisico's te 
bepalen. Eén daarvan is dat patiënten met diffuus-type maagkanker en schisis of met schisis 
in de familie in aanmerking komen voor CDH1 mutatie-analyse, om zo meer inzicht in de rol 
van kiembaan CDH1 mutaties bij schisis te krijgen, en ook het risico op het ontwikkelen van 
maag- en lobulair borstkanker bij schisispatiënten met CDH1 mutaties te bepalen. Ook pati-
enten met bilateraal lobulair borstkanker op jonge leeftijd of met meerdere familieleden met 
lobulair borstkanker kunnen getest worden voor CDH1 mutaties. Daarnaast moet een test 
overwogen worden voor patiënten waarbij er in situ zegelringcellen en/of pagetoide spreiding 
van zegelringcellen in de maag worden gevonden (hoofdstuk 2.3).
In het grootste deel van de maagkankerfamilies die voldoen aan de 2010 HDGC criteria kan 
geen CDH1 mutatie worden gevonden en deze families blijven onverklaard. Zonder kennis 
van de eventueel onderliggende mutaties in deze families en bijbehorende kankerrisico's is 
het niet mogelijk om deze families adequate surveillance en presymptomatische interventies 
aan te bieden. Bij sommige patiënten geeft het fenotype van de patiënt en/of familieleden 
aanwijzingen over het onderliggende genetische defect. In een 23-jarige patiënt met diff-
uus-type maagkanker en terugkerende infecties met Candida albicans vonden we een kiem-
baan homozygote missense variant in MYD88. Aangezien infecties met Candida albicans be-
schreven waren in patiënten met MYD88 deficiëntie, leek dit een heel logisch kandidaatgen. 
In vitro studies met cellen van de patiënt lieten een gedeeltelijk eiwitdefect zien, veroorzaakt 
door de variant. Onze studie laat voor het eerst zien dat een genetisch defect dat leidt tot een 
afwijkende immuunrespons na infecties met Candida albicans ook de onderliggende oorzaak 
kan zijn voor maagkanker (hoofdstuk 3.1).
In een andere familie ontwikkelden drie familieleden van een patiënt met een biallellische IL-
12RB1 mutatie maagkanker. Op basis van deze observatie waren IL12RB1 en zijn bindings-
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partner IL12RB2 kandidaatgenen voor maagkankerpredispositie. De genen zijn gesequen-
ced in nog 29 maagkankerpatiënten, de meerderheid met diffuus-type maagkanker, maar er 
werden geen additionele mutaties gevonden. Mutaties in deze genen zijn dus geen veelvoor-
komende oorzaak van maagkanker in families zonder CDH1 mutatie. Aangezien de patiënten 
met de IL12RB1 mutatie intestinaal-type maagkanker ontwikkelden, zouden deze genen wel 
betrokken kunnen zijn bij predispositie voor intestinaal-type maagkanker (hoofdstuk 3.2).
De meest recente technologische ontwikkeling in het identificeren van ziektegenen is de in-
troductie van 'next-generation sequencing', zoals exoom- en genoomsequencing. We hebben 
exoomsequencing uitgevoerd voor 54 patiënten van 53 families die verdacht worden van 
erfelijke maagkanker, maar geen CDH1 mutatie hebben. Voor de data-analyse hebben we ge-
keken naar genen waarin een verrijking van truncerende varianten werd gevonden ten opzich-
te van controles, naar 'pathways' die betrokken zouden kunnen zijn bij de ontwikkeling van 
maagkanker, naar genen met truncerende varianten waar we gekeken hebben naar functie 
van het gen en we hebben varianten geselecteerd op basis van het fenotype van de patiënt, 
zoals hierboven is beschreven. Als laatste hebben wij een vergelijking gemaakt tussen onze 
dataset en genen waarin somatisch mutaties in maagkanker worden gevonden, omdat deze 
ook in de kiembaan betrokken zouden kunnen zijn bij de ontwikkeling van maagkanker. Met 
deze verschillende analyses hebben we een aantal kandidaatgenen gevonden, die nader 
moeten worden geëvalueerd in andere cohorten (hoofdstuk 4).
Net als bij maagkanker is het merendeel van de patiënten met darmkanker sporadisch; on-
geveer 20% is familiair. Lynch syndroom, veroorzaakt door mutaties in de 'mismatch-repair' 
(MMR) genen (bijvoorbeeld MLH1 en MSH2), is de meest voorkomende erfelijke vorm van 
darmkanker en wordt gekenmerkt door microsatelliet-instabiele (MSI-H) tumoren. Dragers 
van een mutatie die Lynch syndroom veroorzaakt hebben een risico van 80% om in hun leven 
darmkanker te ontwikkelen. Daarnaast hebben zij een hoog risico op het ontwikkelen van 
endometriumkanker en andere typen kanker (hoofdstuk 1 en hoofdstuk 5.1).
Er is een groep patiënten met MSI-H tumoren die geen kiembaanmutatie in de MMR genen 
hebben, de zogenaamde 'Lynch-like' patiënten. Om te onderzoeken of twee somatische muta-
ties de MMR-deficiëntie in (een deel van) deze groep zouden kunnen verklaren, hebben we 
met een combinatie van Sanger sequencing en ion semiconductor sequencing mutatie- en 
LOH analyse uitgevoerd. In ons cohort werd de MMR-deficiëntie in ruim de helft (52%) van de 
patiënten veroorzaakt door 2 somatische verandering in MLH1 of MSH2. Patiënten met twee 
somatische veranderingen in hun tumor worden niet langer gezien als 'Lynch-like' en de sur-
veillance voor deze patiënten en hun familie kan gebaseerd worden op de familieanamnese 
(hoofdstuk 5.1).
Hypermethylering van MLH1 in darmtumoren komt vaak voor en is geassocieerd met spora-
dische, microsatelliet-instabiele tumoren die op latere leeftijd ontwikkelen. In hoofdstuk 5.2 
beschrijven we drie families met een constitutionele MLH1 epimutatie. Deze families delen 
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een haplotype van ongeveer 2.6 Mb op chromosoom 3p22, wat aangeeft dat deze families 
verwant zijn. Op dit haplotype liggen twee varianten in MLH1 (c.-27C>A and c.85G>T), die 
geassocieerd zijn met MLH1 promoter methylering en daarmee samenhangend verlies 
van transcriptie van dit allel in normale weefsels. Deze varianten kunnen gebruikt worden 
als marker om dragers van dit haplotype, die een hoog risico hebben op Lynch syndroom- 
geassocieerde tumoren, te herkennen (hoofdstuk 5.2).
In hoofdstuk 6 worden de hierboven beschreven hoofdstukken uitgebreid bediscussieerd en 
worden suggesties voor verder onderzoek gegeven. Het is naar mijn mening belangrijk dat de 
interpretatie van missense varianten gaat verbeteren, omdat het voor zowel onderzoek als in 
de diagnostiek belangrijk is om goed te kunnen beoordelen of een bepaalde missense variant 
pathogeen is. De rol van immuundeficiënties bij maagkanker lijkt belangrijker dan voorheen 
aangenomen werd en verdient nader onderzoek met een systematische analyse van het 
kankerrisico voor patiënten met een immuundeficiëntie en hun familieleden. Bij genetisch 
onderzoek van deze groep patiënten is het essentieel dat er rekening gehouden wordt met 
deze mogelijkheid. Door internationale samenwerkingen op te zetten kunnen nieuwe predis-
positie genen voor maagkanker worden gevonden. In de tumoren van een deel van de groep 
'Lynch-like' patiënten verklaren twee somatische mutaties de MMR-deficiëntie. Sommige van 
deze patiënten hebben echter ook een positieve familieanamnese en zouden dus een pre-
dispositie voor erfelijke kanker kunnen hebben. Voor deze patiënten en hun families is het 
belangrijk om het genetisch defect te vinden, om zo een goed surveillance advies te kunnen 
geven en eventuele nieuwe kanker zo vroeg mogelijk op te sporen.
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2011-2014 
 
2010-2012 
 
2011-2013 
 
2011-2013 
 
2014 
 
4.25 
 
4 
 
4.75 
 
1.75 
 
1.25 
 
1.5 
 
1 
d) Other 
- Literature discussion series*** 
- Theme discussion series*** 
- Review of scientific paper 
- Organisation RIMLS Technical Forum 
- Organisation International Gastric Cancer Linkage Consortium 
meeting 
 
2010-2014 
2010-2014 
2013 
2013-2014 
2013-2014 
 
 
 
0.2 
1 
0.5 
TEACHING ACTIVITIES 
e) Lecturing 
- Tutor Cancer Research 
- Tutor Capita Selecta 
 
2013 
2013 
 
0.5 
0.5 
f) Other 
- Student supervision 
- Assistance student practical 
 
2012-2014 
2012 
 
4.9 
1 
TOTAL 37.3 
*Oral presentation, #Poster presentation 
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